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that provide insight into the molecular basis of disease. Neurodevelopmental disease affects the quality of life
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ABSTRACT 
 
BIOLOGICAL ROLE AND DISEASE IMPACT OF COPY NUMBER VARIATION  
IN COMPLEX DISEASE 
 
Joseph Glessner 
 
Hakon Hakonarson 
 
 In the human genome, DNA variants give rise to a variety of complex 
phenotypes. Ranging from single base mutations to copy number variations (CNVs), 
many of these variants are neutral in selection and disease etiology, making difficult the 
detection of true common or rare frequency disease-causing mutations. However, allele 
frequency comparisons in cases, controls, and families may reveal disease associations. 
Single nucleotide polymorphism (SNP) arrays and exome sequencing are popular assays 
for genome-wide variant identification. To limit bias between samples, uniform testing is 
crucial, including standardized platform versions and sample processing. Bases occupy 
single points while copy variants occupy segments. Bases are bi-allelic while copies are 
multi-allelic. One genome also encodes many different cell types. In this study, we 
investigate how CNV impacts different cell types, including heart, brain and blood cells, 
all of which serve as models of complex disease. Here, we describe ParseCNV, a 
systematic algorithm specifically developed as a part of this project to perform more 
accurate disease associations using SNP arrays or exome sequencing-generated CNV 
calls with quality tracking of variants, contributing to each significant overlap signal. Red 
flags of variant quality, genomic region, and overlap profile are assessed in a continuous 
score and shown to correlate over 90% with independent verification methods. We 
compared these data with our large internal cohort of 68,000 subjects, with carefully 
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mapped CNVs, which gave a robust rare variant frequency in unaffected populations. In 
these investigations, we uncovered a number of loci in which CNVs are significantly 
enriched in non-coding RNA (ncRNA), Online Mendelian Inheritance in Man (OMIM), 
and genome-wide association study (GWAS) regions, impacting complex disease. By 
evaluating thoroughly the variant frequencies in pediatric individuals, we subsequently 
compared these frequencies in geriatric individuals to gain insight of these variants’ 
impact on lifespan. Longevity-associated CNVs enriched in pediatric patients were found 
to aggregate in alternative splicing genes. Congenital heart disease is the most common 
birth defect and cause of infant mortality. When comparing congenital heart disease 
families, with cases and controls genotyped both on SNP arrays and exome sequencing, 
we uncovered significant and confident loci that provide insight into the molecular basis 
of disease. Neurodevelopmental disease affects the quality of life and cognitive potential 
of many children. In the neurodevelopmental and psychiatric diseases, CACNA, GRM, 
CNTN, and SLIT gene families show multiple significant signals impacting a large 
number of developmental and psychiatric disease traits, with the potential of informing 
therapeutic decision-making. Through new tool development and analysis of large 
disease cohorts genotyped on a variety of assays, I have uncovered an important 
biological role and disease impact of CNV in complex disease. 
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Chapter 1  
1.1 Introduction and Significance 
Francis Crick and James Watson used the clues of Chargaff’s base ratio rules and 
Franklin’s X-ray crystallography to deduce the biochemical interactions that create the 
DNA double-helix, the fundamental information source for human health and disease 
biology. In an iterative process, the Human Genome Project has created the first draft 
sequence of the human genome and a number of major revisions (builds) every few 
years. The HapMap project assessed common (>5%) minor allele frequency variants in 
populations across the globe using SNP arrays. The ongoing 1000 genomes project aims 
to assess rare (<1%) minor allele frequency variants in populations across the globe using 
SNP arrays, in addition to exome and genome sequencing.  
 
1.1.1 Copy Number Variation 
 
Copy number variants (CNVs) are deviations from the expected one maternal and 
one paternal copy of DNA in a given genomic segment. Similar to considering four 
possible nucleotide bases at each DNA point (A, T, C, and G), we consider five possible 
copy states at each DNA point (0, 1, 2, 3, and 4). We expect that at most genomic loci, 
individuals have copy state two, termed diploid. Similar to linkage disequilibrium blocks 
where base genotypes are found in discrete patterns termed haplotypes, CNVs typically 
show larger segments with the same copy state at each point, although it is not clear to 
what extent these segments co-localize. While linkage disequilibrium is mediated by 
recombination hotspots, CNV segments are mediated by unequal crossing over due to 
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highly similar base sequences such as segmental duplications or repeats. Non-allelic 
homologous recombination is the primary mechanism for CNV formation. While base 
changes may affect the resulting 
amino acid at a given point, 
CNV affects the gene dosage 
and expression level in most 
cases of the entire amino acid 
chain product. The deleted copy 
number (CN) one or duplicated 
CN three or four may be 
maternal or paternal with the 
corresponding bases in the 
segment causing different impact, especially in imprinted regions. The duplication may 
be tandem or dispersed. A run of homozygosity (ROH) is similar to a deletion with 
respect to a singular base genotype sequence for a given segment, but having two 
identical copies. Mosaicism is defined as a percentage of cells being diploid and a 
percentage of cells having a CNV leading to a complex mixing pattern and possible cell-
type or organ-type specific pathology. Inversion is a segment where the maternal copy is 
inverted with respect to the paternal copy. Insertion is a novel sequence inserted into a 
segment. Since ROH, mosaicism, inversion, and insertion do not fit the strict definition of 
CNV, they are termed more broadly as structural variations (Figure 1.1). 
Rare and common CNVs 
Figure 1.1. Schematic representations of copy number 
variation (CNV) stages evaluated in the human genome 
 
 
 
Example structural variation deviations from reference. 
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Typically, we look for rare recurrent CNVs present in <1% of the population, but in more 
than one patient to identify if the phenotype is consistent. The vast majority of samples 
possessing normal diploid signals forms a reference baseline and supports the assumption 
made by clustering that the majority of samples in the population are diploid. However, if 
there is a relatively high standard deviation of normal samples, a sample observed in 
isolation may appear falsely to have a CNV. A common CNV has more of the population 
with the CNV signal, forming a representative profile for each CN state, but can be 
unclear due to some copy alleles being out of Hardy-Weinberg equilibrium due to 
embryonic lethality. Therefore, a three CN clustering SNP may be (0,1,2), (1,2,3), or 
(2,3,4) based on which mode is considered the diploid mode. Consequently, it is good to 
have baseline known CN state samples for particular genomic loci. 
1.1.2 Copy Number Variation Assays 
 
Historically, CNVs were first identified by karyotyping. Today, there are four 
major genome-wide assays used to assess CNV, ordered in terms of sophistication and 
price: array comparative genomic hybridization (aCGH), SNP microarray (array), whole 
exome sequencing (WES), and whole genome sequencing (WGS). aCGH provides 
intensity data (normalized at 0 for diploid) only so modes of relative less intensity are 
indicative of deletion. Modes of relative more intensity are indicative of duplication. 
Higher degrees of mosaicism may also be detectable, although mostly simplified into the 
discrete deletion or duplication states. SNP microarray provides both intensity and 
genotype data (normalized at 0, 0.5 and 1 for AA, AB, and BB, respectively) for 
haplotype tagging points across the genome. The paired genotype data is important 
confirmatory information, in which deletions have only homozygous genotypes in the 
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less intensity segment, and multiple heterozygote allelic genotype banding in the more 
intensity segment. Furthermore, ROH may be detected when many homozygous 
genotypes are paired with expected normal diploid intensity. Genotype frequencies show 
banding indicative of mosaicism. WES uses targeted exon capture genome wide to assess 
only protein coding gene content, which is of primary importance for base and copy 
variants, alike. However, due to the discontinuous coverage and larger gaps between 
exons of neighboring genes, flanking diploid data may not be available to observe a clear 
mode shift for state transition Hidden Markov Model (HMM) detection and boundary 
resolution of CNVs. Only exon-level intensity is used to inform CNV detection following 
principal components analysis (PCA) outlier removal and z-score normalization of wavy 
read depth data from exome capture. Therefore, the WES data utilization remains 
constrained to deletion and duplication detection, similar to aCGH with less uniform 
genomic coverage. WGS has the ultimate data potential to resolve the whole spectrum of 
structural variation, leveraging novel complementary features of pairs and split to resolve 
inversion and insertion, which are 
elusive to the other major 
technologies. In addition to low 
intensity and only homozygous 
genotypes at dbSNP positions, pairs 
distance high and split observed 
supports deletion calling. In 
addition to high intensity and 
triallelic genotypes at any position, low pairs distance and split reads rescuing orphan 
Figure 1.2. Assay resolutions for CNV platforms 
 
 
 
Different genomic platforms are shown delineating 
different coverage and density. 
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read pairs support duplication calling. While the whole genome is theoretically 
sequenced, some regions are poorly sequenced or mapped to the genome creating 
residual variability and imperfect continuous coverage (Figure 1.2). 
The broad scope of this dissertation includes CNV detection in assays (SNP array 
and whole exome sequencing) and association with diseases, including congenital heart 
disease, neurodevelopmental disease and a few other major disease categories together 
with longevity.  Comparisons are also being made between different study designs, where 
both family-based de novo and transmitted CNVs are being evaluated together with 
standard case-control design. 
 
Sample sources 
Blood is the DNA source of choice for ease of collection and quantity of quality 
DNA for genotyping. Saliva is easier for collection in infants but does not reliably yield 
the proper DNA for non-wavy intensity signals in genotyping. Cell-lines yield great 
quantities of DNA but can cause CNV artifacts from Epstein-Barr Virus transformation 
and immortalization. Tumor samples have many complex CNVs and heterogeneity from 
clonal expansion of cell subpopulations acquiring new CNVs. Over 95% of the 68,000 
samples presented here are blood-derived. 
CNV Verification 
For verification, PCR probes are sufficient to confirm CNV presence, as hybridization to 
specific regions in the CNV sample yields differing amplification curves compared to a 
normal diploid sample.  Experimental validation is additionally performed to verify 
specific CNV sizes and frequencies to ensure the CNV calls are accurate. 
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Key Biological Questions 
We have one genomic reference sequence, which is present with high fidelity throughout 
the human body, yet we have different programs in operation stabilizing distinct cell 
types. How does one genome encode 200 cell types? There are many CNVs detected by 
certain assays but less is known about which CNVs contribute to complex disease. The 
assays provide discontinuous and variable-quality data. How do we decipher 
discontinuous genome/gene data? We wish to optimize the number of true positives 
without missing any true signal, yet being too aggressive will lead to false calls. How do 
we balance maximizing true signals and minimizing false signals? We will explore these 
motivating questions throughout the dissertation. 
1.2 Landscape in Genetic Disease 
Monogenic Disease 
By reviewing families in pedigrees, simple recessive and dominant modes of 
inheritance are apparent, where the mutations of a single gene penetrate into a disease 
phenotype. Phenylketonuria, cystic fibrosis, sickle-cell anemia, and oculocutaneous 
albinism are examples of human autosomal recessive diseases. Huntington's disease, 
myotonic dystrophy, familial hypercholesterolemia, neurofibromatosis, and polycystic 
kidney disease are examples of human autosomal dominant diseases. Incomplete 
penetrance, genomic imprinting, uniparental disomy, and a variety of other factors 
account for imperfect inheritance models.  Most monogenic diseases are caused by 
mutations that are SNVs. 
Complex Disease 
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Most genetic disorders are complex and multi-factorial, or polygenic, meaning 
they are likely associated with the effects of multiple genes in combination with lifestyles 
and environmental factors. Multi-factorial disorders include heart disease, diabetes, 
asthma and arthritis to name a few. Although complex disorders often cluster in families, 
they do not have a clear-cut pattern of inheritance, making it difficult to determine the 
risk of inheriting these disorders. Complex disorders are also difficult to study and treat 
because the specific factors that cause these disorders have not yet been identified. 
Based on pedigree information, polygenic diseases do tend to run in families, but 
the inheritance pattern does not fit simple Mendelian disease patterns; however, this does 
not mean that the genes cannot eventually be located and studied. There is also a strong 
environmental component to many of these polygenic diseases (e.g., high blood 
pressure). 
 
1.3 Study Design for Genetics Disease Discovery  
Case-Control 
To identify complex disease loci, it is crucial to uniformly genotype large patient 
cohorts of those affected and unaffected by the disease of interest. Doing so allows for a 
more generalized scope of the case and control populations, as well as flexible patient 
recruitment. Population stratification must be corrected, using the principal components 
analysis as a covariate in association. With an arbitrarily large control cohort, we gather a 
more robust control minor allele frequency definition and increase the power for 
association p-value compared to family-based studies.  In addition, unaffected parents 
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used as controls may indeed have subtle phenotypes related to the disease; thus, an 
unaffected population control may be more suitable. 
 
Family Trios and Transmission Disequilibrium Test 
Families are immune to population stratification biases. For cases where a parent is 
heterozygous for an allele, the major or minor allele may be biased in its transmission 
rate across many families, specifically with unaffected parents and an affected child. 
Families require verification through a reasonably low inheritance error rate. 
 
De novo 
De novo is a Latin expression meaning new. De novo mutation is a genetic 
mutation that neither parent possessed nor transmitted. de novo CNVs are the clean 
explanation of unaffected parents, but an affected child, namely a novel variant not 
present in the parents is present in the child. True de novo CNVs are exceedingly rare, 
especially when considering the desired recurrent de novo at a particular locus associated 
recurrently with a disease phenotype. 
Statistics 
Fisher’s Exact Test involves defining a two by two contingency table of: counts 
case CNV (a), case not CNV (b), control CNV (c), and control not CNV (d). Instead of 
all CNV, we may count deletions separately from duplications of each copy number state 
separately. The probability is given by the hypergeometric distribution: 
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 The transmission disequilibrium test is defined as: the quantity transmitted minus 
untransmitted squared divided by the quantity transmitted plus untransmitted. The 
distribution follows a chi squared with 1 degree of freedom.  
Χ2 = (transmitted – untransmitted)2 / (transmitted + untransmitted)  
1.4 Congenital Heart Disease 
 
Heart defect subtypes, clinical picture 
 
Congenital heart disease 
(CHD) is a leading cause of infant 
mortality and accounts for one 
third of all birth defects. While 
population and familial studies 
have improved our understanding 
and diagnosis of CHD,  only about 
20% of the genetic architecture of 
CHD defects has been resolved. 
Present at birth, CHD is a 
defect of the heart and great 
vessels structure. Numerous types 
Figure 1.3. Heart Defect Locations 
 
 
 
Locations of heart malformations that are usually identified 
in infancy, and estimated prevalence based on the 
CONCOR database. Numbers indicate the birth prevalence 
per million live births. AS indicates aortic stenosis; ASD, 
atrial septal defect; AVSD, atrioventricular septal defect; 
CoA, coarctation of the aorta; Ebstein, Ebstein anomaly; 
HLH, hypoplastic left heart; MA, mitral atresia; PDA, 
patent ductus arteriosus, PS, pulmonary stenosis; PTA, 
persistent truncus arteriosus; TA, tricuspid atresia; TGA, 
transposition of the great arteries; SV, single ventricle; 
TOF, tetralogy of Fallot; and VSD, ventricular septal 
defect. 
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of heart defects occur, either by obstructing blood flow in the heart or vessels, or by 
causing blood to flow through the heart in an abnormal pattern, mixing oxygenated with 
deoxygenated blood (Figure 1.3).  
The most common heart defect is ventricular septal defect (VSD) at a prevalence 
of 0.36% of live births based on the CONCOR database, a national registry and DNA-
bank of patients with CHD in the Netherlands. The ventricular septum serves as a 
separating wall between left and right ventricles. The ventricular septum contains many 
cardiomyocytes. 
Atrial septal defect (ASD) occurs in 0.09% of live births, and is a defect of the 
interatrial septum, allowing blood to flow incorrectly between left oxygenated and right 
deoxygenated blood atria. Oxygen levels in arterial blood are often lower than normal, 
depending on the size of the defect. 
Patent ductus arteriosus (PDA) occurs in 0.08% of live births. In PDA, the ductus 
arteriosus remains open incorrectly after birth causing abnormal blood transmission to the 
aorta and pulmonary artery. 
 Pulmonary stenosis (PS) occurs in 0.07% of live births, and is a defect that 
obstructs the flow of blood from the right ventricle to the pulmonary artery. 
Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), and aortic stenosis (AS) 
each occur in 0.04% of live births. TOF involves four anatomical abnormalities of the 
heart: pulmonary infundibular stenosis (right ventricular outflow narrowing), overriding 
aorta (aortic valve with biventricular connection), ventricular septal defect (hole between 
bottom chambers), and right ventricular hypertrophy (hyper-muscular right ventricle). 
11 
 
CoA involves narrowing of the aorta, where ductus arteriosus inserts. AS involves 
narrowing of the aortic valve connecting the left ventricle with the aorta. 
Atrioventricular septal defect (AVSD), transposition of the great arteries (TGA), 
and hypoplastic left heart (HLH) each occur at 0.03% of live births. AVSD is an 
atrioventricular septum deficiency. TGA is an abnormal arrangement of superior/inferior 
venae cavae, pulmonary artery, pulmonary veins, and aorta. HLH is an 
underdevelopment of the left ventricle. 
Persistent truncus arteriosus (PTA), single ventricle (SV), tricuspid atresia (TA), 
and Ebstein anomaly (EA) each occur at 0.01% of live births. PTA involves the truncus 
arteriosus not dividing into the pulmonary trunk and the aorta, as expected. SV means the 
left ventricle feeds both left and right atrium. TA involves an absent tricuspid valve; thus, 
the right atrioventricular connection, ASD and VSD, is required to maintain blood flow 
into the pulmonary arteries. EA involves the septal leaflet of the tricuspid valve being 
displaced towards the apex of the 
right ventricle of the heart. 
 
Known Causes of CHD 
Large chromosomal abnormalities, 
such as trisomies 21, 13, and 18, 
cause 5-8% of cases of CHD. 
Microdeletion of 22q11 (DiGeorge 
syndrome), 1q21, 8p23, and other 
loci identified by array 
Figure 1.4. Genomic Regions of Congenital Heart Disease 
Associations   
 
 
 
Blue: Developmental Syndromes With Prominent CHD 
Phenotypes 
Red: Copy Number Variations (CNVs) Associated With 
Recurrent Cases of Non-syndromic CHD(31, 50, 78, 132, 
165, 186, 187, 203) 
Black: Genes That Cause Isolated CHD 
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comparative genomic hybridization (aCGH), are cataloged in the database CDHWiki. 
 
Mutations of a heart muscle protein, α-myosin heavy chain (MYH6), are 
associated with atrial septal defects. Several proteins that interact with MYH6 are also 
associated with cardiac defects. The transcription factor GATA4 forms a complex with 
TBX5, which interacts with MYH6. Another factor, the homeobox (developmental) gene, 
NKX2-5, also interacts with MYH6. Mutations of these proteins are associated with both 
atrial and ventricular septal defect. In addition, NKX2-5 is associated with defects in the 
electrical conduction of the heart; TBX5 is related to the Holt-Oram syndrome, which 
includes electrical conduction defects and abnormalities of the upper limb. Another T-
box gene, TBX1, is involved in velo-cardio-facial syndrome, or DiGeorge syndrome, the 
most common deletion syndrome, which has extensive symptoms, including defects of 
the cardiac outflow tract and 
tetralogy of Fallot. The Notch 
signaling pathway, a regulatory 
mechanism for cell growth and 
differentiation, plays broad roles in 
several aspects of cardiac 
development.  Mutations of a cell 
regulatory mechanism, the 
Ras/MAPK pathway, are 
responsible for a variety of 
Figure 1.5. Genes That Cause Isolated CHD Protein-
Protein Interaction DAPPLE Network 
 
 
 
Permutation p-value of connectivity is shown by shade of 
color. 
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syndromes, including Noonan syndrome, LEOPARD syndrome, Costello syndrome, and 
cardiofaciocutaneous syndrome.  A significant proportion of this thesis work focuses on 
CNV analysis in children with CHD and their family members. 
 
Numerous genomic loci are implicated in CHD phenotypes (Figure 1.4). A network of 
interacting genes, based on protein-protein interactions, is also emerging (Figure 1.5). 
1.5 Neurodevelopmental Disease  
The following diseases are briefly reviewed and CNV analysis subsequently performed 
jointly across all disease phenotypes. 
Autism 
Autism presents as impaired social interaction, distinct verbal/non-verbal 
communication, and restricted/repetitive behavior typically in children by three years of 
age. Autism affects neural development and information processing in the brain by 
altering how nerve cells and their synapses connect and organize. Autism spectrum 
disorders (ASD) include Asperger syndrome and pervasive developmental disorder, not 
otherwise specified (PDD-NOS). Autism has a strong genetic basis based on very high 
heritability in families, although the genetics of autism are complex and it is unclear 
whether ASD is explained more by rare mutations, or by rare combinations of common 
genetic variants. All of these phenotypes are examined in detail in this thesis project. 
ADHD  
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental psychiatric 
disorder characterized by issues with attention, hyperactivity, or impulsive activity that 
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are inappropriate for a person's age, presenting typically by ages six to twelve. ADHD is 
diagnosed approximately three times more frequently in boys than in girls. 
ADHD management usually involves some combination of counseling, lifestyle 
changes, and medications. Medications are only recommended as a first-line treatment in 
children who have severe symptoms, and may be considered for those with moderate 
symptoms who either refuse or fail to improve with counseling. Long-term effects of 
medications are not clear and they are not recommended for preschool-aged children. 
Schizophrenia 
Schizophrenia is a mental disorder often characterized by abnormal social 
behavior and failure to recognize reality. Common symptoms include false beliefs, 
auditory hallucinations, confused or unclear thinking, inactivity, and reduced social 
engagement and emotional expression. Symptoms begin typically in young adulthood 
(13-18) and about 0.3–0.7% of people are affected during their lifetime. 
The mainstay of treatment is antipsychotic medication, which primarily 
suppresses dopamine receptor activity. Counseling, job training, and social rehabilitation 
are also important in treatment. In more serious cases, where there is risk to self or others, 
involuntary hospitalization may be necessary, although hospital stays are now shorter and 
less frequent than they once were. 
Bipolar Disorder 
Bipolar disorder is a mental illness characterized by episodes of elevated moods, 
known as mania, alternating with episodes of depression. During manic episodes, an 
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individual feels abnormally happy, energetic, or irritable, but often makes poor decisions 
due to unrealistic ideas, or poor regard of consequences. Manic and depressive episodes 
can impair the individual's ability to function in ordinary life. The most common age at 
which symptoms begin is 25. 
About 3% of people have bipolar disorder worldwide, a proportion consistent for 
both men and women and across racial and ethnic groups. Treatment commonly includes 
mood stabilizing medications and psychotherapy. 
Depression 
Major depressive disorder (MDD) is a mental disorder characterized by a 
pervasive and persistent low mood that is accompanied by low self-esteem and by a loss 
of interest or pleasure in normally enjoyable activities. The most common time of onset is 
between the ages of 20 and 30 years, with a later peak between 30 and 40 years. 
Typically, people are treated with antidepressant medication and, in many cases, 
also receive counseling. Psychological treatments are based on theories of personality, 
interpersonal communication, and learning. Most biological theories focus on the 
monoamine chemicals serotonin, norepinephrine and dopamine, which are naturally 
present in the brain and assist communication between nerve cells. 
 
Known CNV Gene Associations in Neurodevelopmental Disease 
CACNA 
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Voltage-dependent calcium channels mediate the entry of calcium ions into excitable  
cells, and are also involved in a variety of calcium-dependent processes, including muscle 
contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are 
multi-subunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The 
channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as 
auxiliary subunits regulating this activity. The distinctive properties of the calcium channel 
types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, 
D, E, and S.  
GRM 
G-protein coupled receptor for glutamate. Ligand binding causes a conformational 
change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and 
modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-
calcium second messenger system. GRM may participate in the central action of glutamate in 
the CNS, such as long-term potentiation in the hippocampus and long-term depression in the 
cerebellum. 
 
CNTN 
The protein encoded by this gene is a member of the immunoglobulin 
superfamily. It is a glycosylphosphatidylinositol (GPI)-anchored neuronal membrane 
protein that functions as a cell adhesion molecule. It may play a role in the formation of 
axon connections in the developing nervous system. Contactins mediate cell surface 
interactions during nervous system development. CNTN is involved in the formation of 
paranodal axo-glial junctions in myelinated peripheral nerves and in the signaling 
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between axons and myelinating glial cells via its association with CNTNAP1. CNTN 
participates in oligodendrocytes generation by acting as a ligand of NOTCH1. Interaction 
with Tenascin-R induces a repulsion of neurons and an inhibition of neurite outgrowth. 
SLIT 
The protein encoded by this gene is secreted, likely interacting with roundabout 
homolog receptors to effect cell migration. SLIT may act as molecular guidance cue in 
cellular migration, and function may be mediated by interaction with roundabout 
homolog receptors. 
Given this perspective on the field of CNV detection and association that I have 
already contributed to in a significant way, we proceed into the specific aims and scope 
of this dissertation project aimed at improving CNV discovery, analysis and 
interpretation. 
1.6 Specific Aims 
 
Revealing functionally important variants in the human genome for different cell types, 
in complex disease such as heart, is a major challenge.  Congenital heart defects are a 
leading cause of infant mortality and contribute to one third of all birth defects(52). 
 Population and family studies look to advance the early diagnosis and treatment of heart 
defects by understanding the genetic architecture, a quarter of which has been resolved 
(52).  Efforts in DNA data assessment are shifting from SNP array and aCGH to whole 
exome and genome sequencing (36, 146).  However, the use of these methods presents a 
significant limitation in confident association of variant bases (SNPs) and copies (CNVs 
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The overall goal of this project is to revolutionize the association of genetic variation to 
complex disease, representatively addressed through in-depth examination of 
neurodevelopmental disorders ad congenital heart defects, by fundamentally improving 
the integrated array and exome analysis for copy variation.  This work is now possible by 
having access to large disease populations on exomes with high resolution on genes.  Our 
lab has unique access to a large family cohort of heart defect patients studied on array and 
exome platforms.  My previous CNV work  from SNP array data importantly uncovered 
rare recurrent CNVs impacting ubiquiting and neuronal cell adhesion molecule genes 
impacting  brain cell function in children with autism (65), CNV enrichment in synaptic 
transmission genes in schizophrenia  (67), and disruption in metabotropic glutamate 
receptor genes in ADHD(49). 
 
To advance the field, it is necessary to improve confidence related to association of 
exome and array variants with heart defects, thus opening up better detection and 
treatment options.  I am proposing to test the hypothesis that de novo CNVs contribute to 
the etiology of complex diseases, such as CHD with the following specific aims: 
 
Aim 1: To determine impact of de novo CNVs in complex disease, I will compare de 
novo CNV frequency between CHD families and healthy control families (termed 
burden). 
I hypothesize that uncovering de novo CNV in critical genes and pruning false genes will 
yield a more complete and accurate genomic architecture of heart defect tested by 
validation. 
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We have uncovered and reported significantly increased burden of de novo CNVs in 
congenital heart disease compared to controls with an odds ratio of approximately 4.  To 
optimize CNV results, we prioritize putative de novo CNVs by the trio recall option in 
PennCNV, use at least 2 algorithms to call de novo events (PennCNV, QuantiSNP, and 
Nexus), evaluate parental origin (if enough informative markers), ensure there are greater 
than 5 SNPs per locus and we have low/absent untransmitted CNV rate.  We also make 
sure there is low/absent control rate in public databases (DGV, SSC healthy trios, CHOP 
control, Framingham), that BAF/LRR inspection passes quality control measures (full 
trio in case false negative parent), and that the CNV is confirmed by ddPCR validation. 
Non-allelic homologous recombination (NAHR) is the primary biological mechanism to 
create CNVs (1 mother and 1 father copy deviation) which intriguingly affect expression 
dosage (86, 196) and imprinted (45) heart loci. CNV is noisier than SNP data and 
occupies genomic non-standard ranges rather than points, posing novel challenges 
addressed here by capturing significant CNV profiles which may be atypical. Here, I will 
implement bi-directional (detrimental, neutral, protective) gene/pathway based 
association to improve sensitivity over existing collapsing methods. I will create a formal 
CNV association confidence score based on a variety of rare genomic, variant, and 
overlap features to improve specificity over existing heuristics, validated by qPCR. 
 
Aim 2: To identify and define CNV genes, I will look for true recurrent de novo 
CNVs. 
20 
 
I hypothesize that relatively dense and uniform genome coverage will provide good CNV 
detection and boundary definition yielding significant heart biology further evidenced by 
gene expression. 
We observed novel recurrent de novo CNVs in four families on 15q11.2 encompassing 
CYFIP1, NIPA1, and NIPA2.Study experiments include diagnosed heart defect, parents 
and healthy control blood samples collected in the clinic, DNA extracted, and Array and 
Exome genotyping performed in the lab. Using improved association methods from Aim 
1, I can now confidently evaluate array data of heart defect families and controls boosting 
discovery of 1 gene with existing methods to 10 genes. These genes will aggregate in 
biological categories of transcriptional regulation, signal transduction, cardiac structure, 
and histone-modifying. I will use the latest sequencing informed SNP array Illumina 
Omni2.5 on 400 trios, 900 cases, and 1000 controls for de novo, TDT, and case-control 
analysis. Potential de novo CNVs will be prioritized using trio recall prior probability, 
parental origin, untransmitted (TDT), and control (case-control) data. Given low 
heritability of heart defect, de novo variants may play a large role. I will further prioritize 
the heart biology search informed by our parallel research finding of 4,162 genes 
expressed in the top 25% of developing heart by RNA-seq analysis. 
 
Aim 3: To assess biological gene function of single de novo CNVs, I will perform 
integrative gene network analysis of multiple datasets. 
I hypothesize that a gene focused CNV study will better resolve functional boundaries of 
complementing CNVs shown to exist by array and novel submicroscopic CNVs. 
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De novo CNV genes form a significant protein-protein interaction network hub 
elaborated by de novo base variant genes. After the heart genome association map is 
elucidated by Aim 2, I can now enhance the picture by fine resolution on genes. Exome 
sequencing exhibits very discontinuous data and most platforms have wavy read depth 
due to DNA capture and sequencing mapping biases normalized by PCA. Exon based vs. 
base level intensity, genotype, pairs, and split will be used for filtering higher confidence 
variants. Exome sequencing specific confidence features will be devised for CNV 
association.  
 
Much emphasis is placed on CNV detection but relatively little is placed on 
association. PennCNV arose as the dominant CNV calling algorithm for SNP arrays, but 
no accompanying association tool existed.  In chapter 2 I describe a new tool I developed 
to confidently evaluate CNVs for association with biological traits. In the following 
chapters I address the biological impact of CNVs in CHD and neurodevelopmental 
disorders as outlined in Specific Aims 1-3. 
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Chapter 2  
2.0 ParseCNV Integrative Copy Number Variation Association 
Software with Quality Tracking 
 
Summary 
A number of copy number variation (CNV) calling algorithms exist, however 
comprehensive software tools for CNV association studies are lacking. Here, we 
developed ParseCNV, unique software which takes CNV calls and creates probe-based 
statistics for CNV occurrence in both case-control design and in family-based studies 
addressing both de novo and inheritance events which are then summarized based on 
CNV regions (CNVRs). CNVRs are defined in a dynamic manner to allow for a complex 
CNV overlap while maintaining precise association region. Using this approach, we 
avoid failure to converge and non-monotonic curve fitting weaknesses of programs such 
as CNVtools and CNVassoc and while Plink is easy to use, it only provides combined 
CNV state probe-based statistics, not state specific CNVRs. Existing CNV association 
methods do not provide any quality tracking information to filter confident associations, a 
key issue which is fully addressed by ParseCNV. In addition, uncertainty in CNV calls 
underlying CNV associations is evaluated to verify significant results including CNV 
overlap profiles, genomic context, number of probes supporting the CNV, and single 
probe intensities. When optimal quality control parameters are followed using ParseCNV, 
90% of CNVs validate by polymerase chain reaction (PCR), an often problematic stage 
due to inadequate significant association review. ParseCNV is freely available at 
http://parsecnv.sourceforge.net. 
23 
 
2.1 Introduction and Significance 
CNV association is being increasingly adopted in genetic investigations of disease 
susceptibility loci (64, 116). Large de novo CNVs were once considered to be the cause 
of syndromes, but more complete CNV maps now show that CNVs pervade the genome 
and small CNVs can also be disease causing (35). Thus, CNV frequency difference 
between cases and controls at specific loci is necessary to determine if a given CNV 
plays a role in disease or impacts the expression of a clinical trait. Conceptually, the most 
important variables involved in CNV analysis include disease under study, sample 
cohort, array data, CNV calling algorithm and data interpretation using an algorithm 
implementing CNV statistics. CNV calling and methods of demonstrating association 
have been hampered by many challenges which has discouraged researchers from 
investigating CNVs. ParseCNV is designed to simplify  data processing and improve 
transparency to render CNV studies more accessible to researchers. 
Many CNV calling algorithms have been developed but relatively few CNV 
association methods exist. As a result, streamlined implementation of association 
methods is lacking. CNV calling algorithms evaluate allelic intensity and genotype states 
in the case of SNPs, whereas CGH signal is based on intensity alone. Typically, both 
SNP and CGH arrays assess raw data for CNVs at the genome wide level with discrete 
genetic determinants.  The latter include  CN=0, 1, 2, 3, 4 copy number states captured by 
both SNP and CGH arrays, together with AA, AB, BB genotype states for SNP arrays.   
Since the intensity of array probes have a Gaussian distribution, clustering algorithms are 
used to determine the expected value for a given state based on a population from which 
variation of a given sample can be quantified as a LogR-Ratio/Log2-Ratio, together with 
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B allele frequency for SNP arrays (156).  PennCNV (211) is a popular option for SNP 
array analysis, implementing a hidden Markov model algorithm. A number of other CNV 
calling options are available, including QuantiSNP (34), CNVCALL (24), CNVDetector 
(27), CGHCall (206), and CNV-Seq (222), all of which are publicly available tools and 
highly enabling to researchers. 
While there are several available CNV association methods in the public domain, 
including CNVtools (likelihood ratio trend test)(9), Birdsuite (regression sum number 
copies each allele) (112), Plink (permutation-based test) (167), and CNVassoc (latent 
class model) (197), all of them have significant limitations as they lack simple standard 
input and integrative reporting functions, which limits their discovery power, 
investigation potential, and validation success (Supplementary Note). While CNVtools 
and CNVassoc do both CNV calling and association, they make the actual CNV calls 
hidden to the user and are batch dependent.   Here we demonstrate the robustness of 
ParseCNV in producing high quality CNVR calls by improving transparency and 
accuracy of CNV association studies. 
 
2.2 Materials and Methods 
2.2.1 Upfront Quality Control 
 
Since multiple confounding factors can bias the detection of CNV calls, it is essential to 
apply filters, using sample based quality metrics affecting CNV detection accuracy. 
Several steps are taken upfront to remove samples with outlier values for the CNV 
metrics which can be briefly conceptualized as: low call rate, intensity noise, intensity 
waviness, population stratification, high number of CNVs, and relatedness. In this regard, 
25 
 
there are several important sample quality metrics measures, specifically: 1) sample call 
rate/clustering quality; 2) standard deviation of allelic intensity (SD LRR); 3) G/C base 
content waviness factor (GCWF); 4) count CNV; 5) majority ethnicity cluster using 
principle components analysis from Eigenstrat smartpca (163), multi-dimensional scaling 
(MDS) (125) or population stratification correction by covariate, and; 6) no duplicates.  
For Illumina 550k data and related Illumina chip platforms, the key data quality metric 
thresholds we have observed are: call rate > 98%, SD LRR < 0.3, |GCWF| < 0.05, and 
count CNV< 100.  For Affymetrix 6.0 data, these measures include: call rate > 96%, SD 
LRR < 0.35, |GCWF| < 0.02, and count CNV < 80.  In addition, observations of quality 
metric modes from individual labs and sample sources are advisable to determine 
appropriate QC thresholds. The distribution of these metric measures are constantly 
reviewed to include only those that fall within three standard deviations from the mean or 
a linear mode of the quality metric outside exponential modes for any given genotyping 
platform. Sample call rate/clustering quality and standard deviation of allelic intensity are 
crucial minimal sample exclusion metric measures that have been established as a field 
consensus (158). By providing the PennCNV log files (i.e., summary lines), together with 
GenomeStudio/GenotypingConsole/Plink missing call rates as input, ParseCNV 
generates images of the distributions of these quality metrics values to make informed 
decisions of the necessary data thresholds needed (balancing the tradeoff between sample 
number attrition and study bias). Also, different CNV calling programs provide different 
quality control fields so less standardization of input is possible. Among several high-
quality programs that are available, we find PennCNV to provide the most complete 
quality metrics. 
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2.2.2 Input Files 
 
After generation of CNV calls, independent of algorithm, CNV association is 
performed by the newly developed ParseCNV algorithm. ParseCNV utilizes four 
standard inputs: case CNV calls 
(PennCNV format is the default but 
any CNV calling method may be 
used), control CNV calls 
(PennCNV format), fam file (Plink 
format), and probe map file (Plink 
format) (Figure 2.1).  
 
Optional input of raw signal 
files used as input to the CNV 
calling algorithm allows raw 
genotype (B-allele frequency 
(BAF) if available) and intensity 
(LogR-Ratio (LRR) or Log2-Ratio) 
(156) signals of associated regions 
to be parsed with an image that is 
automatically generated for review. Sample batches can be defined to track their expected 
vs. observed contribution to significant associations. 
2.2.3 Probe-Based CNV Statistics 
 
The general outline of data processing involves mapping the individual level CNV calls 
into population level probe-based CNV statistics followed by filtering significantly 
Figure 2.1. CNV Analysis Workflow. 
 
 
 
Pre-processing, file formats, and post-processing. This 
general framework shows the stepwise procedure to 
prepare input data to utilize and evaluate ParseCNV output. 
“...” represents additional columns not shown. 
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associated population CNV Regions (CNVRs). CNV calls are mapped onto probe based 
statistics defined by the probe map file and tested for significance based on Fisher’s exact 
test. The Fisher’s exact test statistic consists of a two by two contingency table (with 
cases deleted vs. cases not deleted and controls deleted vs. controls not deleted) and is 
evaluated separately for 
duplications. This is a conceptual 
medium between associating all 
CN states separately and all CNVs 
together (Figure 2.2).  
Singular state and combined 
state statistics are also calculated 
for reference. Probes without 
nominal significance (p<0.05) are 
discarded from further association 
testing. Case-enriched significant 
probes are then separated from 
control-enriched significant probes.  
If a family based study is 
being done, the transmission disequilibrium test (TDT) is calculated and used to drive 
CNVR definition. Quantitative trait association is also supported by running ParseCNV 
with the includePed option, Plink association, and InsertPlinkPvalues (part of 
ParseCNV). 
2.2.4 Merging Probe Based Statistics into CNVRs 
 
Figure 2.2. Possible Statistical Contingency Table 
Definitions to Capture CNV Frequency Difference in Cases 
vs. Controls.  
 
 
The middle statistical definition of deletions signifying loss 
of function mutations and duplications signifying gain of 
function mutations is used predominantly. This is in 
contrast to a view that all CNVs are all similarly 
detrimental put forth by the top statistical definition and the 
view that all CNV states lead to a unique outcome put forth 
by the bottom statistical definition. 
28 
 
Flexibility in probe aggregation incorporated into CNVRs allows for boundary 
truncation variability problems inherent in many CNV calling algorithms and dynamic 
case/control overlap to be made, while refining the association region. The above 
mentioned probe-based statistic output is then merged into CNVRs based on probe 
proximity (less than 1MB) and comparable significance (+/- one log p-value) of 
neighboring probes. One Mb allows for extension of CNVRs over sparse probe coverage 
regions. This can be tuned by command line option in keeping with the average probe 
spacing of the dataset or can be made region-specific based on the distance of 5-10 
proximal probes.  
CNV boundary 
determination remains a challenge 
to differentiate true boundary 
variations vs. variability in the 
probe’s ability to differentiate CNV 
states.  The difficulty is typically 
attributed to noisy probes within 
true CNVs.  Thus, certain 
fluctuation in CNV frequency of 
cases vs. controls is captured by the 
respective p-values. Some case 
calls may stop and others start within the CNVR making p-value based merging of probe 
based statistics highly flexible. Therefore, the next probe with available data may be 
noisy and any probe available substantiating the similar p-value within 1 Mb can be used 
Figure 2.3. Complex CNV Overlap and CNVR Definition 
Examples. 
 
 
 
Rectangles represent individual sample CNV call 
boundaries as provided by a CNV calling algorithm. Each 
assayed point represented by the probe framework listed in 
the map file input determines the possible boundary 
assignments. The CNVR definition assigned by ParseCNV 
is shown as a dashed box. Small variance in individual 
CNV call boundaries allows extension of CNVR definition. 
CNV peninsula is shown as the most common false 
positive based on variable extension of CNV boundary 
(typically the region common to cases and controls has 
many probes while the case only extension has few 
probes). 
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to extend the CNVR. Noisy probes cannot be filtered out before CNV calling due to lack 
of metrics with specificity for noise and not for true CNV with both behaving similarly in 
classic probe-based call rate metrics. 
Many CNV detection and association tools have difficulties handling CNVR breakpoints 
and some algorithms make the assumption of considering CNVR breakpoints as static, 
which is an oversimplification often leading to false negative results. For example, a 
static CNVR may extend outside the boundary in some cases with only partial overlap in 
controls, while having pathogenic impact. Merging neighboring probes based on 
proximity and p-value supports dynamic CNVR definition and is flexible for the CNV 
boundary variations of complex CNVs (Figure 2.3). The most significant sub-region is 
included when multiple significant proximal extensions of the respective CNVR exist, to 
reduce redundancy. 
 
2.2.5 Review of Association Signals by Quality Tracking 
 
Based on various parameters that have been referenced in the CNV literature and 
review of many putative CNV associations by informatics and PCR validation, we have 
amassed red flags for evaluation of significant CNVRs for confidence. These contributing 
CNV call features are automatically annotated, viewable in the UCSC browser and are 
specifically tailored towards reducing false positive calls from the following criteria:  
1) Many segmental duplications (i.e., nearly identical DNA segments), representing 
genomic segments that are difficult to uniquely hybridize probes to, which could underlie 
false positive CNV detection (185).  
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2) Overlapping multiple Database of Genomic Variants (DGV) (225) entries, 
representing CNV signals observed in “healthy” individuals, suggesting that a potential 
association result in the study at hand may be false. 
3) Residing at centromere and telomere proximal regions as they often have sparse probe 
coverage and only have a single flanking diploid reference to base CNV calls.  
4) Harboring high or low GC content regions that bias probe hybridization kinetics even 
after GC model correction is done by CNV calling algorithms, producing false CNV 
calling and biasing the result.  
5) CNVs captured with low average number of probes, contributing to association with 
low confidence. If an association depends on a preponderance of small CNVs, the 
likelihood of false positive is high.  
6) Locus frequently found in multiple studies such as T cell receptor, immunoglobulin, 
human leukocyte antigen, and olfactory receptor genes. T cell receptors undergo somatic 
rearrangement due to somatic recombination causing inter-individual differences in the 
clonality of T-cell populations (119) and thus are not true CNVs, necessitating exclusion. 
7) CNV regions with high population frequency (for rare CNV focused studies) indicate 
that probe clustering is likely biased due to a high percentage of samples with CNV used 
in clustering definition thus biasing CNV detection. 
8) CNV peninsula of common CNV (sparse probe coverage and nearby high frequency 
CNV) indicates that within the range of contributing CNV boundaries there is a non-
significant (p>0.05) p-value which is notably different from the CNVR association 
typically due to random extension of common CNVs to neighboring sparse or noisy 
probes (Figure 2.3).  
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9) The same inflated sample driving multiple CNV associations signals. Certain samples 
have many noisy CNV calls arising in rare regions despite upfront sample quality 
filtering.  
All these features are built into ParseCNV and are annotated automatically for optimal 
CNVR association confidence. 
10) Sparse coverage with large gap in probe coverage exists within the CNV calls 
indicating uncertainty in the continuity of a single CNV event, typically due to dense 
clusters of copy number (intensity only) probes with large intervening gaps. 
11) Low BAF AB Frequency (0.1,0.4) or (0.6,0.9) are important for duplications, AB 
banding of BAF at 0.33 and 0.66 for CN=3 or 0.25 and 0.75 for CN=4 are very important 
observations given the relatively modest gain in intensity observed in duplications. 
12) Low average confidence based on the HMM confidence score of calls contributing to 
a CNVR association in PennCNV is a superior indication of CNV call confidence 
compared to numsnps and length in studies comparing de novo vs. inherited CNV calls, 
giving an indication of the strength of the CNV signal or aggregate difference in 
probability between the called CN and the next highest probability CN. Other CNV 
calling algorithms give different range confidence scores or lower values might mean 
more confidence (i.e. call p value) so threshold may need modification. It is 
recommended to be in .rawcnv file as column 8 i.e. “conf=20.659” but not required. 
13) Low average CNV length is a classical confidence scoring parameter of interest. If 
the CNV is too small, it is submicroscopic and even if many probes are tightly clustered, 
bias of local DNA regions and probe overlap make confidence low. 
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2.2.6 Multiple Testing Correction 
 
To inform the assessment process of statistical significance of CNVR association 
and reject the null hypothesis of no association of CNVs to the disease under study, 
various CNV metrics are calculated including:  1) the number of probes with a nominal 
frequency of CNV occurrence (only probes with some CNV detected are informative) 2) 
the number of probes with enrichment in cases vs. controls and vice versa (evidence of 
more case enriched loci than control enriched loci above certain significance thresholds) 
3) probes with less than 1% population frequency of CNV (optionally for rare CNV 
studies);  and 4) the number of CNVRs (multiple probes are needed to detect a single 
CNV and these do not count as separate events for multiple testing correction). These 
calculated values provide a realistic number of statistical tests to correct for. In practice, 
using the Illumina and Affymetrix high density SNP arrays, we find p=5x10
-4
 
uncorrected p-values meet conservative multiple testing significance based on these 
criteria. 
2.2.7 CNV Validation by Quantitative Polymerase Chain Reaction (QPCR) 
 
To validate the PennCNV algorithm I performed experimental validation.  For the 
experimental CNV validation I used qPCR, including sample input of 60 ul at 6.25 ng/ul 
(to run a random set of discovery lloci and 4 house-keeping genes in triplicate at 4ul each 
run). Twenty base forward and reverse primers are developed for each locus. Universal 
Probe Library (UPL; Roche, Indianapolis, IN) probes are selected using the ProbeFinder 
v2.41 software (Roche, Indianapolis, IN). Quantitative PCR is performed on an ABI 7500 
Real Time PCR Instrument or on an ABI Prism™ 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA). Each sample is analyzed in quadruplicate either 
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in 25 ul reaction mixture (250 nM probe, 900 nM each primer, Fast Start TaqMan Probe 
Master from Roche, and 10 ng genomic DNA) or in 10 ul reaction mixture (100 nM 
probe, 200 nM each primer, 1x Platinum Quantitative PCR SuperMix-Uracil-DNA-
Glycosylase (UDG) with ROX from Invitrogen, and 25 ng genomic DNA). The values 
are evaluated using Sequence Detection Software v2.2.1 (Applied Biosystems, CA). Data 
analysis is further performed using either the ΔΔCT method or qBase. Reference genes, 
chosen from COBL, GUSB, and SNCA, are included based on the minimal coefficient of 
variation and then data was normalized by setting a normal control to a value of 1. 
The data output is 0.5 for deletions, 1 for diploid, 1.5 for duplications with standard error 
values from replicate runs. 
 
TaqMan® Copy Number Assay experiments are also run on Applied Biosystems 
7900HT Fast Real-Time PCR System to validate the presence of CNVs. Applied 
Biosystems CopyCaller™ Software performs relative quantitation analysis of genomic 
DNA targets using the real-time PCR data from TaqMan® Copy Number Assay 
experiments. Two replicates are run with confidence score >0.99 for CNV calls. Positive 
and negative controls are used to confirm probe accuracy. 
 
2.3 Results and Discussion 
I have generated a deletion and duplication CNVR report showing significant 
association, including 127 fields in a final output file with 54 highly informative fields 
included in the default output format and 11 fields in a brief report (Table 2.1) to aid 
accessibility for ParseCNV users.  
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Table 2.1.  Significant CNVR Output Fields Description 
 
Column Description 
CNVR CNV Region of greatest significance and overlap coordinates 
CountSNPs 
The number of probes available in the CNVR for this dataset In this case, 
contributing individual CNV calls may be larger 
SNP Tag SNP for ease and clarity of reporting and replication 
DelTwoTailed 
Two Tailed Fisher's Exact P-value based on the contingency table Cases 
Del/Cases Diploid/Controls Del/Controls Diploid as listed separately 
DupTwoTailed 
Two Tailed Fisher's Exact P-value based on the contingency table Cases 
Dup/Cases Diploid/Controls Dup/Controls Diploid as listed separately 
ORDel The Odds Ratio for deletion.  
ORDup The Odds Ratio for duplication.  
Cases Del The number of cases with a deletion detected in this region by PennCNV 
Cases Diploid 
The number of cases without a deletion or duplication detected in this 
region by PennCNV 
Control Del The number of controls with a deletion detected in this region by PennCNV 
Control Diploid 
The number of controls without a deletion or duplication detected in this 
region by PennCNV 
Cases Dup 
The number of cases with a duplication detected in this region by 
PennCNV 
Cases Diploid 
The number of cases without a deletion or duplication detected in this 
region by PennCNV 
Control Dup 
The number of controls with a duplication detected in this region by 
PennCNV 
Control Diploid 
The number of controls without a deletion or duplication detected in this 
region by PennCNV 
IDsCasesDel 
The sample IDs of cases corresponding to the Cases Del column for clinical 
data lookup. To convert to list in Excel: Data-TextToColumns-Delimited-
Space then Copy-PasteSpecial-Transpose 
IDsCasesDup 
The sample IDs of cases corresponding to the Cases Dup column for 
clinical data lookup. To convert to list in Excel: Data-TextToColumns-
Delimited-Space then Copy-PasteSpecial-Transpose 
StatesCasesDel CN states listed corresponding to IDsCasesDel (1(CN=0)/2(CN=1)) 
StatesCasesDup CN states listed corresponding to IDsCasesDup (5(CN=3)/6(CN=4)) 
TotalStatesCases(1) 
The number of cases in Cases Del with a homozygous deletion or both 
copies lost 
TotalStatesCases(2) 
The number of cases in Cases Del with a hemizygous deletion or one copy 
lost 
TotalStatesCases(5) 
The number of cases in Cases Dup with a hemizygous duplication or one 
copy gained 
TotalStatesCases(6) 
The number of cases in Cases Dup with a homozygous duplication or two 
copies gained 
IDsDelControl 
The sample IDs of controls corresponding to the Control Del column for 
clinical data lookup. 
IDsDupControl 
The sample IDs of controls corresponding to the Control Dup column for 
clinical data lookup. 
StatesDelControl CN states listed corresponding to IDsDelControl (1(CN=0)/2(CN=1)) 
StatesDupControl CN states listed corresponding to IDsDupControl (5(CN=3)/6(CN=4)) 
TotalStates(1) 
The number of Controls in Controls Del with a homozygous deletion or 
both copies lost 
TotalStates(2) 
The number of Controls in Controls Del with a hemizygous deletion or one 
copy lost 
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TotalStates(5) 
The number of Controls in Controls Dup with a hemizygous duplication or 
one copy gained 
TotalStates(6) 
The number of Controls in Controls Dup with a homozygous duplication or 
two copies gained 
ALLTwoTailed All CNV states considered together p 
ORALL All CNV states considered together OR 
ZeroTwoTailed Only CN=0 CNV state considered together p 
ORZero Only CN=0 CNV state considered together OR 
OneTwoTailed Only CN=1 CNV state considered together p 
OROne Only CN=1 CNV state considered together OR 
ThreeTwoTailed Only CN=3 CNV state considered together p 
ORThree Only CN=3 CNV state considered together OR 
FourTwoTailed Only CN=4 CNV state considered together p 
ORFour Only CN=4 CNV state considered together OR 
Gene 
The closest proximal gene based on UCSC Genes which includes both 
RefSeq Genes and Hypothetical Gene transcripts 
Distance 
The distance from the CNVR to the closest proximal gene annotated. If the 
value is 0, the CNVR resides directly on the gene. 
Description 
The gene description delimited by "/" for multiple gene transcripts or 
multiple genes listed 
Pathway 
Annotated pathway membership of Gene with reference compiled from 
Gene Ontology database, BioCarta database and the KEGG database 
(definition files in GeneRef folder) 
AverageNumsnpsCaseDel 
The average numsnp of CNV calls contributing to Case Del CNVR. Allows 
for much more informative CNV size (confidence) filtering post-hoc. 
AverageLengthCaseDel 
The average length of CNV calls contributing to Case Del CNVR. Allows 
for much more informative CNV size (confidence) filtering post-hoc. 
CNVRangeCaseDel 
Alternative larger CNV Range  Case Del definition compared to minimal 
common overlap definition of CNVR 
AverageNumsnpsControlDel 
The average numsnp of CNV calls contributing to Control Del CNVR. 
Allows for much more informative CNV size (confidence) filtering post-
hoc. 
AverageLengthControlDel 
The average length of CNV calls contributing to Control Del CNVR. 
Allows for much more informative CNV size (confidence) filtering post-
hoc. 
CNVRangeControlDel 
Alternative larger CNV Range  Control Del definition compared to minimal 
common overlap definition of CNVR 
CNVType Deletion or duplication CNVR Significant in combined report 
Cytoband Cytoband genomic landmark designations 
redFlagCount 
Count red flag from association review of 9 (see text, briefly: SegDups, 
DGV, Centro/Telo,  GC, ProbeCount, PopFreq, Peninsula, Inflated) 
redFlagReasons The failing metrics for association review and their values 
 
Besides p-value and odds ratios for each CNVR for all combined CNV state 
definitions (Figure 2.2), contributing sample IDs, their CN states, closest gene, gene 
description, pathway, and the average number of probes underlying contributing CNV 
calls are provided for confidence scoring and biological interpretation. Such tracking 
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information to enable quality assessment beyond initial sample based quality filtering is 
not available in other CNV association software tools.  
In addition to the main association results file, contributing calls to each 
association are included for trackability. Contributing calls allow for specific breakpoint 
assessment of individual samples and clear correlation of relevant raw input (i.e. intensity 
and genotype state). An UCSC custom track is created for graphical review of individual 
CNV boundaries to assess CNV overlap profiles (Figure 2.3). BAF and LRR value files 
for each CNVR are created with all samples having CNV contributing to association for 
review of the specific association region across many samples (Supplementary Figure 
2.1). Viewing probe intensity data across multiple cases for an associated region allows 
for generalization of robust signal qualities of a CNVR in a relatively quick manner. An 
image is automatically generated showing intensity and genotype raw values evaluated 
by the CNV calling algorithm delimiting each CNVR and each sample (Supplementary 
Figure 2.2). Ped files are created separately for deletion and duplication to allow for 
additional statistical output in Plink, including quantitative trait association. We define 
deletion ped: cn=0 → 1 1, cn=1 → 1 2, other → 2 2, and duplication ped: cn=4 → 1 1, 
cn=3 → 1 2, other → 2 2, designed from lowest to highest frequency in keeping with 
Hardy-Weinberg Equilibrium. An accessory function InsertPlinkPvalues allows for Plink 
generated output files to be imported into ParseCNV for Plink p-value driven CNVR 
definition. Full SNP based statistics are generated in ParseCNV to allow for specific 
locus queries regardless of significance. 
Correction of the CNV association statistics for population stratification can be 
achieved based on the PCA or MDS result. The deletion and duplication CNV peds 
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generated by ParseCNV are run in Plink with PCA/MDS as a covariate for a logistic 
statistical test. The additive model of population stratification corrected p-values is then 
imported into ParseCNV using InsertPlinkPvalues. 
Uncertainty in CNV calls underlying CNV associations is thoroughly evaluated 
by multiple lines of evidence to verify significant results including CNV call overlap 
profiles, genomic context, number of probes supporting the CNV call, and single probe 
intensities. CNV association results review follows four steps (Figure 2.1).   
First, CNV association review is facilitated by automatic red flag annotations 
which can be evaluated more carefully by UCSC track review for spurious association. 
Many segmental duplications, centromere, telomere, CNV peninsula of common CNV, 
extreme GC content regions, low average number of SNPs for CNV calls contributing to 
association, locus frequently found in diverse studies, greater than 1% population 
frequency, and same sample driving multiple CNV associations are all red flags for 
evaluation (See Methods). The number of red flags is scored automatically with their 
failing metric values provided. We use UCSC reference files which can be updated or 
adapted to different genome builds, as instructed.   
Second, intensity signal is reviewed for specific association regions across many 
samples, based on an automatically generated image of BAF and LRR probe values. 
Deletions are only accepted if they show clear drop in intensity (majority are below 0) 
and lack of heterozygous genotypes (BAF 0, 1). Duplications are similarly accepted only 
if they show AAB or ABB banding (BAF 0.33, 0.66) and increase in intensity (majority 
are above 0) although the latter is not always clear cut for duplications which is the 
reason duplications are often under called. 
38 
 
Third, probe based intensity is reviewed for whole chromosome data of a sample 
with each associated CNVR and population probe clusters, as done in Illumina 
GenomeStudio and Affymetrix Genotyping Console.  This review establishes clear 
diploid (CN=2) signal in flanking regions to limit noise likely to increase bias of false 
positive CNV calls. Intensity waves flanking a region with genotype support of CNV can 
be spotted that represent copy neutral loss of hetereozygosity (LOH)/ or run of 
homozygosity (ROH), which are often overcalled as a deletion by coinciding intensity 
waves.   
Fourth, qPCR wet lab review for confirmation of true positives and true negatives 
is critically important. These steps are done in order of increasing effort per locus but the 
number of loci will be filtered down by each step thus providing incremental stringency 
and re-review to establish confidence. Using ParseCNV with the robust quality tracking 
and confidence scoring through red flags, our validation success rate has been 90% in 
studies of autism (65), schizophrenia (67), depression (68), obesity (66), 
immunodeficiency (152) and attention deficit hyperactivity disorder (ADHD)(49). Here, 
we present the results of 409 attempted and 367 successful validation assays from 7 
disease studies with a range of different genomic loci and CN states (Table 2.2, Figure 
2.5).  
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Table 2.2.  Quantitative PCR Validation of CNVR Associations 
 
Project 
Validations 
Attempted 
Cases Controls Loci 
Count 
Del 
CN0 CN1 CN2 CN3 CN4 
PCR 
Failed 
Validation 
Failed 
Success 
Rate 
Autism 37 2,195 2,519 25 13 0 8 13 13 3 0 4 0.89 
Schizophrenia 52 1,735 3,485 8 47 14 21 14 3 0 0 10 0.81 
Obesity 104 2,559 4,075 35 36 0 31 45 27 0 10 5 0.95 
ADHD 135 3,506 13,327 12 57 0 35 56 37 7 7 11 0.92 
AutSczAdhd 10 9 1 1 10 0 9 1 0 0 0 0 1 
OldYoung 23 9,392 7,393 23 12 0 9 3 11 0 1 3 0.87 
Progressive 
Supranuclear 
Palsy 
48 1,855 6,701 24 38 0 32 9 7 0 4 9 0.81 
 
 
Reviewing the failed loci has led to establishment of the various red flag features 
presented. Over time, the validation 
success rate has improved as more 
rare and subtle red flags were 
identified and refined. Validation of 
CNVs with an independent method 
has remained a standard expectation 
due to false positives. With high 
validation success rate due to quality 
tracking and confidence scoring of 
known confounders leading to failed 
validations based on experience, we 
are confident that the majority of 
significant loci with good confidence 
scores can be interpreted for biological relevance to disease without prolonged suspicion 
of a false positive CNV call until PCR validation is done. 
Figure 2.4. Increased Frequency of Specific CNV State 
in Cases 
 
 
 
chr14:104241048-104348254 4:0 (case:control) deletions 2:11 
duplications 6:11 combined ParseCNV provides case enriched 
deletion significance for this region p=0.03 (duplication 
control enriched p=0.09). Since Plink only uses combined 
count definition the p=1 and the region is missed. 
chr11:133663955-133715739 1:3 deletions 5:0 duplications 
6:3 combined ParseCNV provides case enriched duplication 
significance for this region p=0.01 (deletion control enriched 
p=0.65). Since Plink only uses combined count definition the 
p=0.12 and the region is missed. 
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To provide a simplified 
demonstration of the file input 
format and output, we simulated 
data for 4 cases and 4 controls with 
CNV calls derived from 10 probes 
which after running ParseCNV 
results in a 1 probe CNVR deletion 
and a 3 probe CNVR duplication 
with nominal significance due to 
the reported ranges being observed in 4 cases and 0 controls along with other files for 
association and CNV signal review 
(Figure 2.1).  
As an example of a real 
dataset using a case/control publicly 
available dataset, 785 autism cases 
and 1110 controls were assessed 
with 561,308 probes. PennCNV 
called cases CN=0 1,855, CN=1 
19,484, CN=3 11,393, CN=4 1,060 
and controls CN=0 959, CN=1 
10,051, CN=3 6,236, CN=4 579. 
ParseCNV detected Del/Dup Probes p<0.05 Case Enrich: 696/1,309 and Del/Dup Probes 
p<0.05 Control Enrich: 468/1,313. Deletion CNVRs: 103 Duplication CNVRs: 59 were 
Figure 2.5. Quantitative PCR Validation of CNVR 
Associations. 
 
 
 
Each sample with attempted validation for a specific CNV 
at a specific locus is shown. The validation data output is 
0.5 for deletions, 1 for diploid, 1.5 for duplications with 
standard error values from triplicate runs. 
Figure 2.6. Sampling of Different Settings of Distance (1 
MB) and significance (+/- 1 power of ten p-value). 
 
 
 
Based on 785 cases vs. 1110 controls 561,308 probes 
dataset. By this sampling procedure, we show these 
defaults are justifiable based on balancing CNVR extension 
to allow boundary variability while maintaining unique loci 
except in rare instances. The x axis shows the CNVR typed 
and distance setting. The color shows the p-value variance 
setting. The y axis shows the count CNVRs resulting from 
these settings. 
 
41 
 
found (after joining based on 1MB probe neighbors and +/- power of ten p-value) before 
selecting the most significant CNVR in tightly clustering regions with varying 
significance. ParseCNV then condensed these probe based statistics into 57 deletion and 
33 duplication CNVRs with nominal significance. These loci were reviewed with red flag 
annotations, UCSC, raw intensity, and qPCR as described above resulting in 7 deletion 
and 12 duplication CNVRs (65). We used this dataset to sample different settings of 
proximity (1 Mb) and significance (+/- 1 power of ten p-value) (Figure 2.6).  
 By this sampling procedure, we show these defaults are justifiable based on 
balancing CNVR extension to allow boundary variability while maintaining unique loci 
except in rare instances. The rawcnv, fam, and map files can be freely downloaded from 
parsecnv.sourceforge.net to replicate the analysis.  
To further emphasize the unique output features of ParseCNV, we ran Plink on 
the same dataset.  Plink detected the same number of cases and controls at each probe and 
calculated statistical significance with similar values, albeit not the same since ParseCNV 
uses Fisher exact test and Plink uses permutation (Supplementary Figure 2.3). However, 
CNVRs were not called by Plink so part of ParseCNV was used to reduce redundancy in 
the Plink result. 4 deletion CNVRs and 4 duplication CNVRs were missed (not 
significant, p>0.09) by Plink due to the assessment of all CNV states together, while the 
opposite state was enriched in controls (Figure 2.4).  
All CNVRs called via Plink statistics were also significant in ParseCNV results. 
Plink found 92 combined CNV state groups of probes which were called as CNVRs by a 
ParseCNV component script. With combined CNV state statistics in ParseCNV, 79 
CNVRs resulted. Highly significant p-values using Fisher’s exact test were less 
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significant when asessed with permutation while marginally significant with control 
frequency using permutation were more constrained with Fisher’s exact test (i.e. 5:1 
case:control). Overall the counts of CNV per probe match exactly and the p-values 
correlate highly between ParseCNV and Plink providing independent validation of 
correctness (Supplementary Figure 2.3). However, the lack of CNVR calling and quality 
tracking in Plink makes for a strong contrast of Plink with ParseCNV. 
When families are available, inheritance rates of CNVs can improve confidence 
of CNV calls. Importantly, de novo events should show consistent parent of origin across 
genotypes of a given CNV. For example, if mother is AA, father is BB, and child is A, 
the parent of origin is mother for the remaining copy. Trio and joint family based CNV 
calling procedures in PennCNV can further improve the de novo rate (212). Such metrics 
can be developed by retrospective evaluation of raw data contributing to false positive 
associations and failing PCR validation. Waviness of the intensity data can be 
ameliorated using the GC wave correction model options (48). Individual CNV call 
quality metrics include confidence score, number of probes contributing to CNV call and 
physical CNV size. CNV call filtering may create false association by encountering a 
locus with control boundary truncation just under the threshold while case calls were just 
above. If multiple SNP array or exome capture versions are being used with different 
probe sets, filtering for the intersection set before CNV calling is recommended. If 
overlap is minimal between different platforms, a discovery phase with the largest subset 
can be done with replication in other subsets using all probes available on the chip.  
ParseCNV has the flexibility of handling multiple different input files and is optimized to 
handle CNV heterogeneity. 
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In conclusion, the above referenced probe resolution statistics and dynamic 
CNVR definition applied in ParseCNV will become increasingly important as the number 
of CNVs identified in each individual and the resolution of variable CNV boundaries 
expands in dense probe arrays and sequencing. With this increased resolution comes 
additional multiple testing burden although multiple probes are needed to call a given 
CNV and many probes may not detect any CNVs (conservative standard is p<5x10
-4
(65), 
See Methods). Assessment of CNVs across the genome has continued to improve (58, 61, 
94, 105, 140, 175). Recent reports of the extent of discordance between different arrays 
and CNV calling algorithms have been published (158). This can be readily seen in the 
Database of Genomic Variants entries with widely disparate CNV frequencies across 
different healthy populations. This is why large cohorts of cases and controls typed at a 
single facility are important with full tracking of quality metrics for each CNVR provided 
by ParseCNV rather than simply probe based significance values. Success frequency of 
qPCR CNV validation has continued to improve by association signal review enabled by 
ParseCNV. 
Note: Supplementary Data are available at NAR online: Supplementary figures 2.1-3, 
Supplementary methods, and Supplementary reference(221).  
 
 
 
2.4 Model for Continuous Red Flag Score 
 
CNV calling has inherent uncertainty due to imperfect data modes at normal intensity (0) 
and normal genotype (0,0.5,1) and deviations thereof. The stronger the deviation, the 
stronger the PennCNV HMM confidence score, one of the red flags. Red flags were 
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defined over time of reviewing failed qPCR verification underlying intensity and 
genotype.  
Progressing from a heuristic confidence score involving the count red flags exceeding 
predefined thresholds into a formal statistic continuous confidence score will improve 
specificity. Here, I have created a continuous RedFlag score to increase specificity 
robustly correlating to validation and true association. I then provide a Pass/Fail 
annotation based on RedFlags. 
Red Flags are in main categories of genomic annotations, overlap profile, and average 
quality of overlapping calls (Table 2.3). Genomic annotations include SegDups, 
DgvEntries, TeloCentro, and AvgGC. Recurrent overlap profile annotations include 
PopFreq, PenMaxP, FreqInflated, Sparse, and ABFreq.Average quality of overlapping 
calls annotations include AvgConf, AvgProbes, and AvgLength. 
To accomplish a continuous red flag confidence score, first I designed ParseCNV with 
the –includeAllRedFlags command 
line option, plot R histogram of each 
read flag. This design uses 
MakeRedFlagPlots. pl, 
CNVR_ALL_ReviewedCNVRs_bri
ef.txt, and plot R curve.  
Lines(density(a$a)) is used to 
integrate observed value at 
significant CNVR in proper 
direction of red flag (+/-) depending 
Figure 2.7. Continuous Confidence Score 
 
 
 
Histogram of all red flags, curve fitting, and normalization, weights 
based on generalized linear model, correlation/ROC curve to 
independent verification 
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on if low or high values are detrimental. This algorithm uses dens2 <- 
density(a$SegDups, from=0, to=a$SegDups[i]) with(dens2, sum(y * diff(x)[1])), and 
correlate/weight with validation success using Generalized Linear Model weights 
assigned and correlation of 0.8 with validation success achieved with reasonable cutoff 
for GLMWeightedConfidence of 0.2. ROC curve looks solid and the AUC score is 0.983 
using ROCR package. Simple average (same weights) of the integration likelihoods was 
not very well correlated with validation success.  
 
Table 2.3.  ParseCNV Red Flags Definition 
 
RedFlag Default Report 
Threshold Explanation 
SegDups (count, 
max, avg) 
>10, >0.98 max Fraction 
Matching 
Many segmental duplications (i.e., nearly identical DNA segments), representing genomic segments that are 
difficult to uniquely hybridize probes to, which could underlie false positive CNV detection. Segmental 
Duplications inform CNV breakpoints if flanking (include) and noisy regions if overlapping (exclude). 
DgvEntries >10 
Overlapping multiple Database of Genomic Variants (DGV) entries, representing CNV signals 
observed in “healthy” individuals, suggesting that a potential association result in the study at hand may 
be false. 
TeloCentro any overlap Residing at centromere and telomere proximal regions as they often have sparse probe coverage and only have a single flanking diploid reference to base CNV calls. 
AvgGC 31>GC>60 Harboring high or low GC content regions that bias probe hybridization kinetics even after GC model correction is done by CNV calling algorithms, producing false CNV calling and biasing the result. 
AvgProbes <10 CNVs captured with low average number of probes, contributing to association with low confidence. If an association depends on a preponderance of small CNVs, the likelihood of false positive is high. 
Recurrent any overlap 
Locus frequently found in multiple studies such as TCR, Ig, HLA, and OR genes. TCRs undergo 
somatic rearrangement due to VDJ recombination causing inter-individual differences in the clonality 
of T-cell populations and thus are not true CNVs, necessitating exclusion. 
PopFreq >0.01 
CNV regions with high population frequency (for rare CNV focused studies) indicate that probe 
clustering is likely biased due to a high percentage of samples with CNV used in clustering definition 
thus biasing CNV detection. 
PenMaxP_Freq_Hi
ghFreq 
PenMaxP >0.5, Freq >0.5, 
HighFreq >0.05 
CNV peninsula of common CNV (sparse probe coverage and nearby high frequency CNV) indicates 
that within the range of contributing CNV boundaries there is a non-significant (p>0.5) p-value which is 
notably different from the CNVR association typically due to random extension of common CNVs to 
neighboring sparse or noisy probes. PenMaxP is the worst p-value in the span of CNV calls contributing 
to the significant CNVR. Freq is the frequency of this PenMaxP worst p-value. HighFreq is the 
frequency any non-nominally significant p-value (P>0.05). 
FreqInflated 
>0.5 sids at this locus have 
>(maxInflatedSampleCoun
t-2) occurrences in all 
significant results 
The same inflated sample driving multiple CNV association signals. Certain samples have many noisy 
CNV calls arising in rare regions despite upfront sample quality filtering. 
Sparse >50kb 
A large gap in probe coverage exists within the CNV calls indicating uncertainty in the continuity of a 
single CNV event, typically due to dense clusters of copy number (intensity only) probes with large 
intervening gaps. 
ABFreq <1% values (0.1,0.4) or 
(0.6,0.9) 
For duplications, AB banding of BAF at 0.33 and 0.66 for CN=3 or 0.25 and 0.75 for CN=4 are very 
important observations given the relatively modest gain in intensity observed in duplications. 
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AvgConf <10 
The HMM confidence score in PennCNV is a superior indication of CNV call confidence compared to 
numsnps and length in studies comparing de novo vs. inherited CNV calls, giving an indication of the 
strength of the CNV signal or aggregate difference in probability between the called CN and the next 
highest probability CN. Other CNV calling algorithms give different range confidence scores or lower 
values might mean more confidence (i.e. call p value) so threshold may need modification. It is 
recommended to be in .rawcnv file as column 8 i.e. “conf=20.659” but not required. 
AvgLength <10kb 
A classical confidence scoring parameter is the length of the CNV. If the CNV is too small, it is 
submicroscopic and even if many probes are tightly clustered, bias of local DNA regions and probe 
overlap make confidence difficult 
 
 
 
2.5 Comparison of CNV Association Tools 
Multiple CNV tools have been developed and their features are compared in Table 2.4.  
 
Table 2.4. Comparison of CNV Association Tools Features Currently Available 
 
 CONAN BirdSuite Plink CNVineta CNVassoc CNVTools R-Gada CNVRuler HD-CNV ParseCNV 
Input Platform Affymetrix Affymetrix ALL 
Illumina 
Affymetrix 
ALL ALL ALL ALL ALL ALL 
CNV Call Data PennCNV Array data PED1) APT1) CGHcall Text file1) BeadStudio1) Nexus 
PennCNV 
Genomic 
Workbench 
TCGA 
NimbleScan 
APT 
Genotyping 
Console 
Genome Studio 
Text file 
CSV Nexus 
PennCNV 
Genomic 
Workbench 
TCGA 
NimbleScan 
APT 
Genotyping 
Console 
Genome Studio 
Text file 
 QuantiSNP  BirdSuite2) QuantiSNP1) Plink  
Genotyping 
Console1) 
 
 
Genotyping 
Console 
   Text file1)  Text file1)  
 Text file1)        
 MS Exel1)        
         
         
         
         
OS ALL Linux ALL ALL ALL ALL ALL ALL ALL ALL 
Frequent CNV 
Region3) 
CNVR N/A N/A Fragment CGHregions N/A N/A CNVR CNVR CNVR 
       RO  RO 
        Fragment  Fragment 
GUI Yes No Yes4) No No No No Yes Yes Yes 
Required Oracle 
(Optional) 
Annotation File 
Matlab 
R 
Annotation File 
No R R R R R 
Java Swing 
JGraphT 
R 
        
        
Statistical Methods 
Linear 
regression 
Regression CA Trend 
Test 
Fisher’s 
exact test 
Stratified 
Test 
Multi-locus 
Test 
Likelihood 
Ratio Test 
Logistic 
regression 
Linear 
regression 
Logistic 
regression 
Logistic 
regression 
Maximum 
likelihood 
Logistic 
regression 
Fisher’s exact 
test 
Interval 
Graph Fisher’s exact 
test 
Chi-Square 
CA Trend Test 
Stratified Test 
Multi-locus 
Test 
Likelihood 
Ratio Test 
Logistic 
regression 
Linear 
regression 
Confidence 
Score 
  (SNP ref)  
Linear 
regression 
EM 
Likelihood 
Ratio Test 
Chi-Square 
Bron 
Kerbosch 
Clique 
Finder 
Algorithm 
       
Logistic 
regression 
Gephi 
       
Linear 
regression 
 
         
         
         
          
Disadvantage / 
Limitation 
Support 
Platform 
Support 
Platform 
Data 
conversion 
Support 
Platform 
Data 
conversion 
Data 
conversion 
Region 
definition 
User Interface 
No Covariates 
Limited data 
model 
(Binary, 
Normal 
distribution) 
User Interface 
Graphical 
Report 
P-value 
Graphical 
Report 
 
Single Statistical 
Method 
Large data 
handling 
Region 
definition 
Single 
Statistical 
Method 
User Interface   
Confidence 
Scoring 
 
  
Region 
definition 
 
User 
Interface 
     
  User Interface        
          
          
          
Reference Forer et al,2010 Korn et al, 2008 
Purcell et 
al, 2007 
Wittig et al, 
2010 
Subirana et al, 
2011 
Barnes et al, 
2008 
Pique-Regi et 
al, 2010 
Kim et al 2012 
Butler et al 
2012 
Glessner et al 
2013 
1) Manual Conversion required 
2) Supported by BirdSuite 
3) Since each tool named differently for identical region definition, the representative words are chosen from this study for convenience 
4) Supported by 3rd party front-end gPlink 
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ParseCNV was the first CNV association software when the idea was first conceived and 
the groundwork was laid out.  As shown in Table 2.4, there are currently nine other 
published softwares that exist with a variety of features. ParseCNV has the most features 
currently and I continue to improve functionality based on worldwide user feedback. 
ParseCNV has enabled CNV associations to be applied to all major disease categories 
and allows for evaluation of different versions of the SNP arrays and examination of 
CNV profiles in different ethnicities at the population level. The novel association utility 
of ParseCNV is more thoroughly delineated in the chapters presented below. 
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Chapter 3  
3.0 Genome Wide Rare Copy Number Variation Landscape and 
Disease Implications in 68,000 Humans 
 
Summary 
Copy number variants (CNVs) are commonly observed in healthy individuals and have 
gene dosage-sensitive effects on specific phenotypes. Several CNV maps have been 
reported that illustrate the wide-spread impact of CNVs on the human genome, 
implicating compelling biological functions for certain CNV regions; however, they are 
generated from relatively small sample sizes and therefore lack depth of rare CNV 
coverage. Here we evaluate 68,000 individuals typed with 520 thousand probes in 
common and report 4,969 deletion, 2,633 duplication, and 263 homozygous deletion 
CNVRs observed in multiple unrelated individuals. Of those, 17% are novel CNVRs, 
64% overlap genes, and 18% overlap significant genome-wide association (GWA) single 
nucleotide polymorphisms (SNPs) loci. We performed CNV association clustering across 
broad disease categories of cancer, autoimmune, cardio/metabolic disease, neurological 
disease populations in comparison with healthy controls, uncovering strong associations 
with OMIM genes, GWAS genes and non-coding RNAs and we subsequently assessed 
their contributions in different ethnic groups. We show that total CNV burden per 
individual averaged ~600kb and was ethnicity-dependent. We conclude that the rare 
CNVs identified represent a robust frequency definition for large scale rare variant 
association studies, which are enriched for disease associations at OMIM, GWAS and 
non-coding RNA loci with differential ethnicity-dependent impact. 
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Prior to the introduction of CGH- and SNP-microarrays and affordable sequencing, 
detection of CNVs was limited to observation based on karyotyping and fluorescence in 
situ hybridization (FISH). These technologies were limited to the discovery of large 
CNVs that are typically rare and thought to be disease causing based on their startling 
impact on the genome (11). As the SNP array technology developed for assaying the 
diploid human genome in mid-2000, the wide spread and common nature of CNVs 
became more readily apparent and multiple regions of the genome were shown to have 
such high frequency of CNVs that they are referred to as copy number polymorphisms 
(CNPs) (54). As a result, a wave of studies has assessed the frequency of CNVs across 
the human genome using different arrays, algorithms, and presentations (35, 39, 88, 94, 
98, 129, 139, 172, 182, 183, 185, 205). 
The functional consequence of CNVs was first described in model systems (19). In 
addition to conventional Mendelian inheritance of parental CNVs, a small subset of 
CNVs occurs as de novo events.  Both inherited and de novo structural changes can 
impact gene expression, phenotypic variation, adaptation and influence or be causal to 
disease (95). Moreover, association of a rare CNV with a disease trait can flag a more 
common genotype variation by uncovering a new disease pathway potentially impacted 
by other types of variants (213).    
Evolution and genome condensation occurs through various mechanisms, including 
chromosome splicing of highly similar sequences known as homologous recombination 
(HR) (32).  In somatic cells, HR is needed to repair extreme DNA damage such as double 
strand breaks (DSB). If spliced incorrectly, CNVs and genomic instability can result. An 
intermediate state is formed between two DNA strands which proceeds by crossover (two 
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way sharing, meiosis and DSB) or gene conversion (one way sharing and DSB) both of 
which can impact gene dosing and predispose to disease. The human genome has 
numerous regions of segmental duplication that provides similar sequences for HR to 
occur. Segmental duplications can masquerade as allelic sequences during meiosis that 
can lead to erroneous splicing with non-allelic homologous recombination (NAHR). 
Likewise, gene conversion can insert non-expressed sequences into homologous 
expressed genes resulting in reduction in gene function.  Large datasets are required to 
examine the impact of these mechanisms on disease phenotypes and genome evolution.   
To elucidate the impact of CNVs at the genome level and their potential relevance to 
disease states, we analyzed Illumina genome-wide SNP array data sharing 520,017 SNPs, 
including both genotype B allele 
frequency (BAF) and intensity log R 
ratio (LRR), from 68,028 unrelated 
high quality DNA samples. The 
CNVs were distributed in a 
heterogeneous manner throughout the 
genome and no large stretches of the 
genome were exempt from CNVs. 
The proportion of any given 
chromosome susceptible to CNV 
varied from 46.7% to 96.1% 
(Supplementary Fig. 5), due in part to 
SNP resolution. 
Figure 3.1. Individual Sample CNV Burden based on 
Total CNV Length Genome Wide.  
 
 
 
A) High Frequency CNVRs distribution; B) Low 
Frequency CNVRs distribution. The total combined 
length of CNVs impacting individual subject is shown. 
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3.1 Detection of Rare Recurrent CNVs 
CNVs were characterized by assembling a large population CNV map of the human 
genome through the study of 68,028 genotyped individuals from four populations with 
ancestry in Europe (52,321), Africa (12,548), Asia (2,299), and Latin America (860). 
CNV calls per individual sample averaged 18.6 with a median of 16, with CNV state per 
individual as follows: a) CN=0 with average of 1.48 and median of 1; b) CN=1 with 
average of 11.8 and median of 10; c) CN=3 with average of 5.71 and median of 5; and d) 
CN=4 with average of 2.20 and median of 1. The total size of the CNVs called per 
individual sample averaged 68,425.3 Kb with median of 20,750 Kb. The number of SNPs 
in a contiguous region in support of the CNVs call averaged 15.19 SNPs with median of 
7 SNPs. The average individual CNV burden amounted to ~600 kb with rare CNV 
component of ~200 kb (Figure 3.1 and Suppl. Fig. 3.1).  
We detected a total of 5,238 deletion copy number variation regions (CNVRs) and 2,707 
duplication CNVRs based on the above stringent CNV criteria. A CNVR was defined by 
a contiguous region of SNPs within sample frequency (0. 03% corresponding to 20 
samples) with spacing between SNPs not exceeding one MB. This allows for CNVR 
boundary extension to be defined with flexibility to uncertainty in CNV call boundary 
truncation at the sample level manifesting in a population scale and extension of a CNVR 
over SNPs with aberrant frequency (Suppl. Fig. 2). It should be noted that our CNVR 
definition is distinct from CNVRange, which would include minimum and maximum 
boundaries of overlapping CNVs, an alternative CNVR definition specifying a different 
CNV frequency range. While many CNVRs were rare, we detected 4,969 deletion, 2,633 
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duplication, and 263 homozygous deletion CNVRs in multiple unrelated individuals 
(Figure 3.2, Suppl. Figs. 3.3-4, and 
Suppl. Tables 3.5-7).  
The average deletion CNV frequency 
of these CNVRs was 0.22% with a 
median of 0.05%. The average 
duplication CNV frequency of these 
CNVRs was 0.21% with a median of 
0.06%. This indicates that the vast 
majority of the CNVs called were rare 
in keeping with the genotyping platforms used (the shared SNP content resides outside of 
common CNV regions).  We estimated CNV call sensitivity based on our detection rate 
of known CNVs in reference Hapmap individuals and CNVs reported in the Database of 
Genomic Variants. Similarly, we found CNV specificity to be high given positive 
independent experimental validation in 91% of 2,127 samples, testing different CNV size 
ranges across the entire genome, using qPCR (Sup. Fig. 7). We validated both the 
presence and absence of CNVs in various loci across randomly chosen samples. 
Furthermore, the inheritance rate of CNVs was 94% and concordance between biological 
replicates was 100%. 
The Database of Genomic Variants (DGV) is a centralized resource for CNV 
observations(133). There are over 200,000 entries of CNVs reported through various 
studies that have been run on different platforms, by different laboratories at different 
times and ascertained with different CNV calling algorithms (UCSC Table DGVMerged 
Figure 3.2. Genome-wide CNV Frequency of Deletions, 
Duplications, and Homozygous Deletions. 
 
 
 
Frequency plot of the CNV occurrence in the human 
genome with alternating color scheme to delineate each 
chromosome. 
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Downloaded 3-31-14).  Our study identified a common set of SNPs across different 
Illumina chip versions and used a 
unified SNP content of 520,017 SNPs 
to uncover 795 deletion and 265 
duplication CNVRs harboring 
74,516(54,655 and 19,601 
respectively) individual CNVs that 
were not reported in the DGV. We 
additionally uncovered 178 
homozygous deletion CNVRs 
impacting 260 individuals that did not 
have annotation in DGV.   
CNVs can make genome sequence 
assembly difficult (103). By 
referencing the frequency of CNVs 
flanking a given sequence run, the 
true sequence of the genome can 
more accurately predicted with 
improvement in continuity. Of 1,387 
such CNV regions identified 
exceeding 50 kb in size, it is 
noteworthy that many of the largest 
regions of the genome with sequence 
D 
Figure 3.3. PCA Population Genetics and Geographical 
Ancestry. 
 
 
 
 
A) Overall PCA of CVS (Heart Disease), NEU 
(Neurological), AID (Autoimmune), CCR (Cancer), and 
HLT (Healthy). B) Density based PCA differentiating  
areas of high overlap. C) Separate Hapmap and disease 
category overlaid PCAs. D) PCA Population Genetics 
and Geographical Ancestry of Table 2 CNV Loci 
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uncertainty reside at the centromeres (n=70) and telomeres (n=86), especially the 
centromeres of chromosomes 1 and 9 and the p arms of the acrocentric chromosomes, 13, 
14, 15, and 22 (Sup. Fig. 3.5). These regions are not covered by arrays due to highly 
repetitive DNA sequences that are chromosome non-specific. The average CNV 
occurrence on SNPs flanking DNA stretches exceeding 50kb in the Illumina array 
coverage was 58% for deletion and 78% for duplication. This frequency is much lower 
for regions of high SNP density (<18bp) which had an average CNV observation of 19% 
for deletion and 18% for duplication. Thus, sequence gaps in the reference human 
genome assembly are at least in part due to CNVs and segmental duplications and large 
gaps in SNP coverage and lack of continuity of spacing, in general, decrease confidence 
in CNV calls made by SNP platforms. Moreover, to differentiate the pattern of rare 
recurrent CNVs geographically at the population level, we applied principal components 
analysis (PCA) and evaluated identity by descent (IBD)(Figure 3.3). For main CNVR 
finding (Table 3.2), we investigated PCAs in the absence and presence of different 
disease states to determine the impact of ancestry on disease-associating CNVs. 
 
3.2 Deletion and Duplication Frequency and Genome 
Clustering 
We observed homozygous deletions in 894 CNVRs across the genome, with 376 (42.1%) 
homozygous deletion CNVRs residing on segmental duplications (Suppl. Fig. 4). While 
70.6% of homozygous deletion regions were only observed in a single individual, 10% 
were observed in 10 or more individuals encompassing 60 Mb of sequence, suggesting 
that approximately 2% of the human genome may be “disposable.” However, phenotypic 
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information on these individuals is of particular interest with respect to a potential role of 
a given disease gene and direction of intervention at a gene or biological pathway level.  
To determine if CNVs cluster at specific genome hotspots, we investigated the sequence 
content at the sites of CNV. Among 5,378 CNVRs uncovered, 1,725 (32.9%) deletion 
CNVRs and 1,150 (42.5%) duplication CVNRs reside on segmental duplications. The 
majority of CNVRs harbored both deletions and duplications: 5,091 (97.2%) of the 
deletion CNVRs also have duplications and 2,623 (96.9%) of duplication CNVRs also 
have deletions at these loci. Segmental duplication rearrangements are generated by non-
allelic homologous recombination; however, not all annotated segmental duplications are 
fixed in humans, but rather are CNVs. Thus, CNVRs harbor both deletions and 
duplications, whereas pairs of segmental duplications with high sequence similarity, 
including dispersed repetitive elements (Alu elements), retrotransposons, and sequence 
homology within 100bp segments, are all features of the human genome that contribute to 
extensive CNV aggregation over generations (43). 
 
The recombination hotspots of the genome predispose to CNVs and were found to be 
enriched for CNVs (Sup. Figure 3.8) as previously published (39).  To further emphasize 
this point, we have overlaid our CNVRs with publicly available recombination hotspot 
maps in order to make a collective conclusion that recombination hotspots correlate with 
CNV boundaries (Sup.Figure 3.9). 
 
To explore the potential of lethal homozygozity loci as determined by absence of 
expected homozygotes, we evaluated high frequency single copy deletions at specific loci 
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with significantly low homozygous deletion rate in search for loci out of Hardy Weinberg 
equilibrium that are likely to be homozygote lethal.  We observed ATP binding, 
intracellular organelle lumen, transmembrane transport, and metal ion binding genes to 
meet these criteria (Sup. Table 3.17), suggesting that these genes are of fundamental 
biological importance for survival. 
 
We did PCA on the raw GWAS data to address population stratification and to verify 
reported ethnicity. By using the correlates as a covariate for the logistical regression test 
statistic, the correlates are removed from any confounding. 
 
Regarding novelty of the CNV 
content uncovered, 17% of the 
CNVs we observed are novel, thus 
83% concur with previous reports, 
of which about 15% would be 
classified as large CNVs (i.e., 
above 100kb). Of the 17% novel 
CNVs, all CNVs represented with 
10 or more SNPs were 
experimentally validated without 
failure. Over 95% of the large 
CNVs (>100kb) are captured by more than 10 SNPs. These CNVs replicate between 
ethnicities in our study and frequency observed here compares to published studies such 
Figure 3.4. Frequency, Length and Gene Impact Features of 
CNVRs detected in this study. 
 
 
 
Increased frequency CNVRs tend to be biased away from 
genes and be restrained to smaller genomic regions. 
Duplications appear to be less constrained. 
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as Conrad et al., typically used as gold standard.  The ParseCNV algorithm used for the 
analysis (70), has been extensively validated for CNV confidence measures, providing 
another level of QC standard for CNV call validation. 
 
It is noteworthy that in general, deletions tend to be biased away from genes, whereas 
ancestral duplications appear to cluster on certain gene families throughout the course of 
evolution (Figure 3.4). While it can be difficult to define the exact CNV breakpoints, it is 
usually clear if a CNV disrupts genes/exons or not. Common CNVs are less likely to 
disrupt genes and are therefore less likely to impact on disease than are rare CNVs. 
Common variants typically flank disease associated regions, consistent with the intricate 
and fragile balance of such variation.  
 
3.3 Functional impact of CNV loci and relations to specific genomic elements 
 To evaluate the relationship between CNV location and disease impact, we investigated 
functional elements of the genome to see if CNVs were observed in critical regions 
including RefSeq genes, OMIM genes, Ultra-conserved elements, conserved non-coding 
elements, non-coding RNAs, gene exons, and OMIM morbid (Table 3.1), all of which 
have the ability to influence phenotype expression. 
 
We used DAVID(46) to evaluate genes impacted by CNVRs for functional annotation 
clustering by searching through Gene Ontology, INTERPRO and several other functional 
databases. We observed functional enrichment of deletion CNVR impacting several gene 
classes, including secreted proteins, growth factor mediators, molecules involved with 
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regulation of protein kinase cascade, regulation of protein amino acid 
phosphorylation,and tumor necrosis factor-like molecules. In contrast, 
 we observed significant functional enrichment of duplication CNVR in molecules 
 
Table 3.1. Impact of CNVR Loci on Functional Elements at the Genome-Wide Level    
 
involved with negative regulation of signal transduction, negative regulation of cell 
communication, phosphoprotein, DNA binding, as well as in several sequence variants 
affecting diversity of adult human height, or largely opposing effects to those of the 
deletion CNVRs. For homozygous deletion CNVRs, we observed significant enrichment 
for gene classes involving intermediate filament protein and cytoskeletal keratin 
molecules.  The CNV enriched regions of most interest included Coil 1A, Coil 1B, Coil 
2, Head, Linker 1, Linker 12, Rod, Tail, all of which are fundamentally biologically 
relevant with respect to disease influence (Sup. Figure 3.6). 
 
GWAS has been a powerful tool in uncovering disease loci and unfolding new biology in 
hundreds of complex medical disorders; thus, we leveraged the GWAS genotyping data 
from over 68k individuals to detect copy number variation. CNVs likely complement the 
CNVRs 
RefSeq 
genes 
OMIM 
genes 
Ultra-
conserved 
elements 
conserved 
non-coding 
elements 
non-coding 
RNAs 
Gene 
Exons 
OMIM 
morbid 
DGV 
CNV Map 
Study 
Freq High 
Conserved 
>1% 
NHGRI 
GWAS 
Catalog 
Loci Deletions 1.11 1.13 0.92 0.67 2.47 1.18 2.24 1.41 0.44 1.60 
Loci 
Duplications 
1.10 1.13 0.87 0.60 2.68 1.17 2.19 1.42 0.27 1.40 
Loci CN=0 
Deletions 
0.97 0.98 0.96 0.95 4.00 1.04 7.00 1.33 1.67 3.87 
Genes Deletions 1.29 1.07 1.59 0.63 1.70 0.36 1.51 2.14 0.31 1.73 
Genes 
Duplications 
1.41 0.91 1.70 0.46 1.48 0.09 1.56 2.24 0.22 6.12 
Genes CN=0 
Deletions 
0.96 1.32 0.88 1.17 5.00 1.14 8.00 2.00 2.15 10.82 
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genetic burden of many genes identified by genotype association. Among 5,378 CNVR 
loci uncovered, 1,409 resided in GWAS regions associating with one or more complex 
OMIM disease traits (Sup. Table 3.9). Moreover, 28% of deletions, 34% of duplications 
and 39% of homozygous deletions overlapped significant GWAS signals at P<5x10
-8
. 
For comparison, we generated random SNP seeded CNVR windows of equal number and 
size to the observed CNVRs to model the null distribution resulting in 17% deletions, 
24% duplications, 10% homozygous deletions overlapping reported GWAS signals at 
p<5x10
-8
, resulting in p=3.96x10
-38
 for deletions, p=5.94x10
-15
 for duplications and 
p=1.31x10
-47
 for homozygous deletions (p=4.56x10
-78
 combined) in favor of CNV 
enrichment for GWAS loci. Co-localization of CNVs with GWAS genomic regions is 
significantly above expectations, suggesting complementary genetic mechanisms 
perturbing disease genes through both common and rare variants that co-exist at GWAS 
loci. 
 
There are several genomic regions in the human genome that are unstable and hard to 
characterize.  The reasons for this vary but in general, these regions are highly duplicated, 
polymorphically inverted, contain assembly sequence gaps, or may be flanked by 
segmental duplications of variable copy number.  All of these features are being 
increasingly observed in CNV regions of the human genome and their biological 
implications are likely to unfold in the near future. Genotype calls in regions of CNVs 
characterized by homozygous deletions result in random genotyping since there is no 
DNA template to bind. Mendelian discrepancies in families are more often observed in 
deletions and Hardy–Weinberg disequilibrium regions, whereas no call SNP genotypes 
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are more often observed in duplications at the population level. The latter can also flag 
CNVs based on a region of genotypes (172). 
 
Due to the design of the Illumina SNP-array platform, common CNVs are poorly 
captured as SNPs are omitted from the array that resides in such regions.  The platform’s 
SNP tagging approach is based on linkage disequilibrium (LD), which is a measure of 
correlation between markers. When occurring in LD regions, SNP genotype studies have 
the power to tag and associate CNVs with the trait under study. When the LD between 
any two variations (r
2
) is close to 1, then either variation can be typed and the other 
inferred by the tagging approach. We calculated LD between each of the 48 common 
CNVRs we detected with frequency >5%. CNV tagging by SNP genotypes was poor 
with only 5 r
2
 values exceeding 0.8. Loci showing r
2
 of 0.6-0.8 accounted for 5 CNVRs. 
Loci showing r
2
 of 0.3-0.6 accounted for 11 CNVRs. Loci showing r
2
> 0.1 accounted for 
32 CNVRs. Thus, only 10% of CNV events could be effectively tagged by SNP 
genotypes in the surrounding region (Sup. Table 3.10). Since the CNV events dominantly 
captured by the platform are relatively rare (<1% population frequency) for the majority 
of loci while SNP genotypes are typically common (>1% population frequency) the 
common GWAS SNPs have diminished ability to tag rare CNVs. Therefore, these CNVs 
are rare events rather than copy number polymorphisms (CNPs) which could be more 
amenable to SNP genotype tagging. This underscores the value of CNV detection in 
addition to SNP genotype association to reveal novel insights into disease pathogenesis, 
as these are independent variants. 
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The recent Wellcome Trust Case Control Consortium (WTCCC) CNV study typed 
19,000 individuals on targeted Agilent Comparative Genomic Hybridization (CGH) 
uncovering 3,432 polymorphic common CNVs(39). However, a study of association of 
CNVs with disease revealed the same exact loci as the previously done SNP genotype 
GWAS (2), suggesting that analysis of common CNV may be somewhat redundant to 
SNP genotyping. Logically, it follows that rare CNV association may reveal novel 
disease association loci. Comparing the regions with >5% CNV occurrence in the current 
study with those reported by WTCCC, 16/29 deletions agree while 2/5 duplications agree 
for an overall concordance rate of 51% (Sup. Table 3.11). After reviewing the clustering 
of probes underlying these regions we conclude that the discordant calls are most likely 
due to incorrect or biased cluster definition due to high CNV frequency, leading to 
ambiguity of the diploid cluster based on the intensity only CGH array used by WTCCC. 
Thus, the apparent lack of overlap with the previous WTCCC study (39) results from the 
fundamental difference between the platforms used, where our focus is on rare recurrent 
CNVs which is tailored for the Illumina platform used, and that of the WTCCC is tailored 
towards common CNPs, with the two having little in common and yielding 
complementary findings. 
 
3.4 CNV Clustering by Sex and Ethnicity 
 
We assessed the impact from inferring the ancestral linkage disequilibrium blocks of 
African Americans (AA) on rare CNV frequency. Unlike several previous reports from 
smaller studies (141), we did not observe any differences in the overall frequency 
spectrum of duplication and deletions from such a selection process; however, we 
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observed clear differences in the distribution of CNV clustering, which was vastly 
different between the ethnic groups (Sup. Table 3.15). Further, we note that over 95% of 
the key CNV observations presented occur on a single ancestral haplotype so a very 
minor proportion of the CNVs presented are de novo. Thus, the vast majority of our 
observations represents single ancestral events and therefore sits on a single local 
haplotype (with similar CNV breakpoints) with the remaining being de novo events on 
multiple haplotypes with irregular breakpoints. The distribution of these types of events 
in different ancestries was surprising as several previous studies claim that overall CNV 
frequency is greater in African-Americans compared with Caucasians or Asians, 
presumably due the relative evolutionary age of these ethnicities (141). To the extent we 
have family material for subjects of African-American and Asian origin, our family-
based analysis shows that the frequency of such events is comparable between the 
different ethnic groups (Caucasian, African-American and Asian). However, evaluation 
of population specific CNVs has unveiled several genes impacted by CNVs and 
demonstrated ethnicity-specific enrichment in the frequency of specific CNV loci (Sup. 
Table 3.15). While intriguing, overall, the frequency differences in the spectrum of 
duplication and deletions are not informative about selection as the overall CNV 
frequency observed was comparable between the African Americans, Caucasians and 
Asians.  
 
While inference of the ancestry linkage disequilibrium blocks in the African Americans 
and assessment of rare CNVs on different backgrounds did not reveal significant 
differences between the three major ancestry groups presented. Thus, we did not observe 
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differences in our much larger dataset as the overall CNV frequency was not greater in 
subjects of AA origin. Loci with significantly enriched and different frequencies in 
respective ethnicities are included in Sup.Table 3.15. 
 
It is well known that subtle effects of population stratification are particularly 
problematic for rare variants.  It is therefore encouraging that the rare recurrent variants 
we observed impact all ethnic groups showing similar phenotypic effects based on the 
datasets we have reported in the past (49, 65-68, 152), as well as on the data we are 
reporting on here. We used base genotype (A/T/C/G) PCAs as a covariate to successfully 
correct for population stratification for the entire dataset. 
 
As we perform CNV association tests that are well standardized (70), the strength of this 
cohort of 68k subjects is that even many rare events occur recurrently enough to meet 
statistical standards of significance.  In this regard, aggregation, bi-directional, and 
collapsing statistical tests are being adopted from rare genotype variation association 
studies of sequencing data and across the 3 major ethnic populations.  Details on the 
statistical methods used are in our recently published ParseCNV algorithm (70). 
 
3.5 CNV Clustering by Disease Categories 
 
In addition to disease-free “super control” subjects (n=4,352), broad disease categories of 
autoimmune/inflammatory disease (n=11,489), cancer (n=9,105), congenital 
heart/metabolic disease (n=2,581), and neurological disorders (n=14,756) were present 
among the samples analyzed, providing CNV frequency at the population level with high 
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statistical power for association of rare CNVs (Box 1). We first flagged CNVRs with 
significant association to chip version (in addition to intersection set of probes used  
 
 
Box 1. Key CNV Map Study Features 
                                         
 
 
 
 
 
CNV calling involves interpreting the normally distributed values (in terms of genotype red/yellow/green 
continuum (B allele frequency) and fluorescent intensity (Log R Ratio)) of neighboring probes using 
hidden Markov model and Viterbi algorithm implemented in PennCNV to create discrete copy number 
states for genomic segments. Genomic CNV burden of individuals can be determined directly by adding 
the length of CNV calls or sorting large CNVs. The median of total length of CNVs is 600kb (Figure 1) but 
there is a long tail to the distribution representing much of an individual’s genome burdened by CNV 
without significant correlation to severe disease. Therefore, more careful comparison of locus specific CNV 
boundaries and population frequencies stratified by type is needed genome wide. CNV boundaries can vary 
slightly due to differential probe sensitivity so our CNVR determination allows small frequency 
fluctuations. Overlap of genomic functional elements and CNVs is done by comparing the many genome 
annotations provided by UCSC genome browser to determine which elements are enriched or depleted for 
CNVS. Since the healthy population is just a part of the overall study, subjects were assigned to broad 
disease categories and CNV association performed to find meta-features of disease with CNVs in specific 
loci, to maximize the power of rare CNV association with large sample sets. Bias of discernibly different 
subsets of data must be exhaustively considered. Although we used all Illumina beadchips, chip version, 
ethnicity, and sample set bias are key factors for evaluation. The intersect of probes makes datasets from 
different chip versions logically equivalent for CNV calling but SNP clustering modes and clustering 
accuracy may vary due to different probe populations in beadpools and reagent chemistry. Ethnicity has 
shown to have different frequencies of SNP genotypes and CNV states alike due to ancestral lineage of 
CNV generation and inheritance. Sample set bias can be subtle from blood collection, DNA extraction, 
storage, cell line immortalization, quantification, and fragmentation. 
 
 
 
PennCNV ParseCNV 
Genome-wide CNV 
Frequencies 
Genome Feature  
Referencing 
Disease Category  
Association 
Version, Ethnicity, 
Sample Set Bias 
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across all chips to minimize bias) and by ethnicity, which yielded the following 
categories of CNV bias: 304 deletion, 631 duplication, and 12 homozygous deletion 
CNVRs showed significant chip version bias; 335 deletion, 925 duplication, and 32 
homozygous deletion CNVRs showed significant ethnicity bias, both of which were 
adjusted for in relation with disease clustering described below. 
 
For statistical measures, CNVRs were scored based on chi square and Fisher’s exact test. 
In addition to overall CNV analysis and analysis separated by deletions and duplications 
across the entire cohort, we analyzed each disease category, such as autoimmune/ 
inflammatory disease, cancer, neurological disease etc.  Loci reaching P values of 5x10
-8
 
for deletion or duplication CNVs (and 9x10
-4
 in case of homozygous deletion) were 
considered significant after multiple testing correction.  Several chromosomal regions 
aggregated many contiguously significant CNVRs that were subsequently merged (Table 
3.2).  
Table 3.2. Loci enriched with CNVs in Disease Categories  
 
CNVR (hg18) 
CNV 
Type 
Count 
Count In 
Disease 
Category 
P Category RefSeq Genes 
Count GWAS 
Sig 
chr17:73799302-73808867 Del 65 48 1.86E-28 cancer LOC283999# 0 
chr22:17257787-19792353 Del 
120 
(113-
450) 
40 
(37-54) 
6.41E-27 
cardiovascul
ar 
59 0 
chr22:18170308-21353745 Del 119 74 1.95E-21 neurological 61 8 
chr1:2380448-62205688 Del 
70 
(10-427) 
43 1.08E-20 cancer 714 94 
chr17:1403257-7200392 Dup 58 43 2.33E-17 neurological 147 12 
chr4:133156765-135766744 Del 65 46 3.76E-17 neurological 
PABPC4L,PCDH1
0 
1 
chr16:83162917-88131087 Dup 53 40 1.05E-16 neurological 52 16 
chr16:1132214-1781034 Del 338 103 2.64E-16 cancer 26 1 
chr14:103629376-103638225 Del 185 68 1.02E-15 cancer ASPG 0 
chr4:39661333-39722082 Del 130 59 3.56E-14 autoimmune LOC344967 0 
chr19:19762136-20585008 Del 292 121 3.63E-14 neurological 
ZNF[253,486,506,
682,737,826,90, 
93] 
1 
chr11:67505393-67573512 Del 65 34 8.86E-14 cancer 
ALDH3B1,NDUFS
8,TCIRG1,UNC93
B1 
0 
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Disease category enrichment in CNVRs P<9x10
-14
.Complete results P<5x10
-8
 provided in Supplementary 
tables 12-14. Each disease category represents at least 10 distinct specific diseases. #CNVR does not 
overlap a gene so closest proximal gene provided. Count genes overlapped provided when many. Regions 
without parenthesis did not vary by more than 20 samples across the CNVR. 
 
We observed several regions of significant association with disease state, including 
chr1p36.2-p31.3, which was significantly enriched for deletions in cancer; chr17q21.1-
q25.3, which was significantly duplicated in cancer; and chr22q11.21, which was 
significantly deleted in congenital heart/metabolic disease, replicating previous reports 
(28, 136, 149). The significantly associated CNVRs were enriched for association in 
cases for the respective disease category they represented. In addition, several novel CNV 
loci demonstrated associations with the integrative disease category approach, all of 
which were rare, and we show that 55% of significantly associated CNVRs to disease 
category overlapped GWAS significant loci based on previous reports.   
 
In addition to the above CNV enrichments observed at OMIM genes and GWAS loci, we 
also noted significant CNV enrichment at genomic regions harboring noncoding RNAs 
(combined CNV P= 5.97E-91) (Table 3.1). While the biological consequences of the 
latter CNV enrichment are unclear, the data suggest that in keeping with the implications 
of enrichment at disease genes linked to OMIM genes and GWAS loci, CNVs impacting 
noncoding RNAs may confer disease-causing effects. In addition, more attention should 
be paid to noncoding RNAs in disease association studies, as shown by a recent autism 
study (102) where a modern RNA tiling approach uncovered and validated such a 
relationship. 
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Thus, evaluation of population 
specific CNVs has unveiled several 
genes impacted by CNVs and 
demonstrated ethnicity-specific 
enrichment in the frequency of CNV 
loci (Sup.Table 3.15). As noted 
above, we specifically addressed 
CNVR distributions that were 
enriched as a result of specific 
Illumina BeadChip version, subject 
ethnicity or sample source to  
 
3.6 Replication of 
Known CNVs and 
Impact at the 
Population Level 
 
We observed known Mendelian CNV 
disorders at an expected frequency in our sample set of 68,000 samples, including but not 
limited to Prader-Willi syndrome (15q11-13); Smith Magenis (17p11.2); DiGeorge 
(22q11.2); Williams (7q11.23); and X-linked ichthyosis (Xp22.31). As we did not have 
known Mendelian disorders pre-identified in our study, which in fact constitutes healthy 
controls and four major classes of complex diseases, the association of CNVs in these 
Figure 3.5. Deletion CNVR Samples Observed vs. 
Subgroups Represented with circle size as the number of 
CNVRs. 
 
 
 
A) Illumina Chip Version B) Ethnicity C) Sample 
Source. Circle size represents the number of CNVRs at 
each point. 
 
B 
A 
C 
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individuals with OMIM genes is novel and of high biological interest; however, one still 
needs to determine if these are Mendelian phenocopies of complex disease or if CNVs in 
Mendelian diseases are significant pathogenic factors in complex disease – which is a 
subject of future studies.  Moreover, unlike CNVs in the disease cohorts, there were 
clearly no CNVs in the super controls that were enriched at genome-wide significance 
level. We have healthy control enriched loci (Sup. Tables 3.12-14) as indicated in Table 
3.2, but none of those are genome-wide significant. 
 
It is important to note that the CNV associations we have captured are independent events 
and we do not have a measure on if two or more rare recurrent CNVs are disease causing 
– this requires complex biological studies beyond the scope of this manuscript. Indeed, 
two known disease associated CNVs in one individual is extremely rare and we carefully 
prioritized such cases for clinical evaluation. 
 
As noted above, our study is focused on reporting rare recurrent CNVs and, as such, is 
fundamentally different from that of Donnelly and colleagues (39), which is devoted to 
common CNVs.  The fact that rare recurrent CNVs co-occur with GWAS genes is 
unexpected, however, the common GWAS SNPs cannot tag these rare CNVs 
necessitating direct CNV detection herein.   
 
For power reasons, we report on four major disease categories (autoimmune/ 
autoinflammatory; cancer, neurological; metabolic/cardiovascular), as well as healthy 
controls, as individual diseases are underpowered for association with rare variants. This 
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gives us a focus which is fundamentally different from any previously reported GWAS 
study. For example, we demonstrate association to autoimmune/autoinflammatory 
diseases as a class (IBD T1D, JIA, SLE, Celiac disease, asthma). Thus, the observation 
that CNVs associate with the respective disease classes is novel and of important 
biological relevance, as it extends beyond any previous GWAS/CNV report. 
 
We have captured the global impact of rare recurrent CNVs in terms of frequency, 
distribution and the role of such structural variants in health and disease across four major 
disease categories as well as controls, including across different ethnicities following 
thorough correction for population stratification measures. We note that our evaluation of 
population specific CNVs has unveiled several genes impacted by CNVs and 
demonstrated ethnicity-specific enrichment in the frequency of CNV loci (Sup. Table 
3.15); however, no difference was observed in overall CNV frequency across the 
different ethnic groups (EA, AA, Asian). 
3.7 Discussion 
Our results demonstrate that there is an abundance of CNVs across the genome that 
impact and flank functional elements with potential for major disease implications 
(Tables 3.1-2). While CNVs have been shown to importantly contribute to disease 
association studies, it is critically important that databases with CNVs and associated 
phenotypes be annotated along with platform and CNV call confidence scores. The 
Database of Genomic Variants Structural Variation which is available in UCSC genome 
browser is currently one of the most informative and useful resources of CNV 
information for investigators (94). The current CNV map has uncovered numerous novel 
A 
B 
70 
 
CNV regions, many of which are disease associated (Tables 3.1-2). GWAS has similarly 
been highly successful in unfolding novel loci of strong disease and biological relevance 
(2); however, lack of linkage disequilibrium with rare CNVs at over 90% of loci 
underscores the needs for CNV detection to be performed separately, particularly for very 
rare CNVs. SNPs with three or more states and considerable heterozygote frequency are 
well suited to differentiate duplication based on genotype states.  
Copy number variation (CNV) is a commonly observed phenomenon in healthy 
individuals and also has gene dosage-sensitive effects on specific phenotypes.  While 
several CNV maps have been reported that illustrate the wide-spread impact of CNVs on 
the human genome and implicating compelling biological functions for some CNVs, they 
are all built on relatively small sample sizes and lack depth of rare CNV coverage (35, 
39, 88, 94, 98, 129, 139, 172, 182, 183, 185, 205). This study was designed to 
characterize rare CNV by assembling the largest population CNV map of the human 
genome through the study of 68,028 genotyped individuals from four populations with 
ancestry in Europe (52,321), Africa (12,548), Asia (2,299), and Latin America (860). We 
processed genotype and intensity data for CNV detection using Illumina single-
nucleotide polymorphism (SNP) genotyping arrays intersection set of 520,017 SNPs. 
CNVs called per individual averaged 18.6 probes and the length of the CNVs called 
averaged 68 Kb, with average individual CNV burden was 600 kb, including a rare CNV 
component of 200 kb (Figure 3.1).  
 
 
By mapping individual CNVs  into population statistics, 5,378 copy number variable 
regions (CNVRs) were identified, with deletions covering 2.35 gigabases (78% of the 
A 
B 
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genome) and duplications covering 2.46 gigabases (82% of the genome), in keeping with 
the pervasive nature of CNV (Sup. Tables 3.5-7). While most CNVRs were rare, 4,969 
deletion, 2,633 duplication, and 263 homozygous deletion CNVRs were detected in 
multiple unrelated individuals (Suppl. Tables 3.5-7). Reported GWAS loci were present 
in 2,729 of the CNVRs identified demonstrating strong enrichment for CNVs at GWAS 
loci (P=5.97E-91) and similarly 1,531 CNVRs overlapped OMIM disease associated 
genes. A total of 964 deletion and 343 duplication novel CNVRs were uncovered that 
were not reported in the DGV. Of the CNVRs detected, 64% overlapped genes. Of note, 
genes functionally enriched for growth factor signaling and other signal transduction 
processes and intermediate filaments, were most commonly enriched for CNVs.  Genes 
residing in segmental duplications and disease associated regions were also notably 
enriched for CNVs.  
All CNVRs were controlled for beadchip version, ethnicity, and sample source to exclude 
any processing bias. Linkage disequilibrium between common SNP genotypes and rare 
CNVs was poor. In addition to determining CNV distribution in healthy subjects, we also 
examined CNV clustering across broad disease categories of cancer, autoimmune disease, 
congenital heart/metabolic disease and neurological populations, with high statistical 
power for comparison, demonstrating significant enrichment for specific chromosomal 
regions impacted by CNVs to these disease categories (Table 3.2 and Suppl. Tables 3.12-
14).  Similar enrichment in CNV association was also observed for noncoding RNAs 
(Table 3.1), suggesting they may be more relevant to human disease that previously 
thought.  
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We additionally demonstrated population frequency differences of CNVs in loci across 
the genome (Figure 3.3 and Suppl. Table 3.15), suggesting the process of evolution 
through gene family extension is enabled by CNVs, and that CNVs impact gene networks 
across all major disease categories (Table 3.2 and Suppl. Tables 3.12-14). 
We thoroughly evaluated our dataset for inflation in the test statistic and adjusted for 
CNV classes.  This approach is fundamentally no different from standard statistical tests 
for GWAS.  Since there is no other cohort of this size that has GWAS performed by the 
same laboratory, we are setting standards for the genetics field with our analysis.  We 
note that details of the statistical methodology used for the CNV reporting herein were 
recently described inParseCNV (70), a novel algorithm developed by our laboratory 
(Suppl. Material).  
 
As noted, the average individual CNV burden is approximately 600kbp (Figure 3.1), 
including distribution of all CNVs across the study cohort.  The median CNV size of 7 
SNPs with minimal call size in SNPs of 3. The mean SNP coverage is 5,280 bp between 
neighboring SNPs. The median SNP coverage is 2,965 bp between neighboring SNPs.  
Our recently published CNV algorithm, ParseCNV, was used for CNV association 
capture, definition of CNVRs and statistical analysis, an algorithm that has been 
extensively validated for CNV call accuracy, based on experimental validation.  Thus, in 
addition to random experimental validation of CNV loci from the 68,000 samples with 
excellent success as presented (>90%), the algorithm used has been independently 
validated providing high level of confidence (>90%) for the results presented here. 
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While somatic alterations and mosaicisms exist in DNA samples derived from blood, 
their contributions overall are minimal and do not impact the results presented here.  
Moreover, we have no example of a common GWAS SNP capturing any of the rare 
recurrent CNVs reported.  The Illumina chips we used are designed to stay away from 
common CNV regions so they are highly underrepresented in our report as a result of 
chip design. We note that 48 common CNVs remained in our observed data despite the 
array being strongly biased away from copy number polymorphisms with >1% 
population frequency, which is a minor subset of what we are reporting here.  
 
The raw CNV counts (Sup. Table 3.16) were used to create randomized set of genomic 
regions of best matched length and number of SNPs to compare to CNVRs for genomic 
features to score statistical significance.  We searched for functional enrichment across 
all CNVRs to find insight into biological functions tempered by CNV as a major 
mechanism. As a result, we specifically reduced the phenotype variables to 4 major 
disease classes, all of which show strong association to specific CNV loci. We note that 
96% of the genome is CNVR-based refined to the portion of the genome we have 
reasonable coverage so the analysis is truly genome-wide and hypothesis-independent. 
The NHGRI GWAS catalog is the source of the GWAS signals that were intersected with 
CNVRs compiled across diverse disease association studies. In the CNV clustering by 
disease categories, we performed 7,602 statistical tests to correct for in association (4,969 
deletions and 2,633 duplications). To be inclusive for ethnicity differences we included 
both the super control cohort and the subjects in the four major disease categories. 
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Our extensive CNV validation measures (including those intrinsically supporting the 
ParseCNV algorithm which was used to make these CNVR calls) included separate 
deletions from duplications with respect to CN state.  Over 100 random deletion and 100 
random duplication validations are presented across diverse genome regions, length, and 
number of SNPs on our array with success rate in the above 90% (70). As we and others 
have reported previously, deletions and duplications co-exist in multiple disease-causing 
CNV regions, including well established disease loci such as16p11 and 15q11-13. We 
note that the population frequency of the alternate event is often much lower but 
recurrent. 
 
One limitation is that if a sample is A, AA, or AAA we cannot differentiate these allelic 
states based on B allele frequency. CNV sensitivity is supported with quantification with 
reference to HapMap samples typed on our arrays compared to the current gold standard 
set by Conrad et al. (35). Population frequency <1% (<680 subjects) defines a rare CNV 
in our study. It is important to note that we need to accurately assess CNVs in a 
“reference genome” sample in order to correctly make genotype A/T/C/G calls. Since 
genome sequencing always does mapping to this “reference genome” sequence assuming 
diploid status, we have implicated more of the genome than previously thought (133) is 
impacted by rare CNV. 
 
We have included the few common CNVs available by our array content to cross 
reference our findings with the popular gold standard paper by Conrad et al.  Otherwise, 
the Illumina arrays stay away from common CNVs, which is in sharp contrast with the 
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aCGH arrays used in the Conrad et al study. For all statistical measures, Fisher’s exact 
test was used as a conservative test.  As described earlier, a maximum variance of 20 
samples between neighboring probes was allowed. 
 
The present CNV study has high rare CNV coverage and encompasses the majority of the 
genome based on the large sample size used (Figure 3.2 and Suppl. Tables 3.5-7). We 
believe that our large population-based frequency characterization provides a unique 
opportunity to characterize the distribution and impact of CNVs in the genome and the 
fact that all samples were typed on comparable platform and with vast majority 
genotyped at the same laboratory accounts for high data quality. Future resequencing 
studies will ultimately improve our resolution and confidence of detecting smaller CNV 
calls of 1kb or less, we are unable to address in this study.  Indeed, combinations of 
sequence assembly comparisons, paired-end sequence relationships, sequence trace 
analysis, and higher-resolution tiling arrays will similarly aid in determining the precise 
CNV breakpoints and genotype state for individual CNVs. While GWAS and genome-
wide CNV analyses have contributed in a major way to the understanding of the 
distribution and biological impact of CNVs, whole-genome sequencing studies (146)will 
ultimately provide the most continuous and confident information of individual CNVs 
and their role in disease.  
 
Taken together, the CNV results reported herein include results from over 68,000 
subjects, an order of magnitude greater in the amount of data previously published. In 
addition, we took the unprecedented step to couple this dense map of SNP data to clinical 
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association findings. As a consequence, we show for the first time that rare CNVs, which 
cannot be tagged by standard genotyping arrays, are associated with the following 
genomic elements genome-wide: 1) GWAS genes; 2) OMIM genes; and, 3) non-coding 
RNAs.  These observations present a fundamental new concept on how GWAS genes 
(linked to common variants), OMIM genes (linked to rare diseases) and non-coding 
RNAs (most of which are thought to play no or unknown role in disease biology), impact 
on common complex disease through rare highly penetrant CNV providing new insight 
into the mechanistic role of rare recurrent CNVs in complex disease biology and etiology. 
 
Moreover, the analyses presented here are highly robust, as demonstrated by the strong P 
values generated and only made possible by the exceptional size of the cohort.  As such 
confidence in these findings is extremely high by adding further support of the key 
findings validated by either family-based analyses (heritable CNVs), visual inspection of 
B-allele frequency/LRRs of the genotyping data or by experimental validation if any 
uncertainty, resulting in over 90% validation success rate of the CNVs reported. These 
validation parameters are further supported in a recent manuscript reporting on a novel 
CNV analysis approach and statistical applications that were used here (70). Moreover, 
our novel CNV reporting, extensive mapping and reporting of homozygous CNVs 
(human knockouts) in the context of novel association findings delineate multiple bona 
fide discoveries that are well powered and of biological interest for others to follow.  
 
Thus, we have mapped multiple novel homozygous CNVs and observed novel 
associations to the four major disease categories we examined, and observed that CNVs 
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co-localize to important genomic elements, including GWAS genes, OMIM genes and 
non-coding RNAs, that surprisingly include the most significant genomic elements at the 
genome wide level that track with disease-associating CNVs.  
 
 
3.8 Methods 
  
The study inclusion criteria included:  1) availability of high-quality genotype data from 
subjects typed on a high-density SNP arrays; 2) sample having de-identified status and 
residing in the bio-repository at the Center for Applied Genomics (CAG) of the 
Children’s Hospital of Philadelphia (CHOP) where they were genotyped; 3) informed 
consent authorizing de-identified use of GWAS data with limited phenotype information.  
Different ancestry populations were analyzed and all 68,028 samples were typed at the 
same genotyping center within a five year interval from August 2006 to July 2011. Over 
95% of the DNA was extracted from fresh blood.  Six incremental versions of the 
Illumina 550k SNP set was used with a total of 520,017 SNPs in common to all the chip 
versions.  PennCNV was used for CNV calls and validated by QuantiSNP.  Quality 
metrics were calculated and their distributions assessed to ensure optimal quality and to 
minimize bias. Only samples with call rate >98% and Log R Ratio (LRR) standard 
deviation <0.35 were included in the analysis.  Furthermore, autosome genotype 
relatedness, excessive CNV calls as a measure of poor sample quality, and intensity wave 
variations following GC content wave correction were assessed for sample exclusion.   
CNV sensitivity was excellent based on CNVs in reference Hapmap individuals and 
CNV specificity exceeded 91% based on validation in 2,127 samples, testing different 
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size ranges across the entire genome, using qPCR. Here, we present the results of 409 
attempted and 367 successful validation assays from 7 disease studies with a range of 
different genomic loci and CN states (Sup. Fig. 7). 
 
Case and control matching was insured by calculating a genomic inflation factor between 
groups. Wave artifacts roughly correlating with GC content resulting from hybridization 
bias of low full length DNA quantity are known to interfere with accurate inference of 
copy number variations. Only samples where the GC corrected wave factor of LRR 
<|0.02| were accepted. If the count of CNV calls made by PennCNV exceeds 100, it is 
suggestive of poor DNA quality, and those samples were excluded. Thus, only samples 
with CNV call count < 100 were included.  Any duplicate samples (such as monozygotic 
twins or repeats on the same patient) were identified and as a result one sample was 
excluded. 
 
CNV frequency was compared between various groups, including between cases and 
controls. Comparisons were made for each SNP using Fisher’s exact test. To determine 
CNV enrichment, we only considered loci that were nominally significant between the 
comparative groups (p<0.05). For case-control comparisons, we looked for recurrent 
CNVs that were observed across different independent cohorts or were not observed in 
any of the control subjects, and were validated with an independent method. Three lines 
of evidence establish statistical significance: independent replication p<0.05, permutation 
of observations, and no loci observed with control enriched significance. We used 
DAVID (Database for Annotation, Visualization, and Integrated Discovery) to assess the 
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significance of functional annotation clustering of independently associated results into 
InterPro categories. 
 
Taken together, apart from unveiling multiple important disease associations, our 
genome-wide CNV analysis in over 68,000 individulas  has provided a robust population 
frequency distribution for rare CNVs in general. Now we proceed onto the challenge of a 
similar meta-view of disease in lifespan. 
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Chapter 4  
4.0 Copy Number Variations in Alternative Splicing Gene Networks 
Impact Lifespan 
 
Summary 
 
Longevity has a strong genetic component evidenced by family-based studies. 
Lipoprotein metabolism, FOXO proteins, and insulin/IGF-1 signaling pathways in model 
systems have shown polygenic variations predisposing to shorter lifespan. To test the 
hypothesis that rare variants could influence lifespan, we compared the rates of CNVs in 
healthy children (0-18 years of age) with individuals 67 years or older. CNVs at a 
significantly higher frequency in the pediatric cohort were considered risk variants 
impacting lifespan, while those enriched in the geriatric cohort were considered longevity 
protective variants. We performed a whole-genome CNV analysis on 7,313 children and 
2,701 adults of European ancestry genotyped with 302,108 SNP probes. Positive findings 
were evaluated in an independent cohort of 2,079 pediatric and 4,692 geriatric subjects. 
We detected 8 deletions and 10 duplications that were enriched in the pediatric group 
(P=3.33x10
-8
 - 1.6x10
-2
 unadjusted), while only one duplication was enriched in the 
geriatric cohort (P=6.3x10
-4
). Population stratification correction resulted in 5 deletions 
and 3 duplications remaining significant (P=5.16x10
-5
-4.26x10
-2
) in the replication 
cohort. Three deletions and four duplications were significant combined (combined 
P=3.7x10
-4
-3.9x10
-2
). All associated loci were experimentally validated using qPCR. 
Evaluation of these genes for pathway enrichment demonstrated ~50% are involved in 
alternative splicing (P=0.0077 Benjamini and Hochberg corrected). We conclude that 
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genetic variations disrupting RNA splicing could have long-term biological effects 
impacting lifespan.  
 
4.1 Introduction and Significance  
 
The idea of extended lifespan has fascinated generations of scholarly thought. Specific 
diseases have been the focus of much biomedical research rather than overarching 
longevity which in essence successfully avoids a variety of diseases. The average lifespan 
of the human population has continued to increase at a slow rate due to medical and 
technological advances that aim at preventing and treating both acute and chronic 
diseases and attenuating morbidity and mortality of old age (208).Identification of 
underlying causes of early fatality provides information that can facilitate preventive 
measures. As hypothesis free approach is the gold standard to assay genomic variants for 
disease states, it is equally important to take a hypothesis free approach to assay 
longevity, one of the most informative measures of health vs. disease states. This 
approach also addresses the complication in genetics of pleiotropy (one gene:many 
diseases) where disease phenotype variability results in insufficient power of single 
disease association studies. 
 
Model systems have demonstrated that lifespan can be dramatically extended by 
mutations in conserved pathways that regulate growth, energy metabolism, nutrition 
sensing, and reproduction (101). A low activity level of organs in many cases extends 
lifespan perhaps by reduction of somatic damage and increase of somatic maintenance 
and repair (101). Strict diet maintaining just above malnutrition has been shown to extend 
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longevity (30). The leap from model system to human is substantial given the lack of 
genetic diversity and protective laboratory environment of model systems. It is more 
probable that significant longevity was achieved by subtle changes in many genes over 
the course of evolution, not by single mutations with large effects, which often increase 
lifespan at a cost to reproduction or survival under stress (100).  
 
Genome instability, macromolecular aggregates, decrease in innate immunity, 
skin/cuticle morphology changes, decreased mitochondrial function, degenerative loss of 
skeletal muscle mass and strength, and decreased fitness are highly conserved phenotypes 
of ageing.  Lifelong accumulation of various types of damage, along with random errors 
in DNA maintenance, might underlie intrinsic ageing. Early findings of mutant C. 
Elegans with extended lifespan (107) and linkage studies (166)showed that longevity 
could be associated with genetic traits. A meta-analysis of 4 cohorts of individuals 
surviving over 90 years of age found MINPP1(involved in cellular proliferation) as well 
as LASS3 and PAPPA2 to be involved (150). Genes impacting lipoprotein metabolism (6, 
7, 10), FOXO proteins (57, 215), and insulin/IGF-1 signaling (16, 110, 153) in humans 
have also been associated with lifespan. 
 
Copy number variations (CNVs) are rare losses and gains in DNA sequences that have 
been importantly implicated in the pathogenesis of various neurodevelopmental and 
psychiatric diseases (65, 67, 116). As opposed to SNP genotypes which have revealed 
common variants conferring modest relative risk to the individual with the variant, CNVs 
are often rare variants not observed or extremely rare in a normal control population and 
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conferring high relative risk. SNP arrays have vastly improved the detection of CNVs 
across the human genome over classical methods of karyotype review under a 
microscope. While the realm of neuropsychiatric and other system disorders have been 
explained in part by CNVs, it remains to be determined if there are certain gene classes or 
networks of genes that are pathogenic or disease-causing in general, and if there are other 
gene networks that may be protective in the same manner.  One way of testing this is to 
compare CNV states and frequencies between pediatric and geriatric subjects and 
determine if certain CNVs are lost in the older age group (i.e. suggesting pathogenic 
impact with shortened lifespan), and if other CNVs are enriched and considered 
protective.  Since the detection of CNVs has greatly improved and continues to improve 
with simultaneous evaluation of genotype and intensity data with continuous coverage of 
the genome and differentiating models of the diploid from the CNV state, we have 
undertaken such comparisons in cohorts of pediatric cases (0-18) and adults above the 
age of 67. 
4.2 Results   
Table 4.1.  Discovery and Replication Case:Control Sample Sets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contributing project totals in discovery and replication phases. The totals represent the number of high 
quality datasets derived from samples. 
 
Cohort 
Samples 
Count 
Country of 
Origin 
Discovery 
CHOP Pediatric 
7,313 United States 
Discovery IHA 
Geriatric 
2,701 Iceland 
Replication 
CHOP Pediatric 
2,079 United States 
Replication 
Geriatric 
4,692 United States 
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The pediatric discovery group included 7,313 children recruited at the Children’s 
Hospital of Philadelphia (Table 4.1). The geriatric discovery cohort included 2,701 
individuals recruited by the 
Icelandic Heart Association in the 
AGES Reykjavik study of 67 years 
or older. Only samples meeting 
strictly established data quality 
thresholds for copy number 
variation were included in the 
analysis. Pediatric subjects were 
genotyped on the Illumina Human 
Hap550 while geriatric subjects 
were genotyped on the Illumina 
HumanCNV370-Duov1.0. To 
ensure comparability of results, 
only the intersection set of 302,108 
SNPs common to both platforms 
was evaluated. All arrays used the 
Illumina Infinium II 
beadchiptechnology with standardized reagents, oligos, and experimental protocol to 
minimize variation between genotyping at different sites. Multiple neighboring SNPs 
Figure 4.1. Principle Components Analysis of Pediatric and 
Geriatric Cohorts.  
 
 
 
Discovery U.S. Pediatric vs. Icelandic Geriatric A) Principal 
components (PC) 1 vs. 2 shows distinct clusters likely due to 
sporadic differential profiles of a specific subset of SNPs 
between arrays. Since CNV calling is based on multiple 
neighboring SNPs and differential clustering SNPs are 
randomly distributed, CNV discovery should not experience 
significant bias. B) PC2 vs. 3 representing population 
structure showing some overlap of pediatric and geriatric 
cohorts C) SNP genotype allele frequency differences 
genome wide showing close correlation. 
Replication U.S. Pediatric vs. U.S. Geriatric D) Replication 
of U.S. pediatric and U.S. geriatric PC1 vs. PC2 showing 
high overlap unlike panel A U.S. pediatric and Icelandic 
geriatric E) Geriatric replication cohort in isolation for 
clarity F) Population structure of pediatric subjects with 
significantly associated risk CNVs for short lifespan 
showing broad normal distribution minimizing test statistic 
inflation for rare variants opposed to tight clustering(37) G) 
Pediatric replication cohort in isolation for clarity. 
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(minimum 3) are required to make a CNV call so one biased SNP in a region will not bias 
the CNV calling. CNVs were scored with both PennCNV (211) and QuantiSNP (34) for 
copy number deviating from normal diploid state 2: states 0 and 1 for deletions and 3 and 
4 for duplications. We compared frequency of deletions and duplications between 
pediatric and geriatric subjects to assess significant enrichment of rare recurrent CNVs in 
either group. Evaluating the SNP 
genotype data revealed tight clustering 
of populations at the origin by principle 
components analysis (PCA) indicative 
of European ancestry. Unfortunately, 
low overlap of populations was 
observed when the pediatric and 
geriatric cohorts were plotted together 
(Figure 4.1A and 4.1B). Many CNV 
and genotype associations made in 
cohorts of European ancestry have 
shown robust replication in Icelandic 
cohorts (53, 76, 79, 189, 191, 202), 
indicating that CNVs observed in the 
more broadly-defined European and 
American Caucasian gene pool are also 
important in the Icelandic population. 
Figure 4.2. Manhattan Plot of (A)Deletion and 
(B)Duplication SNP based CNV Statistics 
 
 
 
Black and gray alternating chromosome coloring to 
differentiate. 
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The Icelandic cohort is unique in having risk factor assessments earlier in life and 
detailed late-life phenotypes of quantitative traits (85). Our rationale for comparing these 
cohorts was the availability of large pediatric and geriatric populations with extensive 
phenotype characterization both genotyped on the Illumina microarray. While the PCA 
analysis clearly shows this comparison to be impacted by population stratification and 
that PCA cannot be applied as covariates due to this lack of overlap, we believe this 
comparison can be hypothesis generating in showing if such associated variants can be 
replicated in an independent 
population with a very good PCA 
overlap, but less phenotype depth. 
 
To associate CNV loci potentially 
contributing to shortened lifespan, we 
applied a segment-based scoring 
approach that scans the genome for 
consecutive probes with more frequent 
copy number changes in pediatric 
compared to geriatric subjects. The 
genomic span for these consecutive 
probes forms common copy number 
variation regions (CNVRs). We uncovered 101 loci with deletion and 76 with duplication 
enrichment in the pediatric cohort. Conversely, we identified 90 loci with deletion and 74 
with duplication enrichment in the geriatric cohort (Figure 4.2).   
Figure 4.3. Independent Technology Validation of 
Presence of CNV Events to Confirm CNVs Detected by 
Illumina Array. 
 
 
 
Error bars denote the standard deviation of quadruplicate 
runs. 
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After raw data QC and genomic context review, a high confidence discovery set of 55 
deletions and 40 duplications that were significantly enriched in the pediatric cohort 
resulted while 53 deletions and 43 duplications were enriched in the geriatric cohort. 
These filtering criteria included exclusion of telomere, centromere, CNV boundary 
uncertainty, extreme GC content, poor SNP coverage, and CNVR sample bias. CNVR 
sample bias refers to the same sample contributing to the association signal of many 
different significant CNVRs, despite up-front sample quality control, often due to 
atypical intensity wave patterns. 
 
We next sought to independently replicate these CNV findings in additional pediatric and 
geriatric subjects. CNVs were called for 2,079 young age subjects from independent 
pediatric cohorts all of which were recruited in the U.S.A and genotyped on the Illumina 
Infinium HumanHap550. We compared the CNV frequency in young with an 
independent cohort of 4,692 older subjects (over 50), all of which were recruited in the 
U.S.A. and genotyped on the Illumina Infinium Human660W-Quad. We replicated in the 
same direction 11 deletions and 10 duplications that were significantly enriched in the 
pediatric cohort, while 1 duplication was enriched in the geriatric cohort. As shown in 
Figure 4.1, in contrast to the Icelandic geriatric vs. U.S. pediatric PCA plot (panel 1A), 
the replication U.S. geriatric vs. U.S. pediatric did show strong overlap (panel 1D) 
indicating comparable population structure.  
Furthermore, we were able to correct for any residual population structure using the first 
three components of the PCA as covariates for logistic CNV association. This gives the 
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unique opportunity to test replication of associated loci between non-overlapping PCA 
populations which cannot be corrected by covariates with well overlapping PCA 
populations controlled by covariates. We can also assess replication between Illumina 
array versions for consistent CNV detection. We believe leveraging existing data with a 
variety of variations may lead to associations more likely to remain significant by further 
studies where these variations are often manifest in addition to data processing variations 
which we were able to control by applying consistent processing across all data. 
 
To assess the reliability of our CNV detection method, we experimentally validated all 
the significant CNVRs using an independent wet lab method, quantitative real time 
polymerase chain reaction (qPCR) (Figure 4.3) on a randomly selected samples with a 
CNV at each associated locus and samples without a CNV to normalize the measurement.  
 
 
This yielded a final confident set of 8 deletions and 10 duplications that were 
significantly enriched in the pediatric cohort (Table 4.2) while 1 duplication was enriched 
in the geriatric cohort (Table 4.3). 
Table 4.2. CNVs Enriched in Pediatric Individuals 
 
CNVR hg18 
CHOP 
Pediatric 
IHA 
Geriatric 
P 
Discovery 
Replication 
Pediatric 
Replication 
Geriatric 
P PCA 
Corrected 
Replication 
P 
Combined 
Gene Type 
chr8:2337918-
2570171 
87 4 3.33E-08 30 24 0.001406 0.00037 AK128880,BC045738 Dup 
chr22:18409878-
18439763 
42 0 3.89E-06 9 4 0.00487 0.003862 C22orf25,DKFZp761P1121 Del 
chr16:3553005-
3590430 
60 1 1.37E-07 16 0 0.9961 0.008209 BTBD12,NLRC3 Dup 
chr1:226561413-
226623411 
50 0 1.87E-07 7 0 0.9975 0.00924 KIAA1639,OBSCN Dup 
chr19:17245267-
17245267 
19 1 0.02286 12 3 5.16E-05 0.018451 HSPC142/BABAM1 Del 
chr1:6240656-
6289806 
26 0 0.0005 8 3 0.002979 0.020119 ACOT7,BACH,GPR153 Del 
chr11:47388879-
47443461 
66 4 9.00E-06 16 0 0.9965 0.038865 PSMC3,RAPSN,SLC39A13 Dup 
chr7:53428180-
53557744 
29 0 0.00019 8 5 0.1969 0.064854 FLJ45974* Del 
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chr17:71112486-
71153309 
20 1 0.02352 9 1 0.002534 0.076432 
LOC643008,MYO15B,REC
QL5 
Del 
chr21:43697488-
44395416 
14 0 0.01601 5 1 0.007178 0.096104 
AGPAT3,C21orf125,C21orf
33,C21orf84,CSTB,HSF2BP,
LOC284837,PDXK,PWP2,R
RP1,RRP1B,TRAPPC10 
Del 
chr4:973060-
1068187 
25 1 0.00626 9 1 0.02017 0.099286 
FGFRL1,IDUA,LOC285498,
RNF212,SLC26A1 
Dup 
chr7:71734626-
71921501 
37 3 0.00369 8 1 0.0426 0.10708 MGC87315 Dup 
chr17:2213549-
2231452 
25 0 0.0005 7 0 0.9981 0.15837 KIAA0397,RUTBC1 Dup 
chr16:1132214-
1138939 
38 3 0.00246 8 0 0.9979 0.26546 CACNA1H* Del 
chr19:10326832-
10403610 
14 0 0.01601 4 0 0.9986 0.46396 CDC37,PDE4A,TYK2 Dup 
chr19:3399694-
3421862 
22 2 0.03849 10 0 0.9974 0.5864 NFIC Del 
chr1:6245523-
6472963 
11 0 0.04318 12 0 0.997 0.60362 
ACOT7,ESPN,HES2,PLEKH
G5,TNFRSF25 
Dup 
chr17:76836926-
76916744 
11 0 0.04318 9 0 0.9977 0.60373 
C17orf55,MGC15523,TME
M105 
Dup 
*Gene not overlapped so closest proximal gene annotated. Gene delimiters were defined based on UCSC 
genes table reference including exons and introns. Any direct overlap of any segment of the gene delimiters 
is considered a hit such that complete overlap of the gene is not required. Combined p-values were 
calculated using Fisher’s method. 
 
To fully correct for population stratification, in addition to multi-dimensional scaling, we 
performed principal component analysis (PCA) on the genotypes and used the resulting 
first three components as covariates of logistic test CNV association in the replication 
cohort. CNV events in our study are rare and arise randomly shown by evaluating the 
 
Table 4.3. CNVs Enriched in Geriatric Individuals  
 
CNVR hg18 
CHOP 
Pediatric 
IHA 
Geriatric 
P 
Discovery 
Replication 
Pediatric 
Replication 
Geriatric 
P PCA 
Corrected 
Replication 
P 
Combined 
Gene Type 
chr5:26,246,320-
26,273,890 
1 7 0.00063 0 24 0.9963 0.17091 CDH9* Dup 
 
spatial distribution of samples having a risk CNV on the PCA plot revealing a Gaussian 
(at minimum uniform due to few data points) distribution which indicating minimal test 
statistic inflation (even less than common variants) as opposed to a small, sharply defined 
region (137) (Figure 4.1F). We verified that population stratification was fully controlled 
for based on a genomic inflation factor of 1.0. Eight of eighteen pediatric enriched CNV 
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loci remained significant (p<0.05) following PCA population stratification correction 
(five deletions and three duplications; see Table 4.2). These results indicate that, while 
population stratification did indeed influence nominal p-value of the associated rare CNV 
variants in the discovery cohort, it could be corrected in the independent replication 
cohort, leaving a number of associated loci that replicated. 
 
Given the diverse etiology of diseases and more generally, lack of fitness in an 
evolutionary context, the genes underlying the broad consideration of ageing are similarly 
diverse. Single significant loci are certainly of interest to the common genomic CNVs 
resulting in specific genes to study. However, strong confidence in the result set 
generated can be achieved by observing the same biological system being perturbed by 
multiple independently significant loci. Motivated by this, genes directly overlapped by 
associated CNVs were prepared as a single list and non-RefSeq hypothetical gene IDs 
were removed. This list was entered into DAVID functional annotation enrichment tool 
in contrast with a background representing genome-wide regions covered by the array. 
Taking into account the size of different genes and the gene family size of different 
annotations, the enrichment of our CNV impacted list was assigned a p-value with 
Benjamini and Hochberg correction for multiple testing. Functional annotations from 
multiple databases were used including KEGG and GO (gene ontology). Functional 
categories were reviewed for genes contributing from distinct genomic regions to reject 
enrichment of closely clustered gene families. 
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To identify potential functional biases specific to CNVs observed at significantly higher 
frequency in young individuals, we evaluated clustering into specific functional 
categories using DAVID (46, 92) (Database for Annotation, Visualization, and Integrated 
Discovery). We found significant overrepresentation of alternative splicing genes 
impacted by the CNVs. To limit contribution of regions with gene families of related 
function, each CNV loci was limited to contributing one gene to a functional cluster, 
done by referencing resulting gene clusters back to the input genes from each CNV 
region. Among the alternative splicing genes are AGPAT3, BTBD12, NLRC3, RECQL5, 
SCAPER, ACOT7, C19orf62, C21orf33, C22orf25, ESPN, HES2, LUZP2, NFIC, 
OBSCN, PDE4A, PLEKHG5, PLXDC1, KCNT1, PDXK, RAPSN, RRP1B, RNF212, 
SGSM2, SLC38A10, SLC39A13, and TNFRSF25 all of which were significantly enriched 
in the young age group (P=0.0077 Benjamini and Hochberg corrected), suggesting that 
genetic variations that disrupt RNA splicing may have long-term biological effects on 
human lifespan. 
 
4.3 Discussion 
 
Limited nutrition, somatic maintenance and growth are pathways to longevity. Emphasis 
on somatic maintenance is more important than early growth and reproduction. Post-
transcriptional modification of mRNA is an important mechanism which results in a 
variety of protein isoforms and occurs in at least 80% of human genes, and known to 
harbor variations that have been associated with human disease (138). It is therefore of 
interest that 50% of the genes impacted by CNV loci significantly enriched in young and 
replicated in an independent cohort were responsible for alternative splicing, suggesting 
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that genetic variants in these gene networks may be pathogenic and disease causing in a 
more global way than previously thought. 
 
Alternative splicing is an abundant violation of the original assumption of one gene one 
protein theory. The exons of an mRNA can be edited producing a variety of combinations 
which result in a variety of protein 
isoforms. This mechanism allows for a 
great diversity of protein products 
based on the same DNA code and 
branches out gene families, in a similar 
mechanism that ancestral duplications 
extend gene families in DNA.  Proteins 
responsible for alternative splicing bind 
to specific RNA sequences to promote 
or repress splicing.  
 
SNPs in the RNA editing genes 
ADARB1 and ADARB2 were associated 
with extreme old age in a United States 
based study of centenarians with replication to four other ethnic backgrounds (181). DNA 
maintenance is of fundamental importance throughout the lifespan and is under assault by 
environmental conditions such as sunlight and chemical exposures. BTBD12 and 
BABAM1 are part of a multi-protein complex containing enzymes involved in DNA 
Figure 4.4. Regions of CNV in Young Individuals 
observed at low levels in Older Individuals. 
 
 
ACOT7 locus shows significant excess of deletions and 
duplications in young individuals. Blue lines indicate 
SNP marker coverage to resolve CNV boundaries. 
Histogram shows the number of subjects with deletion 
and duplication CNVs in the Icelandic older population 
(very low). The red and green boundaries show 
individual CNVs observed in specific young samples 
from CHOP. Genomic region references including GC 
percent, RefSeq Genes, and Database of Genomic 
Variants are provided for reference. 
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maintenance and repair of serious damage such as collapsed replication forks and double-
strand breaks (DSBs)(198). Of note, BABAM1 is the most highly significant CNV 
associated locus following full statistical correction of population stratification 
(p=5.16x10
-5
). 
 
ACOT7 is involved with biosynthesis of unsaturated fatty acids and decreased expression 
is associated with mesial temporal lobe epilepsy. Young individuals showed significantly 
higher frequency of both 
deletions and duplications of 
this locus compared to older 
individuals (Figure 4.4).  
 
Nuclear factor kappa B 
(NFKB1) signaling pathway is 
a fundamentally important 
protein complex that controls 
the transcription of DNA and 
responds to external factors 
such as stress, cytokines, free 
radicals, ultraviolet radiation, oxidized LDL, and bacterial or viral antigens. PLEKHG5 
activates the NFKB1 signaling pathway. TNFRSF25 encodes a receptor that has been 
shown to stimulate NF-kappa B activity and regulate cell apoptosis. The TNF-receptor 
signaling pathway is critically involved in the pathogenesis of inflammatory bowel 
Figure 4.5. Representative Interactions of the Lifespan 
Longevity Associated Genes Identified. 
 
 
 
Gene-gene interactions of independently significant loci. 
Additional genes implicated by interacting with genes in 
significantly associated longevity loci. Alternative splicing 
gene function annotation enrichment of significant loci 
suggests diverse genetic perturbation with a common biological 
role. Extension of this functional category to other genes 
annotated by functional studies with interactions to associated 
genes implicates potential for screening diverse etiology. 
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disease and rheumatoid arthritis (12). Such a pivotal gene is an example of autoimmune 
disease and strong immunity aiding survival in early age but early death as a 
consequence. Increased recombination rate has been shown to occur in older age 
mothers(111). RNF212 is essential for recombination & chiasma formation in C elegans. 
A CNV in a gene controlling recombination could lead to genome instability and 
excessive recombination with more chances for errors. 
 
Given that typical cause of death among different individuals is highly heterogeneous 
from a clinical perspective, the underlying genetic causes of premature death or 
attenuated longevity are likely to have similarly variegated set of genes. Therefore, based 
on the specific loci found significantly associated with lifespan, more integrative systems 
biology is possible leveraging protein-protein interactions using Cytoscape (184) (Figure 
4.5).  
 
Profiling expressed sequence tags (ESTs), smaller numbers of cDNA sequences assayed 
by microarrays and RNA-Seq has allowed for more complete profiling of alternative 
splicing (15). Continuing study on different tissues of the body coupled to CNV findings 
through high-throughput sequencing approaches in the future can help elucidate 
underlying mechanisms of ageing. 
 
This study represents the first genome-wide population based copy number variation 
study of human longevity, applying a unique study design to identify the pathogenic 
nature of CNVs at a global scale in human.  The use of the relatively large cohorts 
assembled here was essential, both to discover and to confirm the findings and 
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demonstrates the potential of genome-wide association in complicated polygenic ageing. 
This type of unbiased study has discovered many novel targets that may underlie short 
lifespan. We have focused on robustly identifying CNVs observed in a large sample of 
pediatric and comparing those observations to a large geriatric sample to see which 
CNVs limit the lifespan from reaching old age. This is distinct from the question of 
longevity to extremely late age but CNV occurrence in these genes reduces longevity and 
its effects need to be counteracted to produce exceptional longevity. These genetic 
variations present risk factors that can be screened in a clinical setting to prognosticate 
the risk of future premature death where preventive measures could potentially be taken 
to reduce risk. 
4.4 Materials and Methods 
 
Ethics Statement 
This research was approved by the Institutional Review Board of the Children’s Hospital 
of Philadelphia. All subjects were recruited and signed written informed consent if age 18 
or older. Parents signed written consent on the behalf of minors/children age 0-17 and the 
child signed a written assent if 7-17 years of age. The Data Protection Commission of 
Iceland and the National Bioethics Committee of Iceland approved this research on adult 
samples. The appropriate written informed consent was obtained for all adult sample 
donors. 
 
Study subjects 
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A cohort of healthy children under the age of 19 recruited within the Health Care 
Network of the Children’s Hospital of Philadelphia was compared with adult subjects 
above the age of 67 (average age 76), recruited for the AGES-Reykjavik study (85). The 
replication cohort was composed of young previously published in the context of autism 
(65) and older individuals accessed from dbGaP, including the Personalized Medicine 
Research Project (PMRP). The average age of the children was 8.6 years and average age 
of the adults was 60 years, with equal numbers of males and females. 
 
Illumina Infinium assay for CNV Discovery 
We performed high-throughput, genome-wide SNP genotyping, using the InfiniumII 
HumanHap550 BeadChip technology (Illumina San Diego CA), at the Center for Applied 
Genomics at CHOP. The genotype data content together with the intensity data provided 
by the genotyping array provides high confidence for CNV calls. Importantly, the 
simultaneous analysis of intensity data and genotype data in the same experimental 
setting establishes a highly accurate definition for normal diploid states and any deviation 
thereof. To call CNVs, we used the PennCNV algorithm, which combines multiple 
sources of information, including Log R Ratio (LRR) and B Allele Frequency (BAF) at 
each SNP marker, along with SNP spacing, a trained hidden Markov model, and 
population frequency of the B allele to generate CNV calls. The intersection set of 
302,108 probes common to the Illumina 550K: 532,898 probes and Illumina 370 Duo: 
370,405 probes was used to make datasets as comparable as possible  
 
CNV quality control 
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We calculated Quality Control (QC) measures on our HumanHap660 GWAS data based 
on statistical distributions to exclude poor quality DNA samples and false positive CNVs. 
The first threshold is the percentage of attempted SNPs which were successfully 
genotyped. Only samples with call rate > 98% were included. The genome wide intensity 
signal must have as little noise as possible. Only samples with the standard deviation 
(SD) of normalized intensity (LRR) < 0.30 were included. All samples must have clear 
European ethnicity based on Eigenstrat smartPCA scoring and all other samples were 
excluded. Wave artifacts roughly correlating with GC content resulting from 
hybridization bias of low full length DNA quantity are known to interfere with accurate 
inference of copy number variations. Only samples where the GC wave factor of LRR 
|GCWF|<0.05 were accepted. If the count of CNV calls made by PennCNV exceeds 100, 
the DNA quality is usually poor. Thus, only samples with CNV call count < 100 were 
included. Any duplicate samples (such as monozygotic twins) had one sample excluded.  
 
Statistical analysis of CNVs 
CNV frequency between cases and controls was evaluated at each SNP using Fisher’s 
exact test. We only considered loci that were significant between cases and controls 
(p<0.05) where cases in the discovery cohort had the same variation, replicated in an 
independent cohort or were not observed in any of the control subjects, and validated 
with an independent method. We report statistical (p-value) local minimums to narrow 
the association in reference to a region of nominal significance including SNPs residing 
within 1 Mb of each other. Resulting significant CNVRs were excluded if they met any 
of the following criteria: i) residing on telomere or centromere proximal cytobands; ii) 
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arising in a “peninsula” of common CNV arising from variation in boundary truncation 
of CNV calling; iii) genomic regions with extremes in GC content which produces 
hybridization bias; or iv) samples contributing to multiple CNVRs. A peninsula is 
defined as a false positive association arising from a region of common CNV extending 
variably due to variability in probe performance and variability in samples. In other 
words, the specific significant subregion is confounded by contributing calls also 
extending to a non-significant subregion. 
To fully correct for population stratification, we performed (PCA) on the genotypes and 
used the resulting first three components as covariates of the logistic test for CNV 
association using Plink. 
Combined p-values were calculated using Fisher’s method. 



k
i
ipX
1
2 )log(2  
Where pi is the p-value for the ith study. Under the null hypothesis, X
2
 follows a chi-
squared distribution with 2k degrees of freedom, where k is the number of studies. In this 
case, there were two studies yielding a chi-squared distribution with four degrees of 
freedom. 
 
To inform multiple testing correction, CNV filtering steps have been performed as part of 
the analysis. Firstly, it is important to note that of the intersection set of 302,108 SNPs on 
the Illumina array, 3,911 (1.295%) showed deletion and 8,830 (2.923%) showed 
duplication in at least eleven or more unrelated cases in the discovery cohort (frequency ≥ 
0.150%). 41,392 (13.701%) deletion and 45,050 (14.912%) duplication SNPs were 
observed in at least two individuals. The threshold of three cases harboring a given CNV 
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is selected because it is the minimal case frequency to provide minimal expectation of 
frequency differences between cases and controls to yield nominal statistical significance 
and reproducibility for the calls in a given region. We find this upfront exclusion to be 
very similar to the inclusion threshold of 1% minor allele frequency in GWA SNP 
genotype studies. These SNPs were collapsed into 101 deletion and 76 duplication 
CNVRs based on necessary multiple neighboring SNP signals to call a CNV and 
resulting redundancy of individual SNP statistics. This results in a total of 171 tests being 
performed corresponding to a multiple testing correction bar of p=2.92E-4 close to the 
p=5E-4 bar we have seen previously. 
 
Gene Category Enrichment 
Given the diverse etiology of diseases and more generally, lack of fitness in an 
evolutionary context, the genes underlying the broad consideration of ageing are similarly 
diverse. Single significant loci are certainly of interest to the common genomic CNVs 
resulting in specific genes to study. However, strong confidence in the result set 
generated can be achieved by observing the same biological system being perturbed by 
multiple independently significant loci. Motivated by this, genes directly overlapped by 
associated CNVs were prepared as a single list and non-RefSeq hypothetical gene IDs 
were removed. This list was entered into DAVID functional annotation enrichment tool 
in contrast with a background representing genome-wide regions covered by the array. 
Taking into account the size of different genes and the gene family size of different 
annotations, the enrichment of our CNV impacted list was assigned a p-value with 
Benjamini and Hochberg correction for multiple testing. Functional annotations from 
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multiple databases were used including KEGG and GO (gene ontology). Functional 
categories were reviewed for genes contributing from distinct genomic regions to reject 
enrichment of closely clustered gene families. 
 
 
A major contributor to lifespan abbreviation is congenital heart disease resulting in the 
narrowing of major blood vessels or other structural anomalies. Congenital heart disease 
also involves holes in the heart leading to mixing of oxygenated and deoxygenated blood 
chambers. In the next chapter, we advance from an assay resolution of 550 thousand SNP 
array data to a resolution of 2.5 million SNP array data and whole exome sequencing to 
achieve high resolution on protein coding genes. 
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Chapter 5  
5.0 Increased Frequency of De novo Copy Number Variations in 
Congenital Heart Disease by Integrative Analysis of SNP Array and 
Exome Sequence Data 
 
Summary 
The rationale of this study is congenital heart disease (CHD) is among the most common 
birth defects. Most cases are of unknown etiology. The objective is to determine the 
contribution of de novo copy number variants (CNVs) in the etiology of sporadic CHD. 
Methods include 538 CHD trios using genome-wide dense single nucleotide 
polymorphism (SNP) arrays and/or whole exome sequencing (WES). Results were 
experimentally validated using digital droplet PCR. We compared validated CNVs in 
CHD cases to CNVs in 1,301 healthy control trios. The two complementary high-
resolution technologies identified 65 validated de novo CNVs in 53 CHD cases. A 
significant increase in CNV burden was observed when comparing CHD trios with 
healthy trios, using either SNP array (p=7x10
-5
, Odds Ratio (OR)=4.6) or WES data 
(p=6x10
-4
, OR=3.5) and remained after removing 16% of de novo CNV loci previously 
reported as pathogenic(p=0.02, OR=2.7). We observed recurrent de novo CNVs on 
15q11.2 encompassing CYFIP1, NIPA1, and NIPA2 and single de novo CNVs 
encompassing DUSP1, JUN, JUP, MED15, MED9, PTPRE SREBF1, TOP2A, and ZEB2, 
genes that interact with established CHD proteins NKX2-5and GATA4. Integrating de 
novo variants in WES and CNV data suggests thatETS1 is the pathogenic gene altered by 
11q24.2-q25 deletions in Jacobsen syndrome and that CTBP2 is the pathogenic gene in 
10q sub-telomeric deletions. In conclusion, we demonstrate a significantly increased 
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frequency of rare de novo CNVs in CHD patients compared with healthy controls and 
suggest several novel genetic loci for CHD. 
 
5.1 Introduction and Significance 
Congenital heart disease (CHD) is the most frequent birth defect, affecting approximately 
7 in 1000 live births,(90) and is a significant cause of childhood morbidity and 
mortality.(199)Rare Mendelian disorders, specific chromosomal abnormalities, and copy 
number variants (CNVs) are known to explain a subset of CHD cases,(52, 187, 199)but 
the cause of over 80% of CHD remains unexplained.(31, 51, 73, 78, 132, 165, 186, 203) 
 
The application of evolving technologies that detect structural variation throughout the 
genome has demonstrated a considerable contribution of CNVs to CHD. Early 
cytogenetic studies recognized an increased prevalence of de novo chromosomal 
abnormalities in syndromic CHD patients, observations that were replicated and extended 
to non-syndromic CHD with successive generations of CNV detection technologies 
including array CGH and low density SNP arrays.(17, 25, 50, 52, 78, 89, 154, 173, 186, 
187, 201, 214) Using these techniques, researchers have demonstrated significant burden 
of large de novo CNV in some specific CHD lesions. Such CNVs are reported to occur in 
13.9% of infants with single ventricles compared to 4.4% in controls,(25)in 10% of non-
syndromic tetralogy of Fallot (TOF) compared to 4% of controls,(78) and in 12.7% 
children with hypoplastic left heart syndrome compared to 2% of controls.(214)Among 
different CHD lesions, the frequency of large de novo CNVs is similar.(214)While many 
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large CNVs are unique to a single CHD patient, several are recurrent in CHD cohorts. A 
3-Mb 22q11.2 deletion is the most common recurrent de novo CNV associated with 
syndromic conotruncal defects (CTDs) and is found overall in at least 10% of TOF,(72, 
170) 35% of truncus and 50% of interrupted aortic arch (IAA) type B cases.(29)Recurrent 
de novo CNVs in CHD patients reported in multiple studies also occur at chromosomes 
1q21.1,3p25.1, 7q11.13, 8p23.1, 11q24-25, and 16p13.11.(78, 214) 
 
The identification of CHD loci that are altered by CNVs provides opportunities to 
elucidate disease pathogenesis. However, discerning the causal gene(s) and inferring 
critical networks and pathways that cause or contribute to CHD has been difficult 
because low-resolution technologies used in many studies (array CGH and low-density 
SNP arrays) typically define large CNVs(>100kb)involving many genes. To address 
these issues, we capitalized on two independent strategies, high-density SNP genotyping 
arrays (Illumina Omni-1.0 and 2.5M) and whole exome sequencing (WES), to detect 
smaller de novo CNVs in a family-based trio study of sporadic CHD cases with 
conotruncal, heterotaxy, and left ventricular outflow tract defects.(155) We compared 
CNVs found in CHD trios to those identified in healthy control trios. Through these 
analyses we sought to compare the robustness of genome-wide CNV detection using 
array-based and sequence-based technologies to determine if there was an increased 
burden of smaller de novo CNVs in CHD patients as was demonstrated with larger 
CNVs, and to determine if fewer genes altered by these CNVs enabled more precise 
detection of gene networks and pathways contributing to the pathogenesis of CHD.  
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5.2 Results 
 
5.2.1 Identification of De Novo CNVs 
We studied 415 CHD trios genotyped by SNP arrays and 356 trios by WES analysis, 
including 233 trios studied by both methods. No trios had an affected first-degree relative 
and the genetic cause of CHD in all studied children was unknown (Supplementary 
Tables 5.1 and 5.2).  
 
Sixty-five de novo CNVs identified in CHD cases were independently confirmed by 
ddPCR (Table 5.1). De novo CNVs were identified in 53 unique probands (9.8%). These 
CNVs ranged in size from 0.1 kb to 12.8 Mb. Fifty of these (74%) were <500kb and half 
were smaller than 110 kb. The number of genes in the CNV intervals ranged from 1 to 
175 with 44 (68%) having ≤ 5 genes. Four de novo intervals contained no genes. Six 
probands had two de novo CNVs, two had three CNVs and one had four CNVs. 
 
The parental origin of deletion CNVs was determined when the haplotype of the 
remaining copy could be uniquely assigned to one parent. Seven de novo CNVs arose on 
maternal chromosomes and10 on paternal chromosomes. The remainder could not be 
assigned due to uninformative or insufficient numbers of informative parent-of-origin 
SNPs. 
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Table 5.1. Confirmed de novo CNVs in Discovery Cohort. 
              Genomic coordinates refer to hg19. 
ID Chr Start 
 
End Band CNV1 Syndrome/ gene Analysis 
Observed2 
Cardiac Lesion: 
(diagnosis)3 
Parent 
Origin 
Extra-
cardiac 
N 
genes 
Size (kb) 
1-01401 1 59247993 59251097 p32.1 1 JUN A  LVOT(HLHS) - - 1 3.1 
1-03171 1 145586403 145799634 q21.1 3 1q21.1 dup/ GJA54 A E CTD(TOF/APVS) - - 7 213.2 
1-01036 1 146631133 147416212 q21.1 3 1q21.1 dup/ GJA54 E  CTD(TOF) M - 15 785.1 
1-01486 1 194201171 194304070 q24.2- q25 3 CDC73 A  LVOT(HLHS) - Yes 0 102.9 
1-01518 1 248750565 248795110 q44 3 OR2T10,OR2T11 A LVOT(HLHS) - - 2 44.5 
1-01536 2 70168995 70359345 p13.3 1 PCBP1 A  CTD(TOF/PA) - - 5 190.4 
1-01401 2 102493466 103001458 q11.2- q12.1 1 MAP4K4 E  LVOT(HLHS) - - 6 508.0 
1-01401 2 145155868 145274931 q22.3 1 Mowat-Wilson/ ZEB24 E  LVOT(HLHS) - - 1 119.1 
1-00762 3 60661 11712230 p26.1 3 ARL8B,ARPC4,CAMK1,CAV3, 
CRBN,EMC3,ITPR1,SEC13, 
SETD5,VGLL4 
A ASD/PS (ASD) - Yes 103 11651.6 
1-01049 3 15637812 15643461 p25.1 3 BTD,HACL1 E  CTD(TOF) - - 2 5.6 
1-01045 3 47780965 48309270 p21.31 3 CDC25A,DHX30, 
MAP4,SMARCC1 
A  LVOT(HLHS) - - 14 528.3 
1-02093 3 197143652 197186111 q29 3 BDH1 A  CTD(TOF/PA) - Yes 0 42.5 
1-00771 4 185603346 185638397 q34.1 1 CENPU,PRIMPOL E  CTD(DTGA/VSD) P Yes 2 35.1 
1-00789 5 136464 232969 p15.33 3 CCDC127,LRRC14B, 
PLEKHG4B,SDHA 
A  CTD(TOF) - - 4 96.5 
1-00113 5 133706994 133730455 q31.1 1 UBE2B A  CTD(TOF/PA) - Yes 1 23.5 
1-00296 5 166386727 173073664 q34- q35.2 1 NKX2.54 A CTD(TOF) M Yes 53 6686.9 
1-01916 6 36646788 36651971 p21.2 1 CDKN1A A HTX(HTX) - - 1 5.2 
1-01049 6 43484783 43485159 p21.1 3 POLR1C E  CTD(TOF) - - 1 0.4 
1-00096 7 50179707 50191153 p12.2 1 C7orf72 E  CTD(TOF/PA) - Yes 1 11.4 
1-00800 7 72719386 74138603 q11.23 1 Williams syndrome4 A CTD(VSD/PS) P Yes 34 1419.2 
1-00540 7 72721123 74140708 q11.23 1 Williams syndrome4 A LVOT(ASD) M Yes 34 1419.6 
1-00977 7 138258252 143807632 q24- q25 1 C7orf55,FAM115A,LUC7L2, 
MKRN1,NDUFB2,UBN2, 
ZC3HAV1L,ZYX 
E CTD(TOF) - - 175 5549.4 
1-01995 7 142334207 142460871 q34 1 MTRNR2L6,PRSS1 E  CTD(TOF) M - 15 126.7 
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1-01562 8 8067768 12530976 p22.1- p23.1 3 GATA44 A CTD(TOF) - - 75 4463.2 
1-02625 8 8102183 12190106 p23.1 3 GATA44 A LVOT(CoA) M Yes 62 4087.9 
1-00566 8 11606428 11710963 p23.1 1 GATA44 A E CTD(TOF) - - 6 104.5 
1-00948 8 119053343 119064098 q24.1 1 EXT1 A LVOT(CoA) P Yes 1 10.8 
1-02360 9 5302500 5337760 p24.1 3 RLN1,RLN2 A CTD(ASD) - Yes 3 35.3 
1-00561 11 18949220 18956690 p15.1 1 MRGPRX1 A  LVOT(ASD) - Yes 1 7.5 
1-02432 11 18949220 18956690 p15.1 3 MRGPRX1 A LVOT(CoA) - - 1 7.5 
1-01852 11 34458230 34460862 p13 1 CAT A CTD(VSD) - - 1 2.6 
1-00565 11 42968283 42970488 p12 3 HNRNPKP3 A  LVOTO(ASD) - - 0 2.2 
1-01536 11 65157239 65408708 q13.1 1 EHBP1L1,LTBP3,MAP3K11, 
PCNXL3,SCYL1,SSSCA1 
A  CTD(TOF/PA) - - 14 251.5 
1-00230 11 86939592 87025456 q14.2 1 TMEM135 A E LVOT(ASD) P Yes 1 85.9 
1-01486 11 125641368 134943190 q24.2- q25 1 Jacobsen / ETS14 A E LVOT(HLHS) P Yes 73 9301.8 
1-00795 11 134598043 134617838 q25 3 LOC283177 A CTD(VSD) M - 0 19.8 
1-00124 12 8003758 8123306 p13.31 3 SLC2A14,SLC2A3 A LVOT(As/HLHS) - - 3 119.5 
1-00050 12 52845952 52862783 q13.13 1 KRT6C A LVOT(HLHS) - - 1 16.8 
1-02411 14 58860893 58881694 q23.1 1 TIMM9,TOMM20L A  CTD(TOF) - - 2 20.8 
1-01049 14 74551632 74551731 q24.3 3 LIN52 E  CTD(TOF) - - 1 0.1 
1-00192 15 22296985 23161330 q11.2 3 1 MB from PW / CYFIP14 A LVOT(CoA) - - 20 864.3 
1-00315 15 22750305 23140114 q11.2 3 1 MB from PW / CYFIP14 A LVOT(CoA) M - 5 389.8 
1-01396 15 22750305 23228712 q11.2 1 1 MB from PW / CYFIP14 A E CTD(TOF/PA) P - 6 478.4 
1-00243 15 22835893 23062345 q11.2 1 1 MB from PW / CYFIP14 E  LVOT(CoA) P Yes 4 226.5 
1-01994 15 28389771 28446734 q13.2 1 HERC2 E  LVOT(ASD) P - 1 57.0 
1-01696 15 44833588 44856873 q21.1 1 EIF3J,SPG11 A E CTD(TriAtresia/DTGA) - - 2 23.3 
1-01941 15 88761539 88779300 q25.3 3 NTRK3 A  CTD(TOF/DTGA) P - 1 17.8 
1-01427 17 21562473 22252439 p11.2 1 FAM27L,FLJ36000,MTRNR2L1 A HTX(HTX) - Yes 7 690.0 
1-00561 17 27962393 28099002 q11.2 1 SSH2 A  LVOT(ASD) - Yes 3 136.6 
1-01995 17 38544624 38548586 q21.1 1 TOP2A A E CTD(TOF) - - 1 4.0 
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1-01049 17 39845210 39846477 q21.2 3 EIF1 E  CTD(TOF) - - 2 1.3 
1-01588 18 65138642 78015180 q22.1- q23 1 NFATC14 A LVOT(CoA) - Yes 58 12876.5 
1-02170 19 20601006 20717536 p12 1 ZNF826P A CTD(TOF) - Yes 1 116.5 
1-00174 19 40515744 40681387 q13.2 1 ZNF546,ZNF780A,ZNF780B A  CTD(TOF/PA) - Yes 4 165.6 
1-01536 19 47792293 47905132 q13.33 1 C5AR1,C5AR2,DHX34 A  CTD(TOF/PA) - - 3 112.8 
1-00730 20 14529657 14583899 p12.2 1 MACROD2,MACROD2-IT1 A  CTD(DTGA) - - 2 54.2 
1-01194 22 18844632 21500000 q11.2 1 DiGeorge / TBX14 A CTD(VSD) P Yes 80 2655.4 
1-00113 22 18886915 22000000 q11.2 1 DiGeorge / TBX14 A E CTD(TOF/PA) P Yes 96 3113.1 
1-01836 22 19020529 21380382 q11.2 1 DiGeorge / TBX14 A E CTD(TOF) M - 70 2359.9 
1-00988 22 20733495 21464479 q11.2 1 DiGeorge / TBX14 A CTD(HLHS/HTX) M Yes 31 731.0 
1-02133 22 25661725 25919492 q11.23 3 22q11 distal microdeletion4 A  CTD(TOF) - - 4 257.8 
1-00425 22 36038076 36149338 q12.3 1 APOL5,APOL6,RBFOX2 A E LVOT(HLHS) - - 4 111.3 
1-01427 22 42522638 42531210 q13.2 3 CYP2D6 A HTX(HTX) - Yes 2 8.6 
1-01941 X 23003525 23086619 p22.11 3 DDX53,RP11-40F8.2 A CTD(TOF/DTGA) - - 1 83.1 
1-00197 X 148685645 148693146 q28 3 TMEM185A E  LVOT(HLHS) - Yes 1 7.5 
1
Copy number: 1- deletion; 3- duplication,  
2
Analysis: A- identified with SNP Array; E- identified with WES 
3
Parental Origin: M- maternal chromosome; P- paternal chromosome 
4
De novo CNV loci that were previously reported as pathogenic 
Abbreviations: CTD-conotruncal defect; LVOT-Left Ventricular Outflow Tract Obstruction;TA-truncus arteriosus;TOF-tetralogy of Fallot;HLHS-hypoplastic left heart syndrome;APVS-
Absent pulmonary valve syndrome ; ASD- Atrial septal defect; CoA-Coarctation of the Aorta ; DTGA-dextro-Transposition of the great arteries; HTX-Heterotaxy; PA- PulmonaryAtresia; 
PS-Pulmonary Stenosis; TriAtresia-Tricuspid atresia ; VSD-Ventricular Septal Defect ; 
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5.2.2 Comparison of SNP Array and WES CNV calling 
To consider the accuracy of identifying de novo CNVs from SNP array data, we first 
considered a set of 40 high-confidence PennCNV de novo CNV calls that contained ≥10 
adjacent SNPs, were >10 kb in length, and passed visual inspection. Among these 40 
high-confidence putative CNVs, 32 (80%) were experimentally confirmed. For smaller 
de novo CNVs identified using the high-density array data, we considered a set of 97 
high-confidence PennCNV putative de novo CNV calls based on 7-9 SNPs. While 88% 
were experimentally validated by ddPCR in the proband, only four of the 97 (5%) were 
confirmed to be de novo. 
 
From the WES data, we selected an initial set of 29 putative CNVs with a size range 
spanning six orders of magnitude from 530 bases in length (two exons) to more than 8Mb 
in length covering hundreds of exons. Twenty-six of the 29 CNVs (90%) confirmed 
experimentally. The three false positive CNVs included one 530-bp region that contained 
only two exon targets and two different inherited CNVs that were miscalled as de novo 
because both parents harbored CNVs at the locus. Based on these considerations, we 
restricted subsequent WES de novo CNV calls to those containing ≥3 exons and for 
which each parental dataset contained no CNVs within the locus. 
 
To evaluate false negative rates of the two platforms and analyses, we tested our ability to 
detect four CNVs (two 22q11 deletions, one 17p11 duplication, and one 10q terminal 
deletion; Supplemental Table 5.5) in clinical cases previously diagnosed with these 
CNVs. These four CNVs served as positive controls and were distinct from the PCGC 
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cohort. Both the SNP array and WES platforms detected each of these four large, 
clinically significant CNVs.  
 
We also compared the results of de novo 
CNVs analysis from the 233 trios 
studied by both SNP array and WES. 
Among 42 confirmed de novo CNVs in 
these trios, 24% (10/42) were identified 
by both platforms while 40% (17/42) 
were identified only with the SNP 
arrays and 35% (15/42) only by WES 
(Figure 5.1). The recognized technical 
limitations of each platform prevented 
detection of some CNVs. For example, CNVs that occur exclusively in noncoding 
sequences are not captured by WES whilst CNVs in coding or non-coding genomic 
regions where the SNP density is sparse can escape detection by SNP arrays. 
From our studies we deduced that de novo CNVs were accurately detected by arrays 
when ≥10 adjacent SNPs were impacted or by WES when greater than three adjacent 
exons were impacted. In our dataset, 29 of 42 CNVs fulfilled both of these criteria and 
should have been identified by both technologies (Figure 5.1). However, only 
34% (10/29) of these CNVs were identified by both platforms. SNP arrays uniquely 
identified 34% (10/29) and WES analyses uniquely identified 31% (9/29). Taken 
together, the false negative rate of each methodology is approximately 30-35%. Overall, 
Figure 5.1. Comparison of CNVs detected by SNP array 
and WES platforms in the subset of 233 probands 
studied by both technologies. 
 
 
 
Based on confirmation data, CNVs that span ≥10 SNPs 
on arrays and ≥3 exons on WES had high confirmation 
rates and were deemed detectable by both technologies. 
We assessed how many CNVs identified by one 
platform could not be identified by the other technology 
because they were below the detection limits. Both SNP 
Array and WES platforms have a false negative rate of 
~30-35% based on detectable regions. 
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the genome-wide analyses of de novo CNVs identified by SNP arrays was reasonably 
concordant with WES data, but each also identified complementary CNVs. The minimum 
CNV size that we reliably detected by SNP arrays was 10 kb and by WES was 1 kb, 
although some smaller CNVs identified by these techniques were validated. 
 
5.2.3 CNV Burden Analysis 
The burden of de novo CNVs in CHD cases and control trios was initially compared 
using analyses from SNP arrays. De novo CNVs were assessed in 841 control trios, 
studied using the Illumina Omni1M array to match the case trio array resolution and 
called using the PennCNV algorithm using computational parameters described 
previously(176) that required >20 SNP probes. Nine de novo CNVs were identified 
among 841 control trios. Twenty-two de novo CNVs were identified among 462 CHD 
patients. These data define a significant burden of CNVs in CHD cases compared to 
controls (OR: 4.6, Fisher p-value: 7 x 10
-5
; Table 5.2). After excluding nine previously 
identified CHD-associated CNVs, the calculated burden of novel CNVs identified in 
CHD cases remained modestly significant (OR:2.7, Fisher p=0.02). 
Table 5.2. Case Control de novo CNV Burden 
 
  N Probands N (%) CNVs OR P-value 
SNP Array SSC1 841 9 (1%) - - 
 PCGC: all CNVs 462 22 (4.7%) 4.6 7 x 10-5 
 PCGC: novel loci  13 (2.8%) 2.7 0.02 
WES SSC2 872 14 (1.6%) - - 
 PCGC: all CNVs 356 19 (5.6%) 3.5 6 x 10-4
 
 PCGC: novel loci  13 (3.9%) 2.3 0.03 
1
Controls derived from State, 2011.(176)  
2
Controls derived from three studies: Iossifov, 2012;(97) Sanders, 2012;(177) and an additional set of 
unpublished controls provided by Matthew State selected by the same criteria and sequenced as described 
in.(177) 
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To provide further support for this finding, we analyzed the burden of de novo CNVs that 
were identified by WES. WES in CHD cases and control trios were technically 
comparable, including the same Nimblegen V2 exome capture chemistry and similar 
sequence read depths obtained on identical Illumina platforms. Sixty percent of control 
trios were sequenced at the same site (Yale Center for Genome Analysis) that sequenced 
the cases. Raw sequence reads were processed through the identical short read aligner 
(Novoalign) for CNV burden analysis. SNP genotyping of CHD and control datasets and 
principal component analysis did not identify any systematic biases (Supplemental 
Figure5.5). Cases and controls were matched for gender as best as possible with slight 
excess of male cases. Using an identical XHMM pipeline (CNVs involving≥3 exons and 
no parental CNVs within 1 MB), we identified 19 de novo CNVs in 358 CHD trios, 
and14 de novo CNVs in 8732 control trios (OR: 3.5, Fisher p=6 x 10
-4
; Table 5.2). 
Excluding the six de novo CNVs previously identified as CHD-associated, we identified 
a similar OR and p-value as in the SNP array data (OR:2.3, Fisher p=0.03). 
Our data identify an increased burden of CNVs, detected by SNP arrays or WES, in CHD 
patients compared to controls. We observed a larger mean size of de novo CNVs with 
increased burden in CHD patients (3.6 Mb) than controls (495 kb; t-test p=0.035) with 
the distribution of CHD CNVs skewed towards the largest CNVs identified in CHD 
cases. The median size of de novo CNVs from CHD cases (522 kb) was also significantly 
larger than controls (118 kb; Mann-Whitney p=0.028). Of the CNVs identified by SNP 
array which were capable of detecting CNVs outside of coding regions, there was a trend 
towards an increased number of de novo CNVs in controls that contained no coding exon 
(4/9) compared to PCGC cases (3/22; Fisher p= 0.15). 
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5.2.4 Putative CHD Loci at 15q11.2 and 2p13.3 
Overlapping de novo CNVs found in multiple cases and not in controls likely contain 
disease genes. Sixteen of 65 (25%) de novo CNVs in CHD probands have been 
previously implicated in CHD(78), 
including four 22q11.2 deletions, 
three 8p23 deletions (involving 
GATA4), two 1q21.1 duplications 
(involving PRKAB2, PDIA3P, 
FMO5, CHD1L, BCL9, ACP6 and 
GJA5), one 22q11.2 distal 
microdeletion, one 2q22.3 deletion 
(that causes Mowat-Wilson syndrome), one 11q24.2-q25 deletion (that causes Jacobsen 
syndrome) and four with CNVs in 15q11.2. 
 
CNVs in four CHD probands (two deletions, two duplications) at the 15q11.2 locus that 
spans approximately 225 kb (chr15:22,836,000-23,062,000) were observed as recurrent 
de novo events (Figure 5.2 and 5.3). Both patients with duplications (1-00192, 1-00315) 
and one with a deletion (1-00243) had LVO due to aortic coarctation. The remaining 
proband (1-01396) had TOF with pulmonary atresia. As there was no de novo CNV 
identified in this region among 814 and 872 control trios studied respectively by SNP 
arrays or WES, this locus has a significant burden of de novo CNVs in CHD cases (4/538 
CHD vs. 0/1301 controls; Fisher p=0.007). CNVs at the 15q11.2 locus were observed at 
low frequency (AF<1%) in the Database for Genomic Variants (DGV). Among the three 
Figure 5.2. Genomic Boundaries of 4 recurrent de novo 
CNVs 
 
 
 
Red rectangles represent de novo deletion calls. 
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genes altered by this CNV (CYFIP1, NIPA1, and NIPA2), only CYFIP1 is highly 
expressed in the developing mouse heart. (224) (223) (222) (221) (215) (216) (214) (213) 
(212) (210) CYFIP1encodes the cytoplasmic FMR1-interacting protein 1, which has dual 
roles in inhibiting local protein synthesis and in promoting actin remodeling.(42) An 
earlier study observed an increased burden of inherited deletions in CHD cases at 
15q11.2
1
 and a recent paper identified a single proband with a 6-Mb de novo duplication 
at 15q11.2-q13.1(214) and two additional cases with inherited 300-400-kb duplications at 
15q11.2. Our data provide additional evidence that de novo CNVs at 15q11.2 may 
contribute to disease risk in CHD.  
 
In addition, a recurrent CNV was observed to alter a novel locus at chromosome 2p13.3. 
A de novo 190-kb deletion was 
identified in a TOF proband (1-01536) 
and was maternally inherited in a 
proband with truncus arteriosus (1-
01805). No 2p13.3 CNV was found in 
control samples or in DGV. Among 
three genes included in the CNV 
interval (ASPRV1, PCBP1 and PCBP1-
AS1), only PCBP1 is highly expressed 
in the developing mouse 
heart.(224)PCBP1 encodes a major 
cellular poly(rC)-binding protein, 
Figure 5.3. A novel recurrent de novo deletion on 
15q11.2. 
 
 
SNP Array PennCNV Plot for diploid mother, diploid 
father, and deleted child with CNV region in red with 
flanking diploid in blue.  
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which controls translation from mRNAs containing the DICE (differentiation control 
element).(143)In Database of Chromosomal Imbalance and Phenotype in Humans using 
Ensembl Resources (DECIPHER), patient 257771 with an atrioventricular canal defect 
had a 7-Mb overlapping deletion of 2p13.3, suggesting this locus may also contribute to 
disease risk in CHD. 
 
5.2.5 Integration of CNV and Sequence Data to Identify CHD Genes 
To improve the identification of specific genes altered by CNVs that might cause or 
contribute to CHD, we searched the WES data for de novo, rare loss-of-function (LOF) 
variants in genes encoded in CNV intervals. We identified a terminal deletion of 
chromosome 11q24.2-q25, which causes Jacobsen syndrome in one CHD patient (1-
01486) with clinical manifestations typical of this dominant disorder (hypoplastic left 
heart, coarctation of the aorta, mitral and aortic valve atresia, strabismus, and short 
stature). ETS1 has been proposed as the critical CHD gene in the Jacobsen syndrome 
locus based on impaired ventricular development in an Ets1-null mouse.(223) WES 
analyses identified a de novo ETS1 frameshift mutation (chr11:128350159GTCCT>G, 
c.1046_1049delAGGA, [p.K349fs]) in another CHD patient without the chromosome 
11q24.2-q25 deletion with cardiac abnormalities observed in Jacobsen syndrome 
(hypoplastic left heart and mitral valve atresia). Our data provide the first human genetic 
evidence to suggest that ETS1 mutations contribute to the cause of cardiac malformations 
in Jacobsen syndrome. 
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We also assessed whether de novo CNVs in combination with a rare or novel deleterious 
variant on the other allele might produce recessive forms of CHD. One CHD patient (1-
01179) with a de novo 10q25-26 deletion also had a novel CTBP2 variant (p.R134W) on 
the remaining allele. The hemizygous variant was absent from public genome 
databases,(1, 62) is predicted to be damaging (Polyphen2 score of 0.998), and altered a 
phylogenetically conserved residue (PhyloP score = 2.54). Cardiac abnormalities are 
present in approximately one third of patients with subterminal chromosome 10q 
deletions and recently CTBP2 was proposed as a candidate CHD gene.(37)The clinical 
manifestations of our patient, truncus arteriosus and right aortic arch, resemble the 
phenotypes identified in a Ctbp2-null mouse (failure of vascular remodeling and cardiac 
looping).(87)We suggest that CTBP2 sequence analyses in individuals with chromosome 
10q deletions may identify additional variants in a subset of patients that modify 
phenotype. 
 
5.2.6 Correlation of CHD Phenotypes and CNVs 
The frequency of de novo CNVs was 10% among conotruncal anomalies, 6% among left-
sided obstructive lesions and 21% in heterotaxy. We observed a modest trend towards 
increased extra-cardiac manifestations such as developmental delay in patients with de 
novo CNVs (Supplemental Table 5.6). Approximately 31% of all CHD patients studied 
with SNP arrays or WES had extra-cardiac manifestations, whilst 40% (21/52; OR:1.5, 
Fisher p=0.2) of patients with de novo CNVs had extra-cardiac features. This association 
has been found in some,(18) but not all,(214) previous studies, perhaps due to differences 
in the ages of the CHD patients studied, methods of clinical data collection, and the 
definition of an extra-cardiac anomaly. 
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5.2.7 Gene Networks Impacted by CNVs in CHD 
We employed pathway and network analysis with DAVID,(91) DAPPLE,(174)and 
WebGestalt,(210) using as input four different lists of genes encoded within all de novo 
CNV loci (Methods and Supplemental Table 5.4). Initial gene lists contained:(1) all genes 
encoded in a de novo CNV interval; (2) genes previously defined as causative within 
CNVs intervals plus all genes in novel de novo CNV intervals; (3) only genes contained 
within novel de novo CNV intervals; (4) all genes contained within de novo CNV 
intervals that are highly expressed (top 25%) in the developing heart.(224) 
 
DAVID identified enrichment of gene pathways implicated in acetylation (p<2.3x10
-4
), 
phosphoprotein (p<3.9x10
-4
), and G protein-activated inward rectifier potassium channel 
(p<2.5x10
-2
) (Benjamini-Hochberg corrected). WebGestalt implicated an enrichment of 
previously identified CHD genes including ELN, NKX2.5, GATA4, and ZEB2 
contributing to Gene Ontology processes: anatomical structure formation involved in 
morphogenesis (p<0.03), cardioblast differentiation (p<0.03), and septum secundum 
development (p<0.02) (Benjamini-Hochberg corrected). 
 
Using DAPPLE, we identified two additional sub-networks of direct protein/protein 
interactions that were consistently observed across four gene lists. Among genes encoded 
within CNVs that are highly expressed in the developing heart, a sub-network consisting 
of NKX2.5 and GATA4 (p<0.1, Figure 5.4a) and a sub-network consisting of ETS1, JUN, 
TOP2A, and MKI67 (p<0.01, Figure 5.4b) were identified. By further expanding the 
CNV gene lists to include genes with de novo LOF mutations, the ETS1/JUN/TOP2A 
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sub-network was significantly elaborated upon and enriched (p<0.005). Each of these 
three genes was directly linked 
through protein-protein interactions 
to sub-networks containing ≥ 10 
additional genes identified in either 
CNV or WES datasets.(224) This 
entire network incorporated over 60 
genes implicated in CHD (Figure 
5.4c). As the ETS1/JUN/TOP2A sub-
network was robust to the specific de 
novo CNV gene list (criteria 2 above) 
and expanded with the addition of 
genes containing rare de novo LOF 
mutations, the data suggest that this 
sub-network contains genes and 
pathways involved in CHD.  
 
5.3 Discussion 
We report whole-genome CNV analyses using complementary detection technologies in 
a large cohort of CHD patients. CNV detection in WES has been investigated in 
schizophrenia(60)and autism,(162) but array-based and sequence-based strategies have 
not previously been directly compared, and our data highlight the differences between 
array-based and sequence-based strategies to detect de novo CNVs. By defining small 
Figure 5.4. Network analysis of CNV loci genes. 
 
 
Two networks of direct protein-protein interactions, (A) 
NKX2.5/Gata4 and (B) ETS1/JUN/TOP2A, were 
consistently identified in the DAPPLE de novo CNV 
loci analysis. P-values from the genes highly expressed 
in the developing heart, the most restrictive gene set list, 
are presented here. (C) The ETS1/JUN/TOP2A network 
was significantly elaborated upon by incorporating 
genes with deleterious de novo point mutations and 
indels in the WES exome sequencing analysis in 
addition to the CNV loci. Of note, two probands had de 
novo ETS1 variants (one CNV and one frameshift), two 
probands had de novo SMAD2 variants (a splice site 
mutation and a highly conserved missense variant) and 
two probands had de novo ELN variants (both Williams 
syndrome CNVs). 
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CNVs with high resolution and integrating these findings with WES data that identified 
rare deleterious mutations, we identified novel de novo CNVs and genes involved in the 
pathogenesis of CHD. We show that 9.8% (53/538) of CHD patients without a previously 
identified genetic etiology have rare de novo CNVs (Figure 5.5). We previously 
demonstrated that 10% of CHD patients in our cohort have de novo single nucleotide or 
small insertion/deletion mutations in genes highly expressed in the developing heart that 
are likely to be damaging.(224) None of the CHD patients with rare de novo CNVs 
reported here carry these variants. Even if all the de novo CNVs and de novo predicted 
pathogenic sequence variants we have identified were causative, we do not yet know the 
etiology for the majority of CHD subjects in our study. 
 
Our detection rate of approximately 
10% de novo CNVs in CHD patients 
is equivalent to previous studies,(18, 
78, 214) despite identifying small 
CNVs. Had we not excluded patients 
with known pathogenic CNVs 
identified through clinical care, we 
expect that de novo CNVs would 
have been identified in approximately 
15% of CHD patients, based on the 
prevalence of common de novo CNVs 
in CHD (e.g., 7% of TOF with 
Figure 5.5. Distribution of de novo rare, damaging 
genetic variants in the case cohort with unknown CHD 
etiology. 
 
 
 
Of the CHD probands without identified genetic 
etiologies based upon clinical evaluations including 
karyotype and chromosome microarray, approximately 
2.5% of CHD probands had de novo CNVs that have 
been previously described as pathogenic and had not 
been clinically recognized upon study enrollment. 7.3% 
of CHD probands had novel de novo CNVs. 10% of 
CHD probands studied by WES had de novo rare, 
damaging variants in genes that are highly expressed in 
the developing mouse heart.(224) 
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chromosome 22q11 deletions, and 1% of TOF to 1q21 CNVs). In our study, these CNV 
loci accounted for <1% of CHD probands 
 
Despite these exclusion criteria, we identified a four-fold increased frequency of de novo 
CNVs relative to the background frequencies of 1.2% (detected by SNP arrays) and 1.8% 
(detected by WES) of de novo CNVs in controls (p=7 x 10
-5
, p=4 x10
-4
 respectively). 
Even after excluding previously defined CNVs, we still observed an approximate two-
fold increase in novel de novo CNVs (p=0.02).  
Since the odds ratio of de novo CNVs in cases vs controls was 3.5-4.6, we estimate that 
between 50-70% of de novo CNVs observed in cases may be disease causing. The 
possibility exists that a higher percentage of de novo CNVs increase the risk of CHD but 
may not be sufficient to cause CHD without other contributing genetic or environmental 
factors. Additionally, subtle anatomic defects in the heart may not have been diagnosed 
in the control group since controls were not systematically examined by echocardiogram. 
Overall, our evidence suggests a model in which de novo CNVs contribute to CHD. 
The comparison of dense array-based platforms and WES analyses to detect 
independently validated CNVs indicate that each strategy identifies only ~70% of the 
CNVs that should be within the detection limitations of each technology. As such, these 
two CNV methodologies provide substantial complementary information. An important 
corollary to this conclusion is that previously published CNV analyses in human disease 
may have significantly underestimated the burden conveyed by these structural variants.  
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Amongst all confirmed de novo CNVs, 61% (41) were deletions and 39% (26) were 
duplications. The proportion of these classes of CNVs are not significantly different; 
whether or not the trend toward more CNV deletions in CHD is biologically meaningful 
or reflects greater sensitivity to detect deletions by these methods will require further 
analyses. De novo CNVs ranged in size from less than 1 kb to 12.8 Mb, with a median 
size of 110 kb. Thus, half of the independently confirmed CNVs were smaller than the 
reported detection limit of most prior studies. While the pathogenicity of the identified 
CNVs remains to be determined, we propose that the smaller CNVs involving fewer 
genes are particularly valuable in defining specific candidate CHD genes in comparison 
to larger CNVs that typically include many more candidates. The ability to reliably detect 
small CNVs is helpful, particularly if they fall within large CNVs previously identified 
and define a critical interval of overlap. For example, we identified one de novo CNV 
that only affected JUN and another that only altered TOP2A, two genes that were 
implicated by network analyses as interacting with transcription factors SMAD2, SMAD4 
and ETS1, molecules that play important roles in cardiovascular development.  
 
Although there is considerable complexity in CHD phenotypes, we observed no 
significant difference in the frequencies of de novo CNVs among distinct CHD sub-
classifications. While CHD patients with CNVs in our cohort were more likely to have 
extra-cardiac phenotypes (OR: 1.5), this trend fell short of significance. Whether this 
finding reflects shared developmental biologic pathways among different organ systems or 
the possibility that CNVs perturb multiple genes that individually contribute to organ 
system development is unknown. 
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We identified several de novo CNVs that impacted established CHD genes including 
GATA4 and GJA5. We also identified a CHD patient with a deletion of chromosome 
5q34-q35.2, encompassing NKX2-5. LOF NKX2-5 mutations are an established cause of 
CHD,(31, 78, 180, 186, 187, 203)and CNVs encompassing NKX2-5 have been previously 
recognized in CHD.(8, 22, 201) 
 
We identified recurrent de novo CNVs involving deletions or duplications at 
chromosome 15q11.2. As the proximal region of chromosome 15 is meiotically unstable 
due to the segmental duplications that serve as breakpoint hotspots, recurrent de novo 
events at this locus might reflect locus genomic instability. However, the excess burden 
of de novo CNVs at this locus in CHD patients compared to controls (Fisher p=0.007) 
suggests significant enrichment. The report of an excess burden of inherited deletions in 
CHD patients at this locus(187) lends further evidence for pathogenicity although this 
study lacked information on inheritance.  
 
The 200-kb CNV that we identified at 15q11.2 is from BP1-BP2 and is encompassed 
within the BP1-BP3 Prader-Willi syndrome interval at 15q11-q13.(21)
,
(20) 
Approximately 20% of Prader-Willi patients have congenital heart defects,(204) and a 
patient with a large 6-Mb duplication in the Prader-Willi locus has been described in 
another CHD cohort.(214) 
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Chromosome 15q11.2 deletions and duplications are implicated in neurodevelopmental 
disorders including schizophrenia, intellectual disability and autism.(106, 190, 192)That 
chromosome 15q11.2 CNVs are also associated with CHD adds to a growing list of loci 
(22q11,(109) 1q21,(78, 142)7q11.23,(75)16p11.2,(63, 74) and 16p13.11(74, 214) that 
link cardiac malformations and neurocognitive disorders. These (and other) genetic loci 
may explain in part the significant co-expression of heart and brain developmental 
phenotypes in many children.  
 
By integrating CNV and sequencing data from WES, we also identified candidate genes 
within CNV regions that may cause dominant or recessive forms of CHD. We present the 
first humanETS1 LOF mutation that likely contributes to Jacobsen syndrome. We also 
identified a rare inherited and predicted deleterious CTBP2 missense variant that is 
hemizygous due to a de novo CNV deletion, associated with a CHD phenotype 
comparable to that observed in Ctbp2-null mice. Continued integration of CNV and 
sequence data should enable more comprehensive assessments of genetic causes of 
disease. The current study provides suggestive data, and sequencing large cohorts of 
CHD patients for mutations in these two genes will be necessary to unambiguously prove 
the role of these genes in CHD. 
 
Network analyses by DAPPLE was more successful in elucidating novel network biology 
than DAVID and WebGestalt, which rely heavily on previously annotated gene sets and 
are challenged by the addition of unrelated genes encoded with CNV intervals along with 
pathogenic genes. If pathogenic CNVs on average contain one main causal gene and 
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approximately five unrelated genes, then we might expect DAVID and WebGestalt to be 
less informative for CNV network analyses.(93) Conversely, DAPPLE, based on 
proteome-wide protein-protein interaction data rather than previously curated gene lists, 
calculates p-values through within-degree node-label permutation, which is more 
permissive to background noise.(174) 
 
DAPPLE network analysis reinforced the central role of transcriptional regulation in 
congenital heart disease. The identification of one network, including NKX2.5/GATA4, 
provided a robust positive control as protein-protein interactions and substantial 
contributions by these molecules to CHD are previously described.(179, 194) Direct 
protein-protein interactions between ETS1/JUN/TOP2A have also been reported,(113, 
130, 147) but this network has not been previously implicated in CHD. In an expanded 
network analysis of these molecules that included rare LOF mutations identified from 
exome sequencing, JUN was linked to SMAD2 and SMAD4, molecules that participate 
in cardiac development through TGF-beta.(23, 26, 134, 209) 
We focused our current analysis solely on de novo CNVs. As the etiology of CHDs is 
known to be polygenic, and incomplete penetrance of genes for CHD has been previously 
described, future analyses of rare inherited CNVs may expand these findings. 
Replication of the overall effect and the magnitude of the risk of these identified variants 
is needed. While it is not yet possible to draw a conclusion about whether any particular 
de novo CNV is causal, the identification of additional CNVs and mutations in specific 
genes within the CNV intervals will be required to validate the new loci identified here. 
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In summary, integration of high resolution complementary platforms for CNV and 
sequence data on large numbers of patients with CHD has proven valuable to define the 
underlying genomic architecture of CHD and expand the genes and networks involved in 
cardiac development and is likely applicable to the study of other diseases. 
 
 
5.4 Methods 
 
5.4.1 Ethics Statement 
The protocol was approved by the Institutional Review Boards of Boston Children’s 
Hospital, Brigham and Women’s Hospital, Great Ormond St. Hospital, Children’s 
Hospital of Los Angeles, Children’s Hospital of Philadelphia, Columbia University 
Medical Center, Icahn School of Medicine and Mt. Sinai, Rochester School of Medicine 
and Dentistry, Steven and Alexandra Cohen Children’s Medical Center of New York, and 
Yale School of Medicine. Written informed consent was obtained from each participating 
subject or their parent/guardian.  
 
5.4.2 Patient cohorts 
CHD probands and parents were recruited into the CHD Genes Study of the Pediatric 
Cardiac Genomics Consortium (CHD genes: ClinicalTrials.gov identifier NCT01196182) 
as previously described,(155) using protocols approved by Institutional Review Boards of 
each institution. Trios selected for this study had no history of CHD in first-degree 
relatives. CHD diagnoses were obtained from echocardiograms, catheterization and 
operative reports; extra-cardiac findings were extracted from medical records and 
included dysmorphic features, major anomalies, non-cardiac medical problems, and 
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deficiencies in growth or developmental delay. The etiologies for CHD were unknown; 
patients with previously identified cytogenetic anomalies or pathogenic CNVs identified 
through routine clinical evaluation were excluded. Whole blood samples were collected 
and genomic DNA extracted. 
 
CHD trios were studied by SNP arrays (n=414) or by WES (n=358), including a subset 
(n=233) that were analyzed by both methods. The distribution by CHD lesions in patients 
genotyped by arrays was: 403 (61%) left ventricular obstruction (LVO); 197 (30%) 
conotruncal defects (CTD); 49 (7%) heterotaxy (HTX); and 12 (2%) other cardiac 
diagnoses (Supplementary Table 5.1). The distribution by CHD lesions in patients 
studied by WES was 284 (46.1%) left ventricular obstruction (LVO); 235 (38.1%) 
conotruncal defects (CTD); 78 (12.7%) heterotaxy (HTX); and 19 (3.1%) with other 
cardiac diagnoses (Supplemental Table 5.2).  
 
Control trios were the unaffected sibling and parents of a child with autism who were 
consented and recruited through the Simons Simplex Collection (SSC). CNVs were 
identified in the same way in the control trios as in the cases using SNP arrays (n=814) or 
WES (n=872), including a subset (n=385) analyzed by both methods.(56, 176, 177) 
 
Additional data on the distribution and prevalence of previously reported CNVs in the 
general population was derived from the Database of Genomic Variants 
(http://dgv.tcag.ca) and from 649 de-identified control subjects who had participated in 
an unrelated psychiatric case-control study, genotyped on the same high density SNP 
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array platforms at the same genotyping center as the CHD probands (438 on the Illumina 
Omni-1M and 211 on the Illumina Omni-2.5M). These controls were used only to 
prioritize the de novo CNVs identified by SNP array methods that were selected for 
confirmation analyses. 
 
5.4.3 Array Genotyping and CNV identification 
A total of 360 CHD parental samples genotyped on the Omni1M and 654 on Omni2.5M 
arrays were applied for cluster definition using Illumina Genome Studio clustering 
algorithm. Raw data is publicly available through the database of genotypes and 
phenotypes (dbGaP) National Heart, Lung, and Blood Institute (NHLBI) Bench to 
Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC) under dbGaP 
Study Accession: phs000571.v1.p1.We removed clusters with outlier values of SNP call 
rate, Hardy-Weinberg equilibrium, AA/AB/BB cluster means, and minor allele frequency 
to improve the intensity noise (Log R ratio standard deviation) from a mean of 0.2 (using 
the default cluster file from Illumina) to 0.1 for CHD samples. Briefly, individual 
samples were filtered through a standard quality control pipeline.(176)B-allele frequency 
(BAF) and LogR ratio (LRR) values were exported from Illumina Genome Studio. Only 
samples with SNP call rate > 98%, standard deviation (SD) of normalized intensity 
(LRR) < 0.3, absolute value of GC-corrected LRR <0.005, as well as CNV call count 
<800 for Omni1-Quadv1 or <300 for Omni2.5-8v1 were included.(71)Samples with high 
inbreeding coefficients, that were duplicated, or had gender mismatches, and trios with 
Mendelian errors > 1% were removed from analyses. We started with 1,536 genotyped 
samples (512 trios), including 561 on the Illumina Omni-1M and 969 on the Illumina 
Omni-2.5M. Four hundred and sixty-one trios had the same array version for all family 
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members. Upon completion of these QC procedures 1,245 samples, including 447 
genotyped on the Illumina Omni-1M and 798 on the Illumina Omni-2.5M high-density 
SNP array platforms, were taken forward for analysis, constituting 415 complete trios 
(Supplemental Table 5.3). 
 
Three groups (CHOP, Harvard, Yale) independently analyzed genotyping data using 
slightly different algorithms to detect putative de novo CNVs. For each of the three 
independent analyses, CNVs were called for each subject using PennCNV(211) with the 
hidden Markov model algorithm and custom-made population frequency of B-allele 
(PFB) and GC model files. CNVs were called when 10 or more consecutive probes 
demonstrated consistent copy number change. The PennCNV detect_cnv --trio option 
was used to boost transmission probability of CNV calling for initially de novo scored 
CNVs. Fragmented CNV calls were merged using clean_cnv. All candidate CNVs were 
visually inspected to ensure the appropriate pattern of LRR and B-allele frequency was 
consistent with the CNV call. Additionally, Gnosis,(176) QuantiSNP,(34) and Nexus 
(biodiscovery.com) were used to increase specificity. De novo CNVs were prioritized for 
quality by genomic length, number of probes, confidence score based on signal strength, 
50% overlap of two or more algorithms, low parental origin p-value using 
infer_snp_allele, and visual BAF/LRR review. All putative de novo CNVs were 
experimentally evaluated by digital droplet PCR (ddPCR, Supplemental Figure 5.1), and 
only validated CNVs are reported. 
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De novo CNV loci that were previously reported as pathogenic were defined by reported 
recurrence in at least two publications using independent data. Although some of the 
CNVs reported here overlap with previously reported CNVs in CHD patients based on 
review of the literature,(207), they do not meet our frequency constraint for previously 
reported pathogenic de novo CNV loci. 
 
5.4.4 CNV identification and variant calling from WES Data 
WES data from 356 CHD trios were analyzed for de novo CNVs (Supplemental Table 
5.2). WES samples were captured with the Nimblegen SeqCap Exome V2 chemistry and 
sequenced on the Illumina HiSeq 2000 platform as previously described.(224) Sequence 
reads were aligned to the human reference genome hg19 using Novoalign 
(http://novocraft.com), BWA,(123) and ELAND.(38)Duplicates were marked with Picard 
(http://picard.sourceforge.net). Indel realignment and Base Quality Score Recalibration 
was done with GATK. XHMM is an algorithm to detect exon-level copy number 
variation and assign CNV quality metrics(60)and was used at four of the PCGC analysis 
sites (CHOP, Harvard, Columbia and Mount Sinai) to identify de novo CNVs 
(Supplemental Figure 5.2). Candidate de novo CNVs were inspected visually. Putative de 
novo CNVs were prioritized for confirmation based on genomic length, low sequence 
depth variability and low prevalence in the XHMM call set data (AF<1%). All putative 
de novo CNVs were independently confirmed by ddPCR. 
 
SNP and short insertions/deletions (indels) were called from the Novoalign alignment of 
WES trios using a pipeline derived from GATK version 2.7 best practices.(47) Briefly, 
aligned reads were first compressed using the GATK ReducedReads module and variants 
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were called on all CHD WES trios using the UnifiedGenotyper joint variant calling 
module. Identified variants were filtered using GATK variant quality score recalibration. 
Variants were annotated using SnpEff.(33) De novo SNPs and indels were independently 
confirmed using Sanger sequencing. 
 
5.4.5 CNV confirmation with digital droplet PCR 
Putative CNVs were experimentally confirmed with ddPCR as previously reported(157) 
using an 18-27 base pair FAM probe designed within each candidate CNV region, 
avoiding homopolymer runs or probes that began with G. A VIC probe targeting the 
RPP30 gene was used as reference. Reaction mixtures of 20 μL volume comprising 
ddPCR Master Mix (Bio-Rad), relevant forward and reverse primers and probe(s) and 
100 ng of digested DNA were prepared, ensuring that approximately 25-75% of the 
10,000 droplets ultimately produced were positive for FAM or VIC signal. For de novo 
CNV confirmations, DNA from the CHD patient and parents was used. After thermal 
cycling, plates were transferred to a droplet reader (Bio-Rad) that flows droplets single-
file past a two-color fluorescence detector. Differentiation between droplets that contain 
target and those that did not was achieved by applying a global fluorescence amplitude 
threshold in QuantaSoft (Bio-Rad). The threshold was set manually based on visual 
inspection at approximately the midpoint between the average fluorescence amplitude of 
positives and negative droplet clusters on each of the FAM and VIC channels. Confirmed 
CNV duplications had approximately 50% increase in the ratio of positive to negative 
droplets as did the reference channel. Conversely confirmed CNV deletions had 
approximately half the ratio of positive to negative droplets as did the reference channel. 
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5.4.6 Network analysis 
Three bioinformatic algorithms were utilized: DAVID,(91) DAPPLE,(174)and 
WebGestalt.(210) Four different gene lists derived from the de novo CNV loci were used 
(Supplemental Table 5.4). The lists were constructed as follows:(1) All genes contained 
within de novo CNV intervals; (2) Published “causative” genes from previously reported 
CHD CNVs intervals in addition to all genes in novel CHD CNV intervals. “Causal” 
genes in previously reported CNV intervals included ELN(Williams syndrome), 
RAI1(Smith-Magenis syndrome),TBX1(22q11 deletion), GATA4 
(8p23.1 deletion), GJA5(1q21.1 duplication),and NKX2.5(5q35.1 deletion); (3) Genes 
contained solely within novel CHD CNV intervals (e.g., exclude genes from previously 
published CNVs); (4) Genes contained within de novo CNV intervals that are highly 
expressed in the developing mouse heart (top quartile of all genes expressed E14.5 mouse 
heart).(224) We anticipated that genes in list 2 and list 4 would have increased specificity 
for CHD in comparison to genes in list 1 and that genes in list 3 would be biased towards 
new disease networks.  
 
We expanded network analysis input gene lists by including both de novo CNV genes 
and de novo single nucleotide variants (SNV) that were previously identified in CHD 
probands by WES.(224) Only de novo SNVs predicted to be deleterious (e.g., loss of 
function (LOF): nonsense, frame-shift, and splice site mutations and missense variants 
that alter highly conserved amino acid residues or predicted to be deleterious by SIFT or 
PolyPhen2) were included in the expanded gene list. The additional gene lists included: 
(5) All genes within a de novo CNV interval (e.g., list 1) and protein-altering SNVs and 
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(6) Published “causative” genes from previously reported CHD CNVs intervals in 
addition to all genes in novel CHD CNV intervals (e.g., list 2) and protein altering SNVs. 
 
5.4.7 Statistical analysis 
Burden calculations were done with a Fisher exact test computed in the R statistical 
computing environment. For analyses using DAVID, networks with an enrichment of 
genes impacted by CNVs were assigned a p-value with Benjamini and Hochberg 
correction for multiple testing with a false discovery rate of 0.05. In DAPPLE, type I 
error was controlled through permutation. p-values of less than 0.05 were considered 
significant. 
 
5.5 Heart Histone Modification Single Nucleotide 
Variants 
Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8% 
of live births. Many cases occur sporadically and impair reproductive fitness, suggesting 
a role for de novo mutations. Here we compare the incidence of de novo mutations in 362 
severe CHD cases and 264 controls by analyzing exome sequencing of parent–offspring 
trios. CHD cases show a significant excess of protein-altering de novo mutations in genes 
expressed in the developing heart, with an odds ratio of 7.5 for damaging (premature 
termination, frameshift, splice site) mutations. Similar odds ratios are seen across the 
main classes of severe CHD. We find a marked excess of de novo mutations in genes 
involved in the production, removal or reading of histone 3 lysine 4 (H3K4) methylation, 
or ubiquitination of H2BK120, which is required for H3K4 methylation. There are also 
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two de novo mutations in SMAD2, which regulates H3K27 methylation in the embryonic 
left–right organizer. The combination of both activating (H3K4 methylation) and 
inactivating (H3K27 methylation) chromatin marks characterizes ‘poised’ promoters and 
enhancers, which regulate expression of key developmental genes. These findings 
implicate de novo point mutations in several hundreds of genes that collectively 
contribute to approximately 10% of severe CHD. 
 
In addition to de novo variants, transmitted variants were assessed for over-transmission 
above expected 0.5 chance for WES (Table 5.3) and array (Table 5.4). 
 
Table 5.3. Exome Transmission Enriched CNVs by TDT in CHD. 
 
CNVR(hg19) TDT P 
Transmit
Untrans
mit 
Gene 
Average 
Numsnps 
Case 
Average 
Length 
Conf 
Case(bp) 
CNV 
Type 
chr7:72023758-
72414061 
0.011412 t=9;u=1 
DQ601342,MIR4650-
1,POM121,SBDSP1,S
PDYE7P,TYW1B 
22.66667 333137.7 94 Dup 
chr1:247835420-
248652837 
0.0455 t=4;u=0 OR11L1,TRIM58 22.75 599049.4 99 Dup 
chr5:37358169-
37725152 
0.0455 t=4;u=0 NUP155,WDR70 55.625 373516.1 96 Dup 
chr11:95568454-
95621425 
0.05778 t=8;u=2 MTMR2 13.05263 42981.53 93.73684 Dup 
chr20:44351007-
44354321 
0.059347 t=13;u=5 SPINT4 3.03125 3831.656 97.84375 Del 
chr2:97815016-
97849405 
0.071861 t=17;u=8 ANKRD36 26.95 113748.7 93.85 Del 
chr1:65858114-
65897602 
0.083265 t=3;u=0 
DNAJC6,LEPR,LEPR
OT 
15 43594 99 Dup 
chr3:1189671-
1427481 
0.083265 t=3;u=0 CNTN6 10.33333 179273.7 97.83333 Dup 
chr6:117730726-
117739697 
0.083265 t=3;u=0 GOPC,ROS1 3.5 12226.5 94 Dup 
chr7:5920501-
5923630 
0.083265 t=3;u=0 OCM 11.83333 100091.7 94 Dup 
chrY:25375731-
25375830 
0.083265 t=3;u=0 DAZ2,DAZ3,DAZ4 1 100 31 Dup 
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Table 5.4A. Array Transmission Enriched CNVs by TDT for Common CNVs. 
 
CNVR(hg19) P TDT CNV Transmit : Untransmit 
CNV Gene 
Distance 
from 
Gene (bp) 
Copy 
Number 
chr19:20801607-
20802000 1.52E-13 t=184;u=67 ZNF626 745 1 
chr3:131711896-
131712898 1.87E-11 t=249;u=120 CPNE4 0 1 
chr20:42272198-
42273045 9.24E-11 t=155;u=60 IFT52 0 1 
chr16:23048233-
23049446 9.84E-10 t=131;u=49 USP31 23282 1 
chr18:54946766-
54948517 3.36E-09 t=126;u=48 ST8SIA3 71204 1 
chr16:25341372-
25343049 9.26E-09 t=137;u=57 ZKSCAN2 72517 1 
chr11:29967596-
29968238 3.52E-07 t=108;u=45 KCNA4 63050 1 
chr15:39744425-
39744669 5.13E-06 t=120;u=59 THBS1 128611 1 
chr15:86057437-
86059128 6.94E-06 t=81;u=33 AKAP13 0 1 
chr17:41517705-
41518185 5.93E-05 t=92;u=45 MIR2117 3989 1 
chr15:65817527-
65819037 6.33E-05 t=0;u=16 PTPLAD1 3790 3 
chr11:65642127-
65642343 6.68E-05 t=100;u=51 EFEMP2 1722 1 
chr14:54711242-
54713593 0.000451 t=85;u=45 CDKN3 150080 1 
 
Table 5.4B. Array Transmission Enriched CNVs by TDT for Rare CNVs. 
CNVR(hg19) P TDT CNV 
Transmit : 
Untransmit 
CNV 
Gene 
Distance 
from 
Gene 
(bp) 
Copy 
Number 
chr12:73988439-
74105393 0.008151 t=7:u=0 LOC100507377 421563 1 
chr2:81519114-
81557442 0.014306 t=6:u=0 5S_rRNA 165896 1 
chr10:13056587-
13060410 0.018422 t=14:u=4 AK311458,CCDC3 0 1 
chr10:62427293- 0.025347 t=5:u=0 ANK3 0 1 
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62428017 
chr22:44564975-
44565393 0.032509 t=11:u=3 PARVB 0 1 
chr12:99994315-
99995706 0.033895 t=7:u=1 ANKS1B 0 1 
chr12:98405248-
98405248 0.033895 t=7:u=1 MIR4303 16022 1 
chr1:17616194-
17619279 0.033895 t=7:u=1 PADI3 5467 3 
chr19:54180400-
54180706 0.034808 t=9:u=2 MIR520E 1349 1 
chr20:44204861-
44378173 0.034808 t=9:u=2 
SPINT4,WFDC10A,WFDC10B, 
WFDC11,WFDC13,WFDC8,WFDC9 0 1 
chr10:55086553-
55086886 0.0455 t=4:u=0 PCDH15 475647 1 
chr5:74182586-
74186901 0.0455 t=4:u=0 FAM169A 0 1 
chr8:122325332-
122341946 0.0455 t=4:u=0 HAS2 283325 3 
 
To assess the control frequency directly in a test statistic compared to controls, we use 
Fisher’s exact test for both WES (Table 5.5) and array (Table 5.6) data. 
 
Table 5.5. WES Case-Control CNV Association in CHD 
 
CNVR(hg19) 
P 
(perm adj) 
Cases 
CNV 
Controls 
CNV 
Gene 
Avg 
Num 
Exons 
Avg 
Length 
Avg 
Conf 
CNV 
Type 
chr1:145273185-
145282043 1q21.1 
0.004 20 2 
NOTCH2NL 
SEC22B, 
NBPF14, 
NBPF9 
25 265,755 80 Dup 
chr19:54197623-
54216713 
19q13.42 
0.03 11 0 MIR517A, 24 48,456 89 Del 
chr7:26245988-
26251828 7p15.2 
0.04 14 1 CBX3 4 17,394 70 Del 
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Table 5.6. Array Case-Control CNV Association in CHD 
 
CNVR(hg19) P CNV 
Logistic 
Cases 
CNV 
Controls 
CNV Gene(s) 
Average 
Numsnps 
Copy 
Number 
Exon 
Distance 
P CNV 
Fisher 
chr15:60090457-
60103464 4.01E-10 14 5 BNIP2 13.0 1 108815 0.017882 
chr1:8359110-
8362754 8.31E-09 15 1 SLC45A1/ RERE 5.4 1 21636 0.000125 
chr14:27479798-
27481036 1.11E-08 8 1 MIR4307 14.3 1 101867 0.014167 
chr5:32106628-
32107084 1.33E-08 36 14 PDZD2 46.7 3 364 0.000242 
chr4:7183984-
7186257 6.93E-08 12 2 SORCS2 8.1 1 8117 0.004893 
chr6:66074421-
66080908 3.57E-07 14 1 EYS 13.0 1 10911 0.000249 
chr3:88706819-
88715097 2.52E-06 9 1 EPHA3 11.2 1 441577 0.007493 
chr12:34438235-
34478239 9.12E-06 9 1 ALG10 152.4 3 256999 0.008521 
chr10:105718227-
105720104 9.54E-06 14 3 SLK 9.8 1 7366 0.002511 
chr11:50543494-
50585298 9.66E-06 64 20 LOC646813 28.2 3 163692 7.7E-09 
chr17:44249838-
44263765 2.22E-05 13 4 KANSL1 25.6 1 240 0.005428 
chr9:66849886-
66861820 2.79E-05 15 1 AK310876 6.7 1 61147 0.000124 
chr6:24325627-
24325627 0.000103 21 3 DCDC2 28.3 1 23355 3.61E-05 
chr4:183570100-
183571844 0.000214 7 1 TENM3 17.5 3 3080 0.028486 
chr21:10858540-
10858651 0.000383 104 107 TPTE 44.7 3 48092 0.000768 
chr16:16203345-
16261251 0.00045 7 1 ABCC1,ABCC6 285.7 3 0 0.028093 
chr1:232460612-
232461177 0.00048 10 2 SIPA1L2 16.4 3 72535 0.016979 
 
 
Now that we have better understood congenital heart disease we move into 
neurodevelopmental disorders and comparing a variety of disorders and different arrays 
in a meta-analysis. 
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Chapter 6  
6.0 CNV Meta-Analysis of 5 Major Neurodevelopmental Disorders 
 
Summary 
Psychiatric disease in children and young adults poses a major health burden and is 
growing rapidly in prevalence. However, diagnostic phenotypes are not necessarily 
distinct from each other suggesting a shared genetic etiology. There is also a potential to 
target a shared associated variant using a shared therapeutic. Here, we investigate copy 
number variants in cohorts of schizophrenia, bipolar, autism, ADHD, and depression. We 
can consider the effected domains of cognition, psychosis, and mood. A total of 11,418 
cases were compared to 14,789 controls. The well-known 22q11 deletion was found to be 
enriched in cases vs. controls (p=5.33x10
-7
). Duplication of DOCK8/KANK1 was found 
to be significant p=7.5x10
-7
. Several known and novel loci were significant by case-
control association with CNVs enriched in cases across the neurodevelopmental 
disorders. 
6.1 Introduction 
Studies of the base variants of DNA in psychiatric disease in very large cohort sizes have 
begun to bear intriguing results (3, 117, 118, 168, 193). However, these single nucleotide 
polymorphisms (SNPs) imprecisely tag nearby genes and have modest odds ratios. Copy 
number variants (CNVs) have more direct gene dosage impacts and have been implicated 
in psychiatric disease by a number of smaller cohort sizes with high odds ratios (49, 65, 
67, 68). Although family studies have been very popular for avoiding population 
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stratification issues, de novo and transmission disequilibrium (TDT) tests lack power to 
find recurrent and significant results respectively. Case-control studies allow an 
abundance of independent controls, population based allele frequency comparisons, 
correction for population stratification of rare CNV variants by linear mixed model, with 
enhanced power for recurrent significant confident results. Ambiguity in CNV calling in 
different cohorts with different array resolutions can be challenging and impinge on 
independent replication efforts. Here we process 5 large psychiatric disease cohorts in a 
systematic manner to promote comparability of results. 
6.2 Results 
Five large psychiatric diseases with matched SNP array version controls were genotyped 
and quality metric filtered (Table 6.1).  
Table 6.1. Psychiatric Disease Cohorts Analyzed 
 
Disease Cohort Cases Controls Array Statistic 
Schizophrenia 
Bipolar cohort 
3,377 1,301 Illumina 1MDv3 GEMMA 
Schizophrenia 2,790 4,500 Affymetrix 6.0 GEMMA 
Autism 3,360 3,288 Illumina 550v3 GEMMA 
ADHD 1,244 4,110 Illumina 550v1 Fisher 
Depression 647 1,590 Perlegen 660k Fisher 
GEMMA and Fisher exact test p-values and Betas/odds ratios were calculated for each 
disease case-control study. The closest gene was used as the marker name instead of the 
rs ID SNP name to allow for more dynamic matching between CNVs derived from 
different arrays (Table 6.2).  
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Table 6.2. SNP ID Matches between SNP arrays  (top panel) and Gene ID Array Matches for Deletions 
(middle panel) and Duplicaitons (bottom panel) 
 
Matches SNPs 
Between Cohorts 
Count 
Significant 
CNVRs 
1,758,390 1 127 
385,436 2 30 
225,641 3 25 
88,750 4 7 
9,976 5 0 
 
Matches Genes Del 
Between Cohorts 
Count 
Significant 
CNVRs 
2,921 1 12 
2,671 2 20 
1,900 3 18 
14,547 4 40 
7,900 5 175 
 
Matches Genes Dup 
Between Cohorts 
Count 
Significant 
CNVRs 
2,865 1 37 
2,776 2 22 
1,844 3 7 
15,297 4 16 
7,262 5 43 
The lowest p-value was used for meta-analysis. Using Genome-wide Efficient Mixed 
Model Association (GEMMA) for the initial discovery cohorts of patients with 
schizophrenia, schizoaffective, and bipolar disease, we performed principal components 
analysis (PCA) and subsequently matched Caucasians cases with Caucasians controls, to 
, correct for residual population stratification while maintaining power for rare CNV 
variants. Correction for population stratification for rare population frequency variants 
which may be geographically concentrated or dispersed while maintaining power, 
remains an important fundamental open challenge of ongoing investigation
(127, 137)
. 
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The known and well characterized 22q11 deletion was found across psychiatric diseases 
and we were able to resolve smaller 
CNVs in a couple patients on COMT 
and PRAME, implicating these genes 
as key drivers in the deletion 
phenotype for these psychiatric 
disorders (Figure 6.3). 
A novel duplication of DOCK8 and 
KANK1 on 9p24 was the most 
significant result with duplication 
CNVs enriched in each of the 5 case-
control cohorts meta-analyzed with 
significant contributions from each cohort (Table 6.3) (Figure 6.1). These were 
subsequently validated visually (Figure 6.4) and experimentally (Table 6.10). 
Table 6.3. DOCK8 Contributing Signals from each Psychiatric Disease Cohort 
 
Cohort ChrPosHg18 SNPID P Beta/OR 
Cases 
Dup 
Cases 
Diploid 
Controls 
Dup 
Controls 
Diploid 
Gene 
Exon 
Distance 
Schizo 
Bipolar 
chr9:435364 rs4741936 0.00693 3.15E-01 6 2911 0 1113 DOCK8 1006 
CHOP 
Schizo 
chr9:383339 
SNP_A-
2057057 
0.00800 10.7119 7 957 1 1465 DOCK8 2773 
CHOP 
Autism 
chr9:432030 rs1887958 0.00384 infinity 7 2071 0 2518 DOCK8 21 
CHOP 
ADHD 
chr9:344334 rs943625 0.08985 3.31932 4 1235 4 4105 DOCK8 11257 
CHOP 
Depression 
chr9:283360 rs943628 0.00731 4.96401 8 639 4 1586 DOCK8 3779 
 
Figure 6.1. DOCK8/KANK1 Duplications 
 
 
 
Green rectangles represent duplication calls. 
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Analysis, using GEMMA for the various disease cohorts in Table 6.1 (Schizophrenia 
Bipolar, Schizophrenia, Autism, ADHD, and Depression) demonstrated significant P 
values across multiple loci (Table 6.4).  
 
Table 6.4. Meta-analysis across five major neuropsychiatric cohorts.  Deletions (top table) and Duplications 
(bottom table) 
 
MarkerName 
Deletion Weight Zscore 
Meta p-
value *Direction 
KIAA1693 4 7.185 6.73E-13 -+++? 
NBPF20 4 7.036 1.97E-12 ++++? 
POTEA 3 5.756 8.59E-09 +?++? 
CYP2A6 4 4.637 3.54E-06 ++++? 
COMT 3 4.494 6.99E-06 +?++? 
GRIN3B 3 -4.482 7.41E-06 -?--? 
CTNNA3 4 -4.439 9.05E-06 ----? 
AK058147 4 4.394 1.11E-05 ++++? 
C21orf56 3 4.112 3.93E-05 +?++? 
DUSP22 3 4.007 6.15E-05 ++?+? 
DKFZp434L187 4 3.916 9.02E-05 +++-? 
ZNF804A 4 3.88 0.000104 ++++? 
MAMDC1 4 3.8 0.000145 ++++? 
PSG11 4 3.743 0.000182 ++++? 
ASB3 4 3.666 0.000247 ++++? 
HCN1 4 3.597 0.000322 +++-? 
 
MarkerName 
Duplication Weight Zscore 
Meta p-
value Direction 
DOCK8 5 4.948 7.50E-07 +++++ 
AK075337 3 4.629 3.68E-06 +?++? 
AF161442 3 4.574 4.78E-06 ?-++? 
KANK1 5 4.141 3.45E-05 +++++ 
AK123120 4 4.128 3.67E-05 +-++? 
FAM60A 5 4.111 3.94E-05 ++++- 
UNKL 3 3.816 0.000136 +?++? 
ALG10B 4 3.748 0.000179 ++++? 
 
*Some arrays had poor coverage or no CNVs observed on certain genes, resulting in missing direction of 
association (“?”); “+” indicates more cases than controls while; “-“ indicates more controls than cases. 
 
141 
 
Analysis of Protein-Protein Interaction Network was performed using brain expression 
filters 
capturing 20 
genes of 55 
(Figure 6.2). 
Topological 
features:  
1. the main 
network is 
around gene 
UBC  
2. smaller 
cluster involving ZWINT neighborhood (also RAB11FIP3 and ERBB4). 
  
Calcium channels have been associated in GWAS meta-analysis of the psychiatric 
diseases(3). These CACNA genes, specifically CACNA1H (p=7.33x10
-5
) demonstrated 
the strongest signal in autism, and more modest signals in schizophrenia, bipolar, and 
depression. Interestingly, ADHD had a significant lack of CNVs in this region. 
6.3 Discussion 
There is mounting evidence for the shared genetic and epidemiological etiology 
of psychiatric disorders. We are the first to perform CNV meta-analysis between all five 
major neurodevelopmental disorders: autism, ADHD, schizophrenia, bipolar, and 
depression. These genetic discoveries pave the way for new drugs and diagnostics which 
Figure 6.2. Protein-Protein Interaction Network Brain Expressed. 
 
 
 
20 genes (of 55). Topological features: 1. the network is around gene UBC 2. small 
cluster involving ZWINT neighborhood (also RAB11FIP3 and ERBB4). 
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can be applied across clinical indications. Using gene based association statistics, we 
were able to robustly meta-analyze different psychiatric conditions across different 
microarrays and generate and uncover novel loci with neurodevelopmental/psychiatric 
disease associations.                                                                                                        
22q11 deletion is a well know locus for schizophrenia and syndromic conditions with 
heart and brain involvement. Here, we are able to partially gain greater resolution of 
pathogenic CNVs in this genomic locus, highlighting COMT.9p24 duplications of 
DOCK8 and KANK1 are intriguing given that these genes have been shown to be 
involved in severe mental dysfunctions of mental retardation and cerebral palsy, 
respectively. DOCK8 is the dedicator of cytokinesis 8, a member of the DOCK180 
family of guanine nucleotide exchange factors (GEF), of which there are 11 DOCK 
genes. Guanine nucleotide exchange factors interact with Rho GTPases and are 
components of intracellular signaling networks. GEF proteins activate some small 
GTPases by exchanging bound GDP for free GTP. Mutations in DOCK8 have been 
shown to cause mental retardation. KANK1 is KN motif and ankyrin repeat domains 1 
(KANK1). There are 4 KANK genes. KANK1 functions in cytoskeleton formation by 
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regulating actin polymerization. Mutations in this gene cause cerebral palsy spastic 
quadriplegic type 2, a central nervous system development disorder. KANK1 inhibits 
neurite outgrowth. KANK1 inhibits actin fiber formation and cell migration. KANK1 also 
inhibits RhoA activity; the function involves phosphorylation through PI3K/Akt 
signaling and may depend on the competitive interaction with 14-3-3 adapter proteins to 
sequester them from active complexes. Inhibits the formation of lamellipodia (projection) 
but not of filopodia (far projection); the function may depend on the competitive 
interaction with BAIAP2 to block its association with activated RAC1. KANK1 inhibits 
fibronectin-mediated cell spreading; the function is partially mediated by BAIAP2. 
KANK1 is involved in the establishment and persistence of cell polarity during directed 
cell movement in wound healing. In the nucleus, KANK1 is involved in beta-catenin-
dependent activation of 
transcription. 
CACNA was first implicated in our 
previous schizophrenia CNV 
association study(REF). A GWAS 
meta-analysis of psychiatric disease 
base genotypes also implicated this 
locus as highly significant. Here we 
show CACNA1H as highly 
significant further underscoring the 
importance of this gene family in 
psychiatric conditions. 
Figure 6.3. 22q11 Deletion in Individual Sample Profiles 
 
 
 
Red rectangles represent deletion calls. 
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These CNVs add to the catalog of neurodevelopmental variants(77) to be further 
investigated and replicated(83) by ongoing studies in this important domain. 
6.4 Conclusion 
With mounting awareness of childhood psychiatric conditions comes mounting need for 
large-scale genetic studies and unified picture of the catalog of rare variants underlying 
these conditions. We take the unprecedented step to meta-analyze CNVs across 
psychiatric diseases and reveal multiple significant genes which could serve as viable 
drug targets with cross-indication clinical utility. 
6.5 Methods 
Sample 
The dbGaP non-GAIN schizophrenia samples were downloaded from the dbGaP website. 
We did have total of 5825 non-GAIN Affymetrix 6.0 raw CEL files. The CEL files were 
converted to raw intensity data using PennCNV Affy workflow 
[http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html].  We 
only included samples with call rate>=98% for generating CNVs.   
 PennCNV and QC 
CNV were generated using PennCNV(211)
 
a Hidden Markov Model(HMM) based 
algorithm which combines multiple source of information including LRR, BAF ,SNP 
spacing and population frequency of B allele to generate the CNV.  The following  QC 
criteria were used to select the CNV’s for further analysis: 1) For all Illumina chip 
platform call rate >98%, SD LRR <0.3, |GCWF| <0.05 and count CNV <100;  2) For 
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Affymetrix 6.0 data call rate >96%, SD LRR <0.35, |GCWF| <0.02 and count CNV <80 
(70)
 
. 
For Affymetrix 6.0 Schizophrenia dbgap non-gain samples, we did LD based SNP 
pruning using Plink(167).We only included the SNP with genotype rates < 5%, minor 
allele frequency > 0.01, as well as HWE P value > 0.0001. We generated the pairwise 
IBD values for samples using genome command and excluded one sample from any pair 
with a PI_HAT value exceeding 0.3. 
We ran PCA on Affymetrix 6.0 data using Eigenstrat(163)
 
package. The first 10 Eigen 
vectors were plotted and samples were excluded if the values were greater than 0.05 for 
the first 2 principal components to select eastern European individuals. 
CNV Association 
ParseCNV(70) was used to conduct the CNV association analysis. Case control CNV 
association  was done on Schizophrenia (case=2790, control=4500), Autism (case=3360, 
control=3288) cohorts separately which generates a deletion, duplication  CNVRs based 
on probe statistics of CNV’s. The –includeped option was used in the ParseCNV(70)  
which generates a ped file for SNP analysis. 
GEMMA 
The bed file was imported into GEMMA version 0.94(227).The relatedness matrix for 
genotype was calculated using the -gk 1 option .The matrix file was then imported for 
univariate linear mixed model association which accounts for population stratification 
estimate the proportion of variance of phenotype and -lmm 4 option was used which 
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includes Wald test, likelihood ratio test and score test statistics, we also removed SNPs 
whose MAF<0.000005.  
InsertPlinkPvalues 
We used InsertPlinkPvalue program from ParseCNV(70) 
 
package to insert the SNP p-
value generated by GEMMA association result to define ParseCNV CNVRs . 
METAL 
For meta-analysis, METAL was used on SNP-based population CNV association 
statistics sorted by p-value to include the most significant SNP in each gene. The 
logarithm of the odds ratio was taken to ensure consistency with Beta for the direction of 
association considerations. 
Statistical Analysis 
Two-tailed fisher’s exact test and Gemma linear mixed model. P-values of less than 0.05 
after correction for 100 independent and informative tests (5x10
-4
 uncorrected) were 
considered significant.  
Table 6.5. GEMMA analysis in Schizophrenia/Bipolar discovery samples together with CHOP samples 
from Schizophrenia, Autism, ADHD and Depression cases. 
A) 
Marker Name 
Del 
Weight Zscore P-value Direction Region(hg19) 
LOC729862 3 7.042 1.90E-12 +?++? chr5:28926976-28927420 
HLA-B 3 4.882 1.05E-06 ++?+? chr6:2618277-2704782 
MED18 3 4.773 1.81E-06 +++?? chr1:28655512-28662478 
C11orf74 3 4.745 2.09E-06 -?++? chr11:36616066-36696390 
NBPF4 3 4.709 2.49E-06 +++?? chr1:108918459-108953434 
HINT1 3 4.698 2.62E-06 +?++? chr5:130494874-130501034 
BC035867 3 4.677 2.91E-06 +?++? chr22:20970516-21011201 
SLITRK6 3 4.671 3.00E-06 +?++? chr13:86366921-86373483 
CPNE4 3 4.669 3.03E-06 +++?? chr3:131253576-132004254 
POTEA 3 4.559 5.13E-06 +?++? chr8:43147584-43218328 
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RNF168 3 4.525 6.03E-06 +++?? chr3:196195656-196230639 
PHACTR4 4 4.455 8.38E-06 ++++? chr1:28696092-28826881 
WDR53 3 4.449 8.64E-06 +++?? chr3:196281058-196295413 
HCN1 3 4.371 1.24E-05 +?+-? chr5:45255051-45696220 
C3orf43 3 4.296 1.74E-05 +++?? chr3:196233749-196242237 
BC070396 4 4.252 2.12E-05 ++++? chr3:103646038-103730578 
RGS18 4 4.207 2.59E-05 ++++? chr1:192127591-192154945 
KHDRBS2 4 4.077 4.57E-05 ++++? chr6:62389864-62996100 
CCDC91 3 4.07 4.69E-05 +?++? chr12:28332209-28703099 
AK093205 4 4.046 5.20E-05 ++++? chr4:33893553-33908510 
LOC10014460
2 
4 4.039 5.38E-05 ++++? chr4:66535678-66559104 
KCND2 3 3.889 0.000101 +?++? chr7:119913721-120390387 
GUCY1A3 3 3.804 0.000143 ++?+? chr4:156587861-156658214 
SESN2 3 3.79 0.000151 +++?? chr1:28585962-28609002 
FBXO45 3 3.766 0.000166 +++?? chr3:196295724-196315930 
BC051808 4 3.711 0.000206 ++++? chr1:108963310-108975804 
PER4 3 3.646 0.000267 +?++? chr7:9673899-9675447 
JARID2 3 3.626 0.000288 +++?? chr6:15246526-15522253 
PRR16 3 3.604 0.000313 +?++? chr5:119800018-120022964 
SEMA5A 3 3.602 0.000315 +?++? chr5:9035137-9546233 
OR12D3 3 3.6 0.000319 ++?+? chr6:29341199-29343068 
AK098570 3 3.587 0.000335 +?++? chr5:29143667-29153802 
KCNJ3 3 3.579 0.000345 ?+++? chr2:155555092-155713014 
ARHGEF16 4 3.563 0.000367 ++++? chr1:3371146-3397677 
BC034799 4 3.561 0.00037 ++++? chr4:58292037-58332152 
SPRY2 3 3.523 0.000427 +?++? chr13:80910111-80915086 
EYS 4 3.493 0.000477 -+++? chr6:64429875-66417118 
DPP10 4 3.482 0.000499 ++++? chr2:115199898-116602326 
 
 
  
B) 
Marker Name 
Dup 
Weight Zscore P-value Direction Region(hg19) 
AF161442 2 6.232 4.60E-10 ??++? chr9:139543061-139554873 
SIK1 3 4.87 1.12E-06 +?++? chr21:44834397-44847002 
BC036345 4 4.725 2.30E-06 ++++? chr4:33897960-34041515 
ZNF85 2 4.358 1.31E-05 +?+?? chr19:21106058-21133503 
AK075337 3 4.217 2.48E-05 +?++? chr19:28129390-28137384 
TRNA_Lys 2 4.15 3.33E-05 ?++?? chr1:55423541-55423614 
TRNA_Pseudo 2 4.026 5.68E-05 ?++?? chr5:151988595-151988771 
GPC5 3 3.99 6.62E-05 +?++? chr13:92050934-93519487 
C19orf36 2 3.77 0.000163 -??+? chr21:11057795-11098937 
TRNA_Gln 2 3.756 0.000172 ?++?? chr20:17855141-17855219 
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AK056166 2 3.732 0.00019 +??+? chr20:17855141-17855219 
AF088005 2 3.726 0.000195 +??+? chr19:13209841-13213974 
HLA-A 3 3.669 0.000243 ++?+? chr6:1150035-1295564 
HCN1 3 3.656 0.000256 +?++? chr5:45255051-45696220 
ITGB2 2 3.639 0.000273 ??++? chr21:46305867-46348753 
BX648270 2 3.637 0.000276 ++??? chr2:132442469-132457442 
ALG10B 3 3.622 0.000293 +?++? chr12:38710556-38723528 
ICOSLG 2 3.619 0.000296 ??++? chr21:45646721-45660834 
AX747706 2 3.616 0.000299 ??-+? chr9:139442078-139444195 
TRNA_His 2 3.512 0.000444 ?++?? chr1:145396880-145396952 
LOC728989 2 3.512 0.000444 ?++?? chr1:146490894-146514599 
 
 
Description of schizophrenia/bioplar discovery cohort samples 
The unrelated schizophrenia (SCZ), schizoaffective (SA), or bipolar I (BP) patients were 
from 28 clinical trials (Table 6.6) conducted by Janssen Research & Development, LLC 
to assess the efficacy and safety of risperidone, paliperidone and an investigative 
compound (R209130). The diagnoses of SCZ, SA, and BP were based on expert clinician 
interviews conducted using DSM-IV-TR criteria. In two studies (NCT00397033 and 
NCT00412373), the diagnosis of schizoaffective disorder was confirmed using an 
interview based SCID (Structured Clinical Interview for DSM-IV-TR). Detailed 
descriptions of these clinical trials can be found at ClinicalTrials.gov, as well as in 
published works
1-30
, and thus, are not repeated here. 
 
A total of 5,544 DNA samples from 5,431 patients and 49 quality control (QC) samples 
were genotyped on the Illumina Human1M-DuoV3. DNA samples from all patients who 
participated in these clinical trials and consented to the genetic study were genotyped for 
21 out of the 28 clinical trials. A small number of DNA samples from the remaining 7 
clinical trials were also genotyped (Table 6.6). The DNA samples were genotyped in 2 
batches, with 3,102 samples in the first batch and 2,491 samples in the second batch. 
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Genotype data were successfully generated on 5,508 samples. A few sample QC steps 
were performed to remove the duplicated and/or problematic samples. First, gender 
discrepancies were examined using both the heterozygosity rate of the X-chromosome 
SNPs and the call rate of the Y-chromosome SNPs. Samples with discrepant and 
ambiguous gender information were excluded. Second, the relatedness of the genotyped 
samples was examined using pairwise Identity-by-State. Planned but not confirmed 
duplicates, as well as unplanned duplicates, with discrepant phenotype data were 
excluded from subsequent analyses. For each pair of samples that were planned and 
confirmed duplicates, unplanned duplicates with consistent phenotype data, or samples of 
related individuals, the sample with a smaller standard deviation of the LogR-ratio (LRR) 
was retained. After the sample QC, there were 4,962 samples (3,251 SCZ, 377 SA, and 
1,334 BP) remaining.  
 
Table 6.6: Summary of the clinical trial samples 
ClinicalTrials.gov 
Identifier 
Disease 
Number of 
Patients 
Genotyped 
Genotyping 
Batch 
Publication PMID 
NCT00791232 SCZ 1 1 Cleton et al 2007 
 
NCT00086320 SCZ 187 1 Kramer M et al 2007 17224706 
NCT00085748 SCZ 93 1 Tzimos A et al 2008 18165460 
NCT00078039 SCZ 473 1 
Kane J et al 2007,  17092691, 
18466043 Meltzer HY et al 2008 
NCT00077714 SCZ 296 1 
Marder SR et al 2007,  17601495, 
18466043 Meltzer HY et al 2008 
NCT00083668 SCZ 333 1 
Davidson M et al 2007,  17466492, 
18466043 Meltzer HY et al 2008 
NCT00334126 SCZ 220 1 Canuso CM et al 2009 19411369 
NCT00397033 SA 173 2 Canuso CM et al 2010 
20492853, 
20957127 
NCT00412373 SA 187 2 Canuso et al 2010 
20814330, 
20957127 
NCT00299715 BP 310 2 Berwaerts J et al 2012 20624657 
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NCT00309699 BP 350 2 Vieta E et al 2010 20565430 
NCT00309686 BP 214 2 Berwaerts J et al 2011 20947174 
NCT00074477 SCZ 168 1 Kramer M et al 2010 19941696 
NCT00111189 SCZ 14 1 
Hough D et al 2010,  19959339, 
21696265 Kozma CM et al 2011 
NCT00210717 SCZ 493 1 
Fleischhacker WW et al 
2011 
21777507 
NCT00210548 SCZ 249 1 Gopal S et al 2010 20389255 
NCT00101634 SCZ 404 1 Nasrallah HA et al 2010 20555312 
NCT00119756 SCZ 17 1 Hough D et al 2009 19481579 
NCT00590577 SCZ 468 2 
Pandina GJ et al 2010,  20473057, 
21569242 Bossie CA et al 2011 
NCT00297388 
SCZ or 
SA 
148 2 Simpson GM et al 2006 16965196 
NCT00061802 
SCZ or 
SA 
62 1 
Gharabawi GM et al 
2006 
17054789 
NCT00076115 BP 120 2 Hass M et al 2009 19839994 
 
SCZ 8 1 Turner M et al 2004 15201572 
NCT00253162 BP 233 2 Smulevich AB et al 2005 15572276 
NCT00257075 BP 186 2 Hirschfeld RM et al 2004 15169694 
NCT00034775 SCZ 16 1 
Lindenmayer JP et al 
2004 
15323593 
 
SCZ 7 1 
  
NCT00063297 SCZ 1 1 
  
 
 
Data presented in table 6.7 below summarize the basic demographic information of these 
patients. 
 
 
Table 6.7: Basic demographic information of the JNJ SZ, SA, and BP patients 
 
Schizophrenia  
(N=3251) 
Schizoaffective  
(N=377) 
Bipolar 
(N=1344) 
Sex, n (%) 
   
F 1240 (38.1) 152 (40.3) 629 (47.2) 
M 2011 (61.9) 225 (59.7) 705 (52.8) 
Age, years 
   
Mean (SD) 40.2 (12) 38.7 (9.5) 37.8 (13.5) 
Median (Range) 40 (17, 81) 39 (19, 61) 39 (10, 77) 
Race, n (%) 
   
Asian 117 (3.6) 52 (13.8) 37 (2.8) 
Black or African American 703 (21.6) 86 (22.8) 247 (18.5) 
White 2360 (72.6) 228 (60.5) 1021 (76.5) 
Other 71 (2.2) 11 (2.9) 29 (2.2) 
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Schizophrenia GAIN and non-GAIN: Inclusion criteria for samples included in the 
analysis were as follows:  The subject must give signed, informed consent.  The proband 
must have a consensus best-estimate DSM-IV diagnosis of SZ (schizophrenia) or of 
schizoaffective disorder with at least 6 months’ duration of the “A” criteria for 
schizophrenia.   The subject must be over 18 years of age at interview (male or female).  
The informant should have known the subject for at least 2 years, be familiar with the 
psychiatric history, and have at least 1 hour of contact per week with the proband (close 
family members preferred). 
Exclusion criteria were as follows:  The subject is unable to give informed consent to all 
aspects of the study.  The subject is unable to speak and be interviewed in English (to 
ensure validity of the interviews). 
Psychosis is deemed secondary to substance use by the consensus diagnostic procedure 
because psychotic symptoms are limited to periods of likely intoxication or withdrawal, 
or there are persistent symptoms likely related to substance use (e.g. increasing paranoia 
after years of amphetamine use, symptoms limited to visual hallucinations after extensive 
hallucinogen use).   The psychotic disorder is deemed secondary to a neurological 
disorder, such as epilepsy, based on the nature and timing of symptoms. For example, 
nonspecific, nonfocal EEG abnormalities are common in SZ, but subjects with psychosis 
that emerged in the context of temporal lobe epilepsy would be excluded. 
The subject has severe mental retardation (MR). A subject with mild MR (IQ ≥ 55 or 
based on clinical and educational history) can be included if SZ symptoms and history 
can be clearly established. 
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Control Population Typed on Affymetrix 6.0 at CHOP 
The control population included de-identified subjects collected at CHOP and UPenn was  
Only Caucasian samples from subjects without psychiatric disease were included and 
validated by Eigenstrat principal components analysis before use. 
 
Autism   
The ASD subjects within the ACC cohort were collected from multiple collaborative 
projects across the US. We assembled an ASD Autism Case-Control (ACC) cohort by 
collecting, from multiple sites within the United States, 859 subjects of European 
ancestry affected with ASD (Table 6.8). Among these subjects, 703 were male and 156 
were female, all of whom met diagnostic criteria for autism based on ADI, and 124 met 
criteria for other ASDs based on ADOS. The best estimate procedure was used with 
autism experts evaluating all available information (including ADI/ADI-R and ADOS 
which was attained for all subjects) to provide the final diagnosis of Autism or ASD. 
Subjects ranged from 2-21 years of age when diagnosis was made. ADI-Autism 
Diagnostic Interview, ADOS-Autism Diagnostic Observation Schedule, IQ-Intelligence 
quotient, NVIQ-nonverbal IQ, VIQ-verbal IQ, FSIQ-full scale IQ. 
 
Table 6.8. ACC Cohort Description 
blood 98%  ADI_dx Autism 859  IQ age (months)  n=496 
cell line 2%  ADI_dx not Autism 0  Median 117 
   ADOS_dx ASD 124  Mean 141.4 
Female 156  ADOS_dx Autism 708  SD 95.5 
Male 703  ADOS_dx not Autism 27    
      NVIQ n=382 
      Median 92 
      Mean 89 
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Control subjects from the Children’s Hospital of Philadelphia 
 
The control group included 2519 children of self-reported Caucasian ancestry (mean age 
was 8.7 years, median=9, SD=5.46 and 52.5% males). All controls had no history of 
ASD. The CHOP controls were recruited by CHOP nursing and medical assistant staff 
under the direction of CHOP clinicians within the CHOP Health Care Network, including 
four primary care clinics and several group practices and outpatient practices that 
included well child visits. The controls are recruited though our primary care and well 
child clinics - they range in age from 1-19 years; both questionnaire data (obtained during 
recruitment) and electronic health care records (average coverage 3-4 years) indicated 
that they have no chronic disease and are developmentally on target; age, sex and ethnic 
background are also reported. The questionnaire data asked specifically if the patient has 
been evaluated for autism; any underlying medical condition and any medication they 
may be taking (so all the controls are negative for autism or any other CNS disorder, 
chromosomal disorder, syndrome or genetic disorder). 
 
      SD 25.5 
        
      VIQ n=378 
      Median 86 
      Mean 81.1 
      SD 29.5 
        
      FSIQ n=453 
      Median 87 
      Mean 85.7 
      SD 25.5 
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Autism Genetic Resource Exchange (AGRE) 
 
The Autism Genetic Resource Exchange (AGRE; http://www.agre.org) has a collection 
of DNA samples and clinical information from families with autism spectrum disorder 
(ASD). We have collected DNA samples from 943 families (4,444 individuals) from the 
entire AGRE collection (as of August 2007). These AGRE families include 917 
multiplex families, 24 simplex families and 2 families without ASD diagnosis (not used 
in analysis). 
The AGRE annotation database classifies autism, broad spectrum (patterns of 
impairment along the spectrum of pervasive developmental disorders, including PDD-
NOS and Asperger’s syndrome) or Not Quite Autism (individuals who are no more than 
one point away from meeting autism criteria on any or all of the social, communication, 
and/or behavior domains and meet criteria for “age of onset”; or, individuals who meet 
criteria on all domains, but do not meet criteria for the "age of onset"). In our analysis, 
AGRE patients with “Autism” (n=1202) and “Broad Spectrum” (n= 134) phenotype 
annotation were treated as a single ASD group. Among them, 11 subjects had autism 
diagnoses assigned by ADOS (Autism Diagnostic Observation Schedule) without ADI-R 
(Autism Diagnostic Interview-Revised). SRS-Social Responsiveness Scale
 
(Table 6.9). 
 
Table 6.9. AGRE Cohort Clinical Description 
 
Multiplex  95%  ADOS_Diagnosis Count   SRS n=821 
Simplex  5%  Autism 775  Median 106 
   not ASD or Autism 76  Mean 104.2 
Cell Line 1336  Spectrum 171  SD 33.7 
        
Female 284  Assessed age yrs   SRS Age yrs  
Male 1052  Median 8  Median 9.49 
   Mean 9.2  Mean 10.0 
Sibs Count  SD 5.3  SD 4.6 
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0 282       
1 438  ADIR Count   Raven IQ n=645 
2 54  Autism 93  Median 103 
3 4  Asperger's 18  Mean 100.7 
   PDD 16  SD 18.9 
AGRE Status  Count       
Autism 1202  Assessed age yrs   Raven IQ Age 
yrs 
 
BroadSpectrum 134  Median 7.08  Median 8 
   Mean 8.0  Mean 8.9 
   SD 4.4  SD 3.9 
 
 
ADHD 
 
Our discovery cohort included a total of 1,013 ADHD cases of European descent 
recruited and genotyped at The Children’s Hospital of Philadelphia (CHOP) consisting of 
664 cases without parents and 349 cases from complete trios. We established a minimum 
inclusion IQ threshold of 70 to exclude cases with intellectual disability. The control 
group included 4,105 healthy children of European ancestry 32% female and 68% male 
aged 6-18 years old. Medical records and parental/self-reported questionnaires were 
screened for developmental delays and special educational needs. Additional 128 cases 
from NIMH and 90 cases from The University of Utah were used for replication. The 
DNA samples were genotyped on different platforms; to manage differences in CNV 
detection between arrays we used controls genotyped on platforms matching case 
platforms. 
 
Additional controls on the Illumina platform were genotyped on the InfiniumII 
HumanHap550 BeadChip technology (Illumina San Diego CA), at the Center for Applied 
Genomics at CHOP. Subjects were primarily recruited from the Philadelphia region 
through the Hospital's Health Care Network, including four primary care clinics and 
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several group practices and outpatient practices that performed well child visits. 
Eligibility criteria for this study included all of the following: (1) disease-free children 
and parents of these children in the age range of 0–18 yr of age who had high quality, 
genome-wide genotyping data from blood samples (defined in Supplemental Methods); 
(2) self-reported ethnic background; and (3) no serious underlying medical disorder, 
including but not limited to neurodevelopmental disorders, cancer, chromosomal 
abnormalities, and known metabolic or genetic disorders. For more details see
33
. 
 
Depression 
 
Case:Control Data 
Raw genotyping data from three Genetic Association Information Network (GAIN) 
projects typed on the Perlegen 600K (Perlegen Sciences Mountain View, CA, USA) array 
were accessed through dbGaP. MDD cases and controls who were at low liability for 
MDD were utilized from the case:control project “Major Depression: Stage 1 
Genomewide Association in Population-Based Samples (phs000020.v2.p1)”. Psoriasis 
Cases and Controls were used to supplement our Perlegen 600K control cohort for MDD 
“Collaborative Association Study of Psoriasis (phs000019.v1.p1)”. Lastly, parents from 
parent-offspring trios were used to further supplement the control from “International 
Multi-Center ADHD Genetics Project (phs000016.v2.p2)”. Parents from the ADHD 
study were used to maximize the number of unrelated individuals that could be leveraged 
for optimal study power. 
 
Case selection 
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MDD cases were recruited through mental health care organizations, general practices 
and in the community setting. The inclusion criteria for the 1,780 (1,693 of which were 
used in this study) participants are: 1) a DSM-IV diagnosis of major depressive disorder 
as confirmed by the CIDI psychiatric interview, 2) an age between 18 through 65 years, 
3) sufficient knowledge of the Dutch language, and 4) North-European ancestry. As the 
samples should be representative of patients seen in different settings, there are few a 
priori exclusion criteria. Excluded patients are: 1) those with a primary diagnosis of 
psychosis, bipolar disorder, obsessive compulsive disorder, severe addiction disorder and 
2) those with insufficient knowledge of the Dutch language. 
 
Control selection 
Age and gender matched control subjects are mainly derived from the Netherlands Twin 
Register, for which data collection in twin, their parents, spouses and siblings occurred in 
1991, 1993, 1995, 1997, 2000, 2002/3 and 2004/5. A total of 1860 (1,697 of which were 
used in this study) controls were selected (only one member from each family) with the 
following inclusion criteria: 1) age 18 through 65 years, 2) never scoring high (> 0.65) on 
a general factor score for anxious depression (a combined measure of neuroticism, 
anxiety and depressive symptoms via questionnaires), 3) never reported a history of 
MDD in any survey, and 4) North-European ancestry. Controls and their parents were 
born in the Netherlands or northwestern Europe. 
 
Additional control subjects were obtained from two other studies both of which were 
unrelated to MDD.  The first one included a case control study on psoriasis who were 
genotyped on the Perlegen platform and included as controls (n=1,600).  The psoriasis 
158 
 
cases were diagnosed by dermatologists and their matched controls had no history of 
psoriasis, no family history of psoriasis or other auto-immune disorders. All subjects 
were 18 years of age or older.  The second control cohort included parents from the 
ADHD parent-offspring trios study who were also genotyped on the Perlegen platform 
and included as controls (n=1,209). For more details see
34
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Figure 6.4. KANK1 Duplications Raw BAF LRR Plots 
 
 
 
Red points show the elevated Log R Ratio (hybridization intensity) and triallelic B allele 
frequency (genotype) in the duplicated region with flanking blue points showing normal 
diploid state. Schizophrenia and bipolar cases are represented. 
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Table 6.10. KANK1 Duplications Independent Validation with Roche Universal Probe Library 
 Assay #: 132 134 135 137 141 145 Duplication call 
 
Chromosomal 
Location 
(hg18): 
chr9:279,035
-279,138 
chr9:326,544
-326,608 
chr9:416,891
-417,000 
chr9:460,349
-460,443 
chr9:537,138
-537,211 
chr9:559,914
-560,007 
Chromosomal 
Location (hg18): 
S
u
b
je
ct
 I
D
 
4303995005 2 2 3 3 3 1 
chr9:474299-
702599 
5026401799 2 2 2 2 2 1 
chr9:549715-
626251 
6626851238 2 3 3 3 3 1 
chr9:323820-
733353 
6921106789 2 2 2 2 3 1 
chr9:516773-
801972 
7015457340 2 2 3 3 3 1 
chr9:396118-
689065 
7565556942 2 3 3 3 4 1 
chr9:323820-
801972 
7720672852 2 2 3 3 2 1 
chr9:490811-
534956 
9392414481 2 3 3 3 3 1 
chr9:287395-
723374 
9527354896 2 3 3 3 2 1 
chr9:308154-
474850 
2885798241 2 2 3 3 3 1 
chr9:468154-
697859 
8697617291 3 3 3 3 2 1 
chr9:263161-
520703 
 
Six assays were run on each subject, with the assays covering much of the region covered 
by the duplications. The copy number calls for each subject for each of the six assays is 
shown. The table has been colored gray for assays that were within the predicted deletion 
call for that subject, and the CNVs detected are highlighted with the red numbers. In 10 
out of 11 samples with duplications of KANK1 by array analysis, duplications were 
observed by independent validation. There are a few regions flanking the called CNVs 
where duplications were observed, refining the CNV boundaries. Four assays were 
designed that fell between chr9:559,000 and chr9:601,000, and only one ran properly in 
the control dilutions that were run. When that assay (Assay #145) was applied to these 
subjects, it repeatedly (3 independent runs) resulted in CN:1 calls in all subjects. It is 
suspected that those results are incorrect, but an experimental reason to discard them was 
not uncovered. They are provided here for completeness and because they were 
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reproducible. Unfortunately, the trouble with the assays in that region means that one of 
the subjects (5026401799) had no predicted duplication region covered by a good assay. 
 
Taken together, we have explored CNVs or the brain in neurodevelopmental disorders, 
the capstone project of this dissertation. We have traveled a long distance through 
different genomic assays, diseases, and study designs and uncovered multiple loci that are 
shared among multiple neuropsychiatric/neurodevelopmental disorders. Future work will 
tell if effective therapies can be developed in relation with the targeted loci observed. 
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Chapter 7  
7.0 Conclusions and Future Directions 
 
7.1 Significance and Impact of My Thesis Work 
My dissertation research, comprised of three broad components, aims to elucidate the 
genetic etiology of complex disease that is mediated through CNVs.  I have used large 
disease projects, including CHD and brain developmental disorders as representative of 
human complex disease in relation to copy number variant analysis. My approach is as 
follows:  First, to examine de novo (variant not present in unaffected parents, but present 
in affected child) CNV frequency in both congenital heart disease and healthy families. 
Second, to find and define genes significantly associated to CHD, true recurrent de novo 
CNVs through a genome-wide analysis. Third, to assess biological gene function of 
single de novo CNVs as well as CNV networks impacting selective biological pathways. 
 
In Chapter 2 I present a computational method that I developed to perform a genome-
wide association study of CNVs in complex disease with quality tracking. ParseCNV 
takes CNV calls as input and creates probe based statistics for CNV occurrence in (1) 
cases and controls, (2) families, or (3) populations with quantitative traits, then calls 
CNVRs based on neighboring probes of similar significance. CNV calls may be from 
aCGH, SNP array, exome sequencing, or whole genome sequencing. I compare other 
methods, such as Plink results from Autism case-controls datasets to ensure consistency 
and compare features. 
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In Chapter 3 I present a large population-based CNV study to robustly define rare CNV 
frequency. The large sample, genotyped at the same lab with the same array content, 
considerably adds to detection power in case-control studies for rare variants. Here, we 
evaluate 68,000 individuals typed with 520,000 probes in common, and report 4,969 
deletion, 2,633 duplication, and 263 homozygous deletion CNVRs observed in multiple 
unrelated individuals. The CNVs uncovered are shown to co-localize with ncRNA, 
GWAS, and OMIM annotated regions above random expectation. We performed CNV 
association clustering across the broad disease categories of cancer, autoimmune, 
cardio/metabolic disease, and neurological disease populations in comparison to healthy 
controls. Subsequently, we assessed their contributions in different ethnic groups. 
 
In Chapter 4 I focused on the potential lifespan longevity impact of CNVs by comparing 
rates of CNVs genome-wide in pediatric populations and geriatric populations. CNVs at a 
significantly higher frequency in a pediatric cohort in comparison with a geriatric cohort 
were considered risk variants impacting lifespan, while those enriched in the geriatric 
cohort were considered longevity protective variants. We performed a whole-genome 
CNV analysis on 7,313 children and 2,701 adults of European ancestry genotyped using 
302,108 SNP probes. Positive findings were evaluated in an independent cohort of 2,079 
pediatric and 4,692 geriatric subjects. We detected eight deletions and 10 duplications 
that were enriched in the pediatric group (P=3.33x10
-8
 - 1.6x10
-2
 unadjusted), while only 
one duplication was enriched in the geriatric cohort (P=6.3x10
-4
). Population 
stratification correction resulted in five deletions and three duplications remaining 
significant (P=5.16x10
-5
-4.26x10
-2
) in the replication cohort. Three deletions and four 
duplications were significantly combined (combined P=3.7x10
-4
-3.9x10
-2
). All associated 
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loci were experimentally validated using qPCR. Evaluation of these genes for pathway 
enrichment demonstrated that ~50% are involved in alternative splicing (P=0.0077 
Benjamini and Hochberg corrected). 
 
In Chapter 5 I present the results from analysis of congenital heart disease (CHD) 
families for CNV association, the first large cohort study using WES and dense state of 
the art SNP arrays. CHD is among the most common birth defects. Most cases are of 
unknown etiology. To determine the contribution of de novo CNVs in the etiology of 
sporadic CHD, we studied 538 CHD trios using genome-wide dense SNP arrays and/or 
whole exome sequencing (WES). Results were experimentally validated using digital 
droplet PCR. We compared validated CNVs in CHD cases to CNVs in 1,301 healthy 
control trios. The two complementary high-resolution technologies identified 65 
validated de novo CNVs in 53 CHD cases. A significant increase in CNV burden was 
observed when comparing CHD trios with healthy trios, using either SNP array (p=7x10-
5, Odds Ratio (OR)=4.6) or WES data (p=6x10
-4
, OR=3.5), and remained after removing 
16% of de novo CNV loci previously reported as pathogenic (p=0.02, OR=2.7). We 
observed recurrent de novo CNVs on 15q11.2 encompassing CYFIP1, NIPA1, and 
NIPA2; and single de novo CNVs encompassing DUSP1, JUN, JUP, MED15, MED9, 
PTPRE SREBF1, TOP2A, and ZEB2 genes that interact with established CHD proteins 
NKX2-5 and GATA4. Integrating de novo variants in WES and CNV data suggest that 
ETS1 is the pathogenic gene altered by 11q24.2-q25 deletions in Jacobsen syndrome, and 
that CTBP2 is the pathogenic gene in 10q sub-telomeric deletions. We demonstrate a 
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significantly increased frequency of rare de novo CNVs in CHD patients compared to 
healthy controls and suggest several novel genetic loci for CHD. 
 
In Chapter 6 I present genome-wide CNV meta-analysis across five major 
neuropsychiatric/developmental disorders. Psychiatric diseases in children and young 
adults pose a major health burden, and are just beginning to be widely diagnosed. 
However, diagnostic phenotypes are not necessarily distinct from each other, suggesting 
a shared genetic etiology. There is also a potential to target this shared variant using a 
shared therapeutic. Here, we investigate CNVs in cohorts of schizophrenia, bipolar, 
autism, ADHD, and depression. We can consider the affected domains of cognition, 
psychosis, and mood. A total of 11,418 cases were compared to 14,789 controls. The 
well-known 22q11 deletion was found to be significant (p=5.33x10
-7
). Duplication of 
DOCK8/KANK1 was found to be significant (p=7.5x10
-7
). Several known and novel loci 
were significant by case-control association with CNVs enriched in cases across the 
neurodevelopmental disorders. 
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7.2 Discussion and Future Directions 
 
7.2.1 Summary of the Thesis Project  
DNA variants abound in the human genome and give rise to complex traits. These 
variants may be base or copy number variants. However, many variants are neutral in 
selection and disease etiology, making detection of true common and rare frequency 
variants impacting disease traits difficult. Comparing allele frequencies in cases and 
controls, and in families, can reveal disease associations. SNP arrays and exome 
sequencing are popular assays of variants genome-wide. Uniform version and processing 
is crucial between samples being compared to limit bias. Bases occupy single points, 
while copy variants occupy segments. Bases are bi-alleleic, whereas copies are multi-
allelic. One genome also encodes many different cell types, such as heart and brain. I 
chose to examine CHD as it is the most common birth defect and cause of infant 
mortality. I have also chosen to examine neuropsychiatric/developmental diseases as they 
affect the quality of life and cognitive potential of a large number of children.  
 
In the thesis, I describe ParseCNV, which I developed to perform disease association 
studies using SNP arrays or exome sequencing generated CNV calls with quality tracking 
of variants, contributing to each significant overlap signal. Red flags of variant quality, 
genomic region, and overlap profile are assessed in a continuous score shown to correlate 
with independent verification over 90%. Comparing congenital heart disease families, 
cases, and controls genotyped both on SNP arrays and exome sequencing, we uncovered 
significant and confident loci with intriguing biological insights. We compared this with 
a large cohort CNV map that gave a robust rare variant frequency in unaffected 
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populations. By evaluating thoroughly the variant frequencies in pediatric individuals, we 
can compare these frequencies in geriatric individuals to gain insight on lifespan. 
Through these investigations, we have uncovered a number of CNVs that are 
significantly enriched in ncRNA, OMIM, and GWAS regions. Congenital heart disease is 
associated with de novo variants in histone modification genes. Longevity associated 
CNVs enriched in pediatric patients aggregate in alternative splicing genes. In the 
neuropsychiatric/developmental domain, CACNA, GRM, CNTN, and SLIT gene families 
show multiple significant CNV signals impacting a large number of developmental and 
psychiatric disease traits, with the potential of informing therapeutic decision-making. 
Through a new tool development and analysis of large disease cohorts genotyped on a 
variety of assays or whole exome sequenced, I have uncovered important biological role 
and disease impact of CNV in complex disease. 
 
7.2.2 Copy Number Analysis in Whole Genome Sequencing Data 
 
WGS can be used to detect CNVs, although there are still many challenges. Indeed, Mills 
and colleagues recently reported that only 53% of CNVs could be mapped to nucleotide 
resolution from 185 human WGS data sets using the previously developed CNV 
detection tools for sequencing (146). The methods that have thus far been developed are 
unreliable as they only make partial use of the information available, such as paired-end 
read distance or region-specific sequence coverage to make calls. The PennCNV(211) 
program, which was used widely to infer CNVs from GWAS data, advanced a new 
adapted hidden Markov model (HMM) based algorithm (PennCNV-SEQ), for reliable 
and efficient detection and localization of CNVs from WES and WGS datasets. The 
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PennCNV-SEQ program is novel, incorporating sequence depth coverage, allelic dosage, 
population allele frequency, and paired-end reads distance to infer CNVs, as well as an 
alignment algorithm for post-calling breakpoints refinement. 
WGS read mapping can be done with BWA or mrsFAST-Ultra(81) for CNV and 
SNP-aware read mapping. Genome STRucture in Populations (STRiP) is the most 
sensitive and specific method available taking into account read depth (RD), aberrant 
distance or orientation read pairs (RP), and split reads (SR) having segments mapping to 
non-contiguous genome regions (84). The continuous nature of whole genome 
sequencing data allows CNV calling with higher confidence than tag SNP microarrays or 
WES. WGS also allows for inversion and translocation detection, which cannot be 
performed using microarrays. By optimizing sequencing properties – coherence (multiple 
read pairs supporting the same deletion), heterogeneity (null expected read depth based 
on a population with low standard deviation vs. an observed aberration in an individual), 
and substitution (CNV alleles often alternative) – confident CNV calls can be made using 
sequencing.  Genome STRiP considers discordant RPs as a starting point and RD as a 
downstream filter. Similarly, DELLY (171) analyzes discordant RPs first, and then 
attempts to strengthen the results with supporting SRs. cnvHiTSeq (13)uses an integrative 
approach to sequencing-based CNV detection and genotyping that jointly models all 
available NGS features at the population level. By organically combining evidence from 
RD, RPs and SRs, cnvHiTSeq provides sensitive and precise discovery of all CNV 
classes even from low-coverage sequence data. Furthermore, the probabilistic model 
employed allows extensive pooling of information across individual samples and 
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reconcile copy number differences among data sources, thus achieving a high CNV 
genotyping accuracy. 
Singular value decomposition is a powerful method to remove high variance 
features contributing to noise and to mitigate sample-to-sample biases in sequencing data. 
High-count chimeric clones found in libraries and loci flanked by homologous sequences 
causing incorrect alignment can be filtered out to limit the false positive rate of CNV 
detection. Visualization of reads at CNV-called loci, using Integrative Genomics Viewer, 
further establishes confidence. We will also attempt to negate the CNV-calling 
limitations of WGS by using de novo assembly of unaligned reads, and the use of a 
number of existing tools, including BreakDancer, CREST and Pindel, which have been 
developed for this purpose. We will also utilize SNP array platforms in union with WGS 
to delineate CNVs in individuals when CNV results are unclear from the WGS data, 
which should greatly assist the de novo assembly process. We anticipate that progress in 
this area will be rapid, and we will adopt new technologies and algorithms as they 
emerge.    
A major challenge we have addressed is to generate B-allele frequency (BAF) values 
from sequencing. Certainly, for each base we can get count reference (A) and count 
variant (B) reads, respectively. These BAF values calculated directly are distributed 
uniformly (0-1) in a test data, due to quality and variability in regions. Thus, some quality 
heuristics as proposed by the VarScan2 paper and expected value of B (variant) allele 
frequency (i.e. clustering) are needed to normalize to 0.5. Specific heuristics VarScan2 
proposed were read position 10-90, strandedness 1-99%, variant reads ≥4, variant 
frequency ≥5%, distance to 3’ ≥20, Homopolymer <5, map quality difference <30, read 
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length difference <25, and mismatch quality sum difference <100. Another challenge is 
binning the per-base BAF into each exon, since the depth is calculated per exon. Three 
ways to obtain the allele counts per sample are: samtools mpileup and VarScan v2 (108) 
yields (1) VarFreq (Allele frequency of variant by read count), (2) GATK VCF contains 
AD (depth per allele by sample) and DP(depth of coverage), and (3) SNVer provides 
both Filtered and unfiltered total depth and allele depth while GATK only provides 
filtered total depth and unfiltered allele depth, which may not always be comparable. We 
calculate a continuous value for genotype (0,1) rather than the static 3 state calls AA 0/0, 
AB 0/1, BB 1/1, NC 
./.. The BAF is a 
continuous value for an 
individual’s genotype 
with expected values: 0-
A/AA/AAA, 0.25-
AAAB, 0.33-AAB, 0.5-
AB, 0.66-ABB, 0.75-
ABBB, 1-B/BB/BBB. 
The straightforward 
approach would simply 
take the frequency of 
reads with the B allele, divided by the total reads. The RPKM (SVD-ZRPKM or 
zPCARD i.e. LRR or intensity) is a value across a targeted exon, whereas BAF would be 
one value per base. Therefore, the BAF values would need to be summarized across the 
Figure 7.1. Mosaicism Profiles by WGS derived BAF and LRR 
 
 
 
Blue dots show representative modes of mosaicism. 
 
171 
 
exon by a majority-voting scheme. If there are more than 10% of values 0.4-0.6, the 
diploid evidence is quite strong and 0.5 would be a reasonable exonic BAF. Else, select 
majority 0-0.1, 0.1-0.4, 0.6-0.9, 0.9-1. This is conditional on the population frequency of 
the B allele.  
Mosaicism is a mixing of cell-populations with different copy number states. 
Liver specific somatic copy number variation could mix with blood cell diploid copy 
number to result in 
mosaicisim. Therefore, 
fractional copy numbers 
must be considered. R-
GADA(160) and 
BAFsegmentation (188) 
can detect mosaicism 
CNV calls using 
normalized intensity and 
allele depth / total depth 
WGS BAF profiles 
(Figure 7.1). Mosaic 
Alteration Detector 
(MAD) (99) is a module 
of R-GADA specifically for mosaic detection. Characteristic genotype (BAF) banding is 
observed in mosaic deletion and duplication in tandem with intensity (LRR) banding. 
 
Figure 7.2. CNV Model for Sequencing with Intensity, Genotype, Pairs 
and Split HMM Emissions 
 
 
 
 
Sequencing features informing CNV detection shown. 
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Depth, genotype, pairs split and assembly can be used in an integrative model to 
optimize CNV break point resolution (Figure 7.2). Split reads can allow for base-pair 
resolution CNV breakpoint detection. Lengths of confidently mapped reads flanking the 
CNV are also important variables for establishing the precise diploid to CNV transition 
point. Pairs and split 
features can be used to 
enhance calling for 
sequencing, which relies 
primarily on normalized 
depth and genotype 
frequency. SR performs 
on deletion and small 
insertions. However, SR 
has low sensitivity in regions with low-complexity, as they rely on unique mapping 
information to the genome. The copy number of each base can be calculated based on its 
number of overlapping high-quality mapped reads to predict breakpoints in base pair 
resolution, at the trade-off of more noisy local signals rather than a smoothed window 
size of 100 base pairs. De novo assembly (AS) first reconstructs DNA fragments 
(contigs) from short reads by assembling overlapping reads. By comparing the assembled 
contigs to the reference genome, the genomic regions with discordant copy numbers are 
then identified. AS is very computationally intensive and requires minimum read depth 
but can resolve to the base pair CNV boundaries. 
 
Figure 7.3. XHMM Test Data Deletion Detected by Intensity 
(Depth/ZPCARD) Verified by BAF 
 
 
 
Sequencing features informing CNV detection shown. 
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ParseCNV (70) was developed at CAG and can be used to perform disease 
association studies using WGS generated CNV calls with quality tracking of variants 
contributing to each significant overlap signal. Red flags of variant quality, genomic 
region, and overlap profile are assessed in a continuous score shown to correlate with 
independent verification over 90%. 
The exome as defined by Nimblegen V2 capture contains 628,118 dbSNP 
reported common SNPs which could inform CNV detection, similar to the utility 
demonstrated by supplementing intensity with genotype in SNP array studies. 
 
My contribution in this dissertation is to explore the genetic etiology of complex disease 
where I have focused on the study of copy number variation in congenital heart disease 
and neuropsychiatric/developmental disorders. 
Others have advanced on similar frontiers of research, I contribute to the scientific 
discussion and provide novel insights and methods for evaluating CNV overlap quality 
for statistically significant associations in ParseCNV. 
These findings seek to serve the greater good of improving patient care through more 
targeted genetic diagnostics and therapeutic interventions. 
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